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ABSTRACT 
 
The capsids of most plant viruses are simple and robust structures consisting of multiple 
copies of one or few types of protein subunits arranged with either icosahedral or helical 
ordered symmetry. In many cases, capsids can be produced in large quantities either by the 
infection of plants or by the expression of the subunits. In view of their relative simplicity, 
stability and easy production, plant chimeric virus particles (CVPs) or empty virus-like 
particles (eVLPs) have attracted attention as potential reagents for applications in 
bionanotechnology.  
In this work CVPs and eVLPs have been exploited for the expression of functional 
peptides, in order to stabilize them and avoid peptide low intrinsic stability and 
susceptibility to degradation.  
In particular, the viral expression platforms chosen for the expression of target peptides are 
based on four plant viruses widely used as scaffold for peptide display: Potato Virus X 
(PVX), Cowpea Mosaic Virus (CPMV), Tomato Bushy Stunt Virus (TBSV) and Turnip 
Mosaic Virus (TuMV). 
The first application explored in this work regards the therapy of Type 1 diabetes (T1D) 
and Rheumatoid arthritis (RA), two autoimmune diseases that share a strong social impact.  
Currently, there are treatments able to manage and/or stem the effects of these disorders. 
In particular, plant viruses displaying peptides associated to T1D and RA have been used 
respectively for the development of a preventive and therapeutic drug. 
Virus particles displaying autoantigenic peptide specific for these diseases have been 
expressed and used for pre-clinical studies in T1D and RA animal models. 
The results observed suggest that the use of viral structure for peptide display works as an 
adjuvant by increasing peptide modulation capability. 
The second part of this work regards the use of plant viruses displaying peptide as reagents 
for the development of innovative kit for the Sjögren’s Syndrome (SjS) and RA diagnosis. 
These two autoimmune diseases are difficult to be diagnosed and either for SjS of RA there 
are subgroups of patient seronegative to the main diagnostic serological markers. In this 
work, the use of filamentous particles for the display of specific SjS peptide allowed to 
increase the diagnostic performances of an ELISA kit in comparison to the use of the 
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peptide alone. Moreover, autoantigenic peptides associated to RA were successfully 
expressed in plants on the surface of viral particles that will be exploited in the future for 
the development of a kit for seronegative RA diagnosis. 
A third part of this PhD thesis regards another possible application of plant viruses as tools 
for peptide display. In particular, viral particles have been used for the expression of a 
antimicrobial peptide (AMP) that could be exploited as eco-friendly pesticide and for 
“nanoagriculture” application. Finally, the possibility of developing a biotechnological 
tool for peptide internalisation into the cells has been exploited by fusing on the surface of 
an icosahedral plant virus a cell-penetrating peptide (CPP) derive from HIV. Regarding 
this third part, CVPs and eVLPs displaying the selected peptides have been successfully 
expressed in plants; however, several drawbacks have been encountered in the purification 
process. 
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INTRODUCTION 
1. Plants as biofactories 
Throughout human evolution, plants have provided us with food, fiber to produce clothes 
and medicine to treat many diseases. Examples of important therapeutic molecules 
historically obtained from plants are morphine, atropine and codeine (Farnsworth et al., 
1985).  At the beginning of 2000s, about 40% of drugs prescribed in the USA and Europe 
came from active compounds found in plants (Rates, 2001; Sivakumar, 2006).  
The chemical synthesis of these plant-derived compounds has led to the production of 
pharmaceuticals at industrial levels. These active compounds from plants are basically 
small molecules, such as aspirin which was developed as an analogue of salicylic acid 
extracted from willow bark in the 19th century (Knäblein, 2005).  
Moreover, the development of more sophisticated extraction and purification procedures 
has allowed the production of alkaloids, such as morphine, from plants and mammals 
(Liénard et al., 2007).  
Although the chemical synthesis of these plant-derived compounds has led to the 
production of pharmaceuticals at an industrial level, this method has some significant 
limitations when producing complex molecules such as antibodies. For this reason, many 
therapeutic molecules have to be isolated and purified from living material, notable blood 
plasma, which involves a high risk of pathogen contamination in the final product 
(Engelhard, 2007). 
The emergence of genetic engineering in the early 1970s has paved the way to the 
production of pharmaceuticals outside their natural host. Genetic transformation 
techniques have allowed the transformation of bacteria, yeasts, animal cells and plants into 
production “biofactories” (Rai et Padh, 2001).  In particular, in the 1980s genetic 
engineering in plants was finally proven and thereafter plants began to be used to produce 
high-value recombinant proteins. 
The first example goes back to 1986, when the chimeric human growth hormone was 
expressed in transgenic tobacco and sunflowers, using the Agrobacterium tumefaciens Ti 
plasmid for the first time (Barta et al., 1986). 
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Since the 1970s it is known that A. tumefaciens is a gram-negative bacterium able to 
transfer the T-DNA region of its tumor-inducing (Ti) plasmid into plants, leading to its 
expression in plant cells (Chilton et al., 1977). Using this evidence, the gene coding for a 
protein of interest can be cloned into T-DNA between the natural borders of the A. 
tumefaciens Ti-plasmid and the resulting vector can be used to transform plants. 
Transformed plants can correctly produce antibodies and other complex recombinant 
proteins (Hiatt et al., 1989; Sijmons et al., 1990). 
In the 21st century, the definitive term “Plant Molecular farming” was coined, which refers 
to a new branch of plant biotechnology mainly focused on exploiting plants as factories 
for biomolecule heterologous production (Lico et al., 2005). Since then, transgenic plants 
have become one of the most interesting and promising pharmaceutical expression 
platforms as they offer many advantages over traditional fermentative systems (such as 
bacteria, yeasts and mammalian cell cultures). 
There are two methods of protein production in plants: stable and transient expression 
transformations. 
Stable transformation has the advantage of allowing production scalability, low-cost 
biomass production and the potential for crossing transgenic lines to obtain complex 
proteins in plant (Taket et al., 1998). 
Transient expression is achieved using A. tumefaciens to deliver foreign nucleotidic 
sequences to plants allowing their expression in plant cells without transgene integration 
into the plant genome. This advanced technology is flexible and quickly produces high 
yields of recombinant proteins unmatched by the production technologies based on 
traditional fermentative expression systems (Qiang et al., 2016). Indeed, transient 
expression avoids the position effects occurring in stable transformation that may suppress 
transgene expression by surrounding genomic DNA following integration (Komorova et 
al., 2010). 
Transient expression allows significant reduction of production time as heterologous 
protein expression can be achieved 3 to 14 days post-infection, depending on the system 
used (Santi et al., 2006). This enables quick and easy testing of a wide variety of different 
constructs in order to optimize protein production. Moreover, transient expression allows 
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a prompt response to emerging epidemics (Kusnadi et al., 1997) by producing high 
levels of therapeutics and vaccines in little time. 
Plant systems to produce therapeutics are scalable and cost-effective. In table 1 production 
costs of therapeutic antibodies are compared (including both upstream and downstream 
processes) and reported in different expression systems. 
 
Table 1 Therapeutic antibodies production costs in different systems (Hood et al., 2002). 
Production system $/g 
Chinese Hamster Ovary Cells 
(CHO) 
300 
Transgenic chickens/Eggs 1-2 
Transgenic goats/milk 1-2 
Microbial fermentation 1.00 
Plants 0.10 
 
 
Furthermore, being eukaryotic organisms, plants are able to correctly fold and assemble 
proteins as well as perform post-translation modifications when necessary for protein 
activity and stability (Kamenarova et al., 2005). Finally, plants ensure a safe final product, 
avoiding contamination with human pathogens or prions, oncogenic DNA sequences or 
endotoxins.  
As a consequence, some companies currently produce human pharmaceuticals using plant 
molecular farming (Table 2). Many studies have been published in the last fifteen years, 
starting from the production of human lysozyme and lactoferrin in rice (Hennegan et al., 
2005; Yang et al., 2002) to the use of tobacco for the expression of human type I collagen 
(Shoseyov et al., 2014). The definitive breakthrough to commercial success was in 2012, 
with the approval from the United States Food and Drug Admnistration (FDA) of 
taliglucerase alfa (table 2), a recombinant form of human glucocerobrosidase developed 
by Protalix Biotherapeutics for the treatment of Gaugher’s disease (Tschofen et al., 2016).   
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Table 2 Companies focused on plant molecular farming for the production of human 
pharmaceuticals (adapted from Yao et al., 2015). 
Company Plant host Lead Product Status 
Mapp 
Biopharmaceutical/ 
LeafBiol, USA 
Tobacco leaves ZMapp
TM for Ebola 
crisis Phase 1 and 2 (2016) 
Protalix 
Biotherapeutics, Israel 
Carrot or tobacco cell 
colture 
ELELYSOTM 
(taliglucerase alfa) 
Enzyme replecement 
Phase 3 completed and 
FDA approved 
(2012) 
 
Icon Genetics, 
Germany 
Nicotiana 
benthamiana leaves 
Vaccine for non-
Hodgkin’s Lymphoma 
Phase 1 completed 
(2014) 
Ventria Bioscience, 
USA Rice seeds 
VEN150 for HIV-
associated chronic 
inflammation 
Phase 2 (2016) 
Greenovation Biotech 
GmbH, Germany Moss 
Moss-GBA for 
Gaucher’s Disease 
Moss-AGAL for 
Fabry Disease  
Preclinical test (2016)  
Phase 1 completed 
(2015) 
Kentucky 
BioProcessing, USA 
Nicotiana 
benthamiana leaves 
Protein expression 
service - 
PhycoBiologics Inc. 
Bloomington, USA Algae 
Vaccine Growth 
Factor and enzyme Phase 2 (2016) 
Medicago, Canada Nicotiana bentamiana Alfalfa 
Vaccine for influenza, 
Pandemic market, 
Rabies and Rotavirus 
Phase 2 completed 
Synthon, Netherlands Duckweed LeafyBiomass 
Antibody for non-
Hodgkin’s Lymphoma - 
Fraunhofer IME, 
Germany Tobacco leaves HIV Antibody 
Phase 1 completed 
(2011) 
Fraunhofer CMB, 
USA 
Nicotiana 
benthamiana leaves Influenza vaccine Phase 1  
PlanetBiotechnology, 
USA Tobacco leaves 
CaroRx for dental 
caries; PBI-220 
antibody for anthrax; 
DPPA-Fc for MERS 
coronavirus infection 
Preclinical test and 
searching for investor 
 
Another important economical application of plant molecular farming concerns the 
recombinant production of non-pharmaceutical protein, such as technical enzymes, 
research reagents, cosmetics and veterinary products. In comparison with pharmaceutical, 
non-pharmaceuticals product can reach the market more quickly because of the much 
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lower regulatory burden. Table 3 shows the plant-derived non-pharmaceutical products 
already on the market. 
 
Table 3 Commercial development of nonpharmaceutical proteins produced in plants 
(Adapted from Tschofen et al., 2016). 
Company Plant host Lead Product Application Status 
ProdiGene/Sigm
a-Aldrich, USA Maize seeds 
Trypsin, avidin, 
endo-1, 4- ß- D- 
glucanase 
Technical 
reagents Commercialized 
Infinite 
Enzymes/ Sigma 
Aldrich, USA 
Maize seeds Cellobiohydrolase I 
Technical 
reagents Commercialized 
Agrenvec, Spain 
Tobacco leaves, 
transient 
expression 
Growth factor, 
cytokines, 
thioredoxin, 
TIMP-2 
Research 
reagents Commercialized 
ORF Genetics, 
Iceland Barley seeds 
Growth factor, 
cytokines 
Research 
reagents Commercialized 
Sif Cosmetics, 
Iceland Barley seeds 
Epithelial growth 
factor Cosmetics Commercialized 
Ventria 
Bioscience/InVit
ria, USA 
Rice seeds 
Albumin, 
lactoferrin, 
lysozyme, 
transferrin, 
insulin 
Research 
reagents Commercialized 
Kentucky Bio-
Processing, USA 
Tobacco leaves, 
transient 
expression 
Aprotinin Research reagents Commercialized 
CollPlant Israel Transgenic tobacco Collagen 
Research 
reagents, tissue 
culture, health 
applications 
Commercialized 
Natural Bio-
Materials, South 
Korea 
Rice cell 
suspension 
Trypsin, 
enterokinase, 
growth factor, 
cytokines 
Research 
reagents, 
cosmetics 
ingredients 
Commercialized 
Center of 
Genetic 
Engineering and 
Biotechnology, 
Cuba 
Transgenic 
tobacco Antibody 
Purification of a 
Hepatitis B 
vaccine 
Commercial 
application 
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Syngenta, USA Maize seeds α-Amylase Bioethanol production Commercialized 
Origin Agritech, 
China Maize seeds Phytase Feed 
Commercial 
pending 
NexGen, South 
Korea 
Tobacco leaves, 
transient 
expression 
Growth factor Tissue culture reagent Commercialized 
 
This evidence confirms the versatility of plants as expression platforms and one can 
thus predict their valuable potential from an industrial point of view. 
 
2. Plant viruses  
Several works describe how plants can be exploited for human virus production (whole 
particles or part of them) as a safe and fast vaccine production system (McGarvey et 
al., 1995; Kong et al., 2001; Thanavala et al., 2005; Peyret et al., 2015; Natsumi et al., 
2015). On the other hand, another facet of plant molecular farming regards plant 
viruses as a tool for recombinant protein expression in plants.  
Recent developments in molecular biology technology have led to new systems for 
transient expression using viral vectors or parts of them (e.g. magnICON, geminiviral 
and pEAQ) (Circelli et al., 2010; Boivin et al., 2010).  
The first viruses transformed into gene vectors were with DNA genomes. This choice 
was done because DNA viruses were easily manipulated genetically for transgene 
insertion in their genome (Porta et Lomonossoff, 2002) but, the complex replication 
cycle of these viruses made them inadequate for expression of heterologous proteins.  
The majority of plant virus genomes are made of one or more molecules of positive-
sense RNA and have the advantage of directly translating RNA positive-sense 
molecules entering the plant cell. Several plants support the replication of these viruses 
and can reach high titres of virions. All these characteristics make positive-sense 
RNAs excellent candidates for transient expression of foreign protein. 
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There are four main strategies for in planta expression of heterologous proteins 
exploiting plant viruses: 
- Gene replacement; 
- Gene insertion; 
- Virus deconstruction; 
- pEAQ vector series. 
The gene replacement strategy uses viral genomes to express recombinant protein, 
using specific vectors in which either the viral genome sequence or the gene coding 
the protein of interest are present. Initially, the development of viral vectors was done 
by replacing the gene sequence coding the protein of interest into viral genome (Figure 
1). 
 
Figure 1 The gene replacement strategy for the transient expression of foreign 
genes using plant viruses. 
 
The gene replacement strategy was drawn-up in order to avoid possible negative 
effects of increasing viral genome size by introducing a foreign gene. The replaced 
viral genes should not be essential for viral amplification and replication in plant cells. 
However, the replacement strategy has limitations due to the deletions of a viral gene 
that, even if nonessential, is likely to contribute to overall virus fitness (Scholthof et 
al., 1996). 
A more successful approach is the gene insertion strategy which is shown in figure 2. 
 
 
Figure 2 The gene insertion strategy for the transient expression of foreign gene 
using plant viruses.  
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The insertion of an added exogenous gene, avoiding the deletion of any viral genes, 
prevents potential negative effects of the gene replacement strategy, leaving the viral 
genome unharmed. 
The deconstructed virus strategy is a new generation strategy, inspired to replace 
approaches for heterologous protein expression in plants.  
This method is based on evidence that the viral genome can be deconstructed in many 
expression plasmids and deconstructed viral vectors can be assembled in planta from 
pro-vectors delivered by Agrobacterium. Indeed, T-DNAs can be delivered to the 
same cell from different Agrobacteria and can recombine efficiently in plant cells. The 
most commonly used vector so far is that based on Tobacco Mosaic Virus (TMV). 
This vector has been engineered to split the TMV genome into two cDNA modules: 
the 5’-module harbouring the RNA dependent RNA polymerase (RdRP) and the viral 
movement protein (MP).  The second module is 3’, containing the sequence code for 
the protein of interest and the viral 3’-untranslated region (UTR) needed for replication 
and amplification of the vector. These modules are delivered to the plant cell by two 
independent A. tumefaciens transformed cell lines, that are assembled together in vivo 
by a site specific recombinase delivered by a third Agrobacterium cell line. 
After recombination, the DNA is transcribed and spliced, thus undesired elements are 
removed and a fully infective replicon carrying the sequence of interest is assembled 
(Marillonet et al., 2004). 
In this method, bacteria and viruses work together to ensure the best performance, in 
particular A. tumefaciens assumes the functions of primary infection, while the viral vector 
provides cell-to-cell spread, amplification and high levels of expression.   
A schematic representation of magnifection system is reported in figure 3. 
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Figure 3 Schematic overview of magnifection system shows in planta assembly of 
5’-module and 3’-module. SD, splice donor site; SA, splice acceptor site. 
(Marillonnet et al., 2004).  
In summary, this technology combines the advantages of two biological systems: vector 
efficiency and systemic delivery capabilities of Agrobacterium, speed and expression 
level/yield of a plant virus (Gleba et al., 2005). 
Finally, regarding the pEAQ vector series, these vectors were developed in the attempt to 
exploit the viral CPMV genome to set up a novel expression system. 
The CPMV genome is composed of two separately-encapsidated RNAs: RNA-1 (6.0 kb) 
and RNA-2 (3.5 kB). The latter encodes for a polyprotein and is entirely dependent on 
RNA-1 for its replication. It has been demonstrated that RNA-2 polyprotein can be 
partially deleted and replaced with a foreign gene without interfering with replication of 
the molecule driven by RNA-1 (Cañizares et al., 2006; Rohll et al., 1993). It has been 
previously demonstrated that the sequences essential for delRNA-2 to be replicated by 
RNA-1 were the entire 3’-UTR and the first 512 nucleotides at 5’, including two in-frame 
AUGs at position 161 and 512 (Rohll et al., 1993). 
This evidence has led to the development of a replication-competent deleted RNA-2 
(delRNA-2) plasmid. In comparison with the system based on the use of native RNA-2, 
delRNA-2 has some advantages mainly in terms of biocontainment. On the other hand, 
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lacking the movement protein means it is unable to spread from cell to cell and for the 
absence of the small CP, which acts as native suppressor of gene silencing (Liu et al., 
2004), delRNA2 has to be agroinfiltrated in the presence of RNA-1 and of a heterologous 
suppressor (Cañizares et al., 2006). 
Subsequently, it was found that the removal of AUG 161 together with another out-of-
frame AUG 115 caused a marked increase in the translational efficiency of the mRNA 
transcribed from the T-DNA of the foreign gene inserted into delRNA-2 (Sainsbury et 
Lomonossoff, 2008). This evidence leads to the set up of a new expression system based 
on a 5’UTR mutated version of delRNA-2 that, being characterised on an enhanced 
translation rather than replication, was called CPMV-hypertrans (or CPMV-HT). This 
system allows the expression of multiple foreign genes in the same tissue.  
Despite several advantages, cloning a gene into the CPMV-HT system required a two-step 
procedure, described in van Engelen et al. (1995). Furthermore, optimal transgene 
expression required co-infiltration with the suppressor of silencing p19. To overcome these 
drawbacks, a series of binary vectors that make cloning and transformation with the 
CPMV-HT system much easier and quicker were developed. These plasmids, called pEAQ 
vectors are modular, allowing the insertion of multiple CPMV-HT cassettes on the same 
T-DNA.  
Once a gene or many genes have been inserted into a pEAQ vector, the DNA is transferred 
into A. tumefaciens that are used for N. benthamiana inoculation.  
In conclusion, this system allows for cloning and expression of the protein of interest to 
take place within 2-3 weeks (Peyret et al., 2013). 
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3. The use of plant viruses for functional peptide display 
One of the most interesting applications that exploits plant viruses for heterologous 
expression in plant, is peptide displaying on the capsid (figure 4). 
 
Figura 4 Plant viruses modified  for in planta peptide expression; A: schematic 
representation of the genome of a representative plant virus: the replicase (in light 
blue), the movement protein (in yellow) and the coat protein (in green), with the 
corresponding unmodified viral particles; B: the sequence coding the peptide of 
interest (in red) genetically fused to the coat protein gene resulting in a Chimeric 
Virus Particle (CVP) bearing the viral genome (in dark green); C: Virus Like Particle 
(eVLP) resulted from the expression in plant of sequence coding the peptide of 
interest (in red) genetically fused to the coat protein gene without the rest of viral 
genome. 
This approach makes peptides easier to produce, cutting the cost associated with their 
production in comparison with traditional methods mainly based on chemical synthesis.  
Indeed, peptides have unique interesting characteristics in terms of efficacy, selectivity and 
low toxicity that makes them particularly suitable as therapeutic, diagnostic and industrial 
reagents. Unfortunately, the main problems of peptides, besides the high costs of 
production, are their metabolic instability and short half-life. Furthermore, in the 
bloodstream they have a low immunogenicity which makes the use of an adjuvant 
necessary (Lico et al., 2012). These issues often make the use of peptides unaffordable.  
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Plant viruses can be used as a strategic tool to overcome these drawbacks; virus capsids 
provide nanoscale particles with interesting sizes and shapes that make them useful for a 
number of chemical and biological applications (Sainsbury et al., 2010). Specifically, the 
sequence coding for a peptide of interest can be inserted into a specific viral vector fused 
to the coat protein gene to the 5’ or 3’ terminus or in a region known to be exposed on the 
viral surface. The result is the assembly in plants of chimeric virus particles (CVPs) with 
the same shape of the original virus, but displaying multiple copies of peptide on its surface 
(Lico et al., 2009). CVPs, maintaining the viral genome, are able to replicate themselves 
and spread into the host plant. In this way, high yields of the peptide of interest are 
achieved, reducing the production costs associated with their chemical synthesis.  
The viral structural coat protein stabilizes the peptide on the surface and acts as a carrier. 
Furthermore, there is some evidence demonstrating that when CVPs are used for vaccine 
development, the viral structure works as an adjuvant, because of the particulate and 
repetitive nature of virion particles (Jegerlehner et al., 2002). 
The coat proteins of some plant viruses can auto-assemble without needing a viral genome, 
leading to the formation of eVLPs which are structurally identical to the plant virus from 
which they are derived but completely lacking the viral genes. VLPs, maintaining all the 
advantages of CVPs but being devoid of viral genome, are non-replicative particles. This 
is a benefit in terms of safety because any possibility of the modified virus to infect other 
plants is avoided. On the other hand, the eVLP expression occurs only in the cells reached 
by the viral vector that might be infiltrated using A. tumefaciens as a delivery vector. 
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4. Plant viruses as biotechnology tools: the protagonists 
Several plant viruses have been developed as a peptide presentation system, among them 
the most commonly used are listed below: 
• PPV: Plum Pox Virus; 
• TMV: Tobacco Mosaic Virus; 
• PVX: Potato Virus X; 
• CMV: Cucumber Mosaic Virus; 
• AIMV: Alfalfa Mosaic Virus; 
• CPMV: Cowpea Mosaic Virus; 
• TBSV: Tomato Bushy Stunt Virus; 
• TuMV: Turnip Mosaic Virus. 
This list is in constant expansion as structural information about more viruses is available. 
The viral systems described below were used in this work. 
 
4.1.  Cowpea mosaic virus (CPMV) 
Cowpea mosaic virus (CPMV) is the first virus exploited in biotechnology as a peptide 
display system, thanks to its growth at high titres in plants, its particles are robust and it 
cannot infect mammalian cells.  
CPMV belongs to the genus Comovirus of the Secoviridae family; it is a bipartite RNA 
plant virus whose particles are made up of 60 copies each of large (L) and small (S) coat 
protein (CP) arranged in an icosahedral symmetry with a diameter of 28 nm (Sainsbury et 
al., 2010). The particle structure is known at an atomic resolution level (Lin et al., 2003), 
thus allowing the identification of possible superficial sites for peptide insertion. 
The CPMV genome structure is reported in figure 5 (A) and is composed of 2 separately 
encapsidated positive-strand RNA molecules of 5889 (RNA-1) and 3481 (RNA-2) 
nucleosides. 
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Figure 5 Peptide presentation system based on CPMV. The red arrow indicates the 
position of ßB-ßC loop of S CP corresponding to the most common site used for 
peptide expression; A: genome organization of CPMV RNAs; B: ribbon diagram 
of the icosahedral asymmetric unit, consisting of the two domains of the large (L) 
coat protein (cyan and green) and the S coat protein (dark blue); C: tridimensional 
CPMV representation displayed a peptide of interest (in red); ProC, proteinase 
cofactor; VPg, genome-linked protein; Pro, 24K proteinase; 48/58K, movement 
protein; L, large coat protein; S, small coat protein. (Sainsbury et al., 2010). 
As shown in figure 5, RNA-1 includes all sequences coding for proteins responsible for 
the replication of viral RNA and polyprotein processing such as the RNA-dependent RNA 
polymerase, a helicase, the 24K proteinase and a proteinase cofactor. RNA-2 encodes for 
proteins required for viral movement (48/58K) and for polyprotein VP60, the precursor of 
the two coat proteins. 
The atomic resolution of CPMV 3-D structure can identify the most exposed external sites 
suitable for peptide display (Lomonossoff et al., 1995). In literature, most cases using the 
CPMV-based system report the display of target peptides into the most exposed loop on 
the virus surface which is the ßB-ßC loop of S CP (red arrow in figure 5-A, B) (Porta et 
al., 1994). However, other loops have also been used successfully, for example the ßC’-
ßC’’ loop of the S CP and the ßE-αB loop of the L CP (Brennan et al., 1999; Taylor et al., 
2000). 
The genome of CPMV has been genetically manipulated at different degrees in order to 
set up vectors for the expression in plants of either CVPs or eVLPs. 
For in planta expression of CPMV-based CVPs, the systems developed so far are based on 
the modification of the sequence of RNA-2 and its co-inoculation with unmodified RNA-
1 to provide polyprotein processing and viral replication functions. 
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Even if the potential of CVPs in several fields are up to now demonstrated, in some cases 
they could show some limitations as described below. 
For their expression, CVPs must retain cell-to-cell movement capability in plant, thus 
placing limitations on the sequences that can be expressed on the particle surface. 
Furthermore, to maintain their movement ability, particles must encapsidate the RNA 
genomes, remaining infective and thus raising biosafety issues. Finally, considering the 
presence of the 2 genomic RNAs inside the particles they can not be loaded with 
heterologous material. 
The most recent development of the CPMV-based expression system allows assembly of 
viral capsids in plants without needing viral RNAs. The result are eVLPs self-assembled 
structures that mimic the viral structure but are not infective because they are devoid of 
viral genome. To achieve CPMV eVLPs in plant, the sequence of the coat protein (S and 
L) precursor VP60 was cloned into the pEAQ-HT expression vector; to process the 
precursor in order to obtain the two coat proteins, the expression construct harbouring the 
VP60 sequence was coinfiltrated in N. bethamiana plants with a second pEAQ-HT 
expression vector in which the sequence of proteinase 24K was cloned (Sainsbury et al., 
2010) (figure 6). 
 
Figure 6 Production of CPMV eVLPs. A. Schematic representation of the plasmid 
used to express eVLPs; gray arrow indicates CaMV 35S promoter; gray box indicates 
the nos terminator. B. Schematic representation of CPMV eVLPs without any genetic 
material inside. 
In literature, there are some technical indications about the characteristics that peptides 
should have for an optimal expression with the CPMV-based systems indicating that 
peptide should be less then 40 amino acids and have an isoelectric point below 9.0 (Porta 
et al., 2003). 
Finally, another interesting face of CPMV based expression system is that it can be adopted 
to load a cargo inside its eVLPs (Hesketh et al., 2015).  
 
A BpEAQ-HT-24K
pEAQ-HT-VP60
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4.2. Potato Virus X (PVX) 
Potato Virus X (PVX) belongs to the genus Potexvirus of the Flexiviridae family. PVX 
has been shown to be an ideal, high ordered and multivalent scaffold to be exploited for 
peptide display (Brennan et al., 1999; Marusic et al., 2001).  
The PVX structure is simple, filamentous and flexible. The virion is 500 nm in length, 15 
nm in diameter and it has helical symmetry. The viral capsid is made up of up to 1300 of 
a single CP that wrap the genome of virus, with 8.9 CP per helix turn (Kendall et al., 2008). 
PVX genome is approximately 6.4 Kb (figure 7) and is made of a single-stranded positive 
RNA. The genome contains 3 open reading frames (ORFs) coding for 5 proteins: the RNA-
dependent RNA Polymerase (RdRP), the CP and 3 movement proteins encoded by 3 
overlapping ORFs that form the Triple Gene Block module (TGBp1, TGBp2 and TGBp3) 
(Sonenbeng et al., 1978).  
 
Figure 7 Schematic representation of PVX features. A. Diagram of PVX genome; B. 
Three-dimensional representation of PVX particle. RdRP: RNA-dependent RNA 
Polymerase; TGBp1/p2/p3: Triple Gene Block proteins; CP: Coat Protein. Arrows 
represent the subgenomic promoters (Lico et al., 2015). 
 
Although the structural organization and CP folding are not known because no atomic-
resolution data is available, it is assumed that the viral CPs are arranged in a helical 
structure with the CP N-terminus exposed on the viral surface (Parker at al., 2002). Given 
this assumption, the use of PVX as a scaffold for peptide display requires the fusion of 
peptide sequence at the 5’ terminus of CP gene. For the production of PVX-based CVP 
expression vectors such as pPVX201, a vector has been developed that harbours cDNA 
which encodes the whole PVX genome (Baulcombe et al., 1995; Chapman et al., 1992). 
Genomic RNA
Viral CP
RdRP TGBp1
TGBp2
TGBp3 CP5’ 3’
A
B
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In Lico et al. 2006, a spontaneous PVX mutant was isolated and characterized by a 21 
aminoacid deletion at the 5’ terminus of the CP gene. This mutant was exploited for the 
generation of a vector that allows the fusion and display of longer peptides. 
With the PVX expression system, CVP production is firstly obtained by direct infection of 
N. benthamiana leaves with plasmid carrying the modified PVX genome, and 
subsequently, infection can be propagated using sap from primary infected leaves. 
The peptide selected for the expression on PVX surface should fit a list of parameters in 
order to avoid interference with the viral structural stability and infectivity. According to 
published (Lico et al., 2006) and unpublished data (Dr. Lico, personal communication), 
the target peptide should meet the following criteria: 
- the peptide isoelectric point should be in the range of 5.24 – 9.18. If the 
isoelectric point of the target peptide does not fit this range, it is possible to 
modify it by the addition of basic or acid aminoacids at the ends of its 
sequence; 
- up to now the length of peptides expressed with this system range between 
10 – 24 aminoacids. This range results optimal although there is no evidence 
that longer or shorter peptides can negatively influence viral assembly and 
movement; 
- the presence of tryptophan (W) residues in the peptide should be avoided 
because this aminoacid critically affects cell-to-cell and phloem movement 
of the virus. However, it has been demonstrated that PVX particles carrying 
a peptide with a 3.7% W content, were correctly assembled in plant and were 
able to move properly while a peptide of 6.2 % W content has not made the 
PVX CVPs infective; 
- it would be desirable to display a peptide containing serine (S) and/or 
threonine (T) because these phosphorylated residues promote virus 
disassembling and viral RNA replication; 
- Finally, to develop a CVP-based vaccine, it is suggested the presence of a 
spacer aminoacid at the peptide N-teminal, because the CP is often acetylated 
and this could interfere with the displayed peptide’s immunological effects. 
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4.3. Tomato Bushy Stunt Virus (TBSV) 
Tomato Bushy Stunt Virus (TBSV) is a prototype member of the Tombusviridae family 
and it belongs to the genus Tombusvirus.  
TBSV has a single-stranded positive RNA genome of about 4.8 kb that contains 5 ORFs. 
The capsid is made up of 180 copies of the unique 41 KDa CP that assembles into particles 
of 30 nm in diameter characterized by an icosahedral symmetry. 
The TBSV CP has a ternary structure defined by 3 separate domains: at the CP N-terminal 
the RNA binding (R), the shell (S) and the C-protruding (P). The CP R domain is placed 
within the virus particles while the C-terminal P domain is exposed on the external surface 
(Harrison et al., 1978; Olson et al., 1983). 
Different vectors were constructed which allow the genetic fusion of the foreign peptide at 
the C-terminal protruding domain of the TBSV CP, resulting in the display of the peptide 
on the surface of the viral capsid. The resulting particles, maintaining their viral genome 
retain infectivity. In literature, it is possible to find several examples of different peptides 
expressed with the TBSV-based system, thus demonstrating the correct assembly in plant 
of TBSV CVPs carrying peptides up to 56 aminoacids in length.  
The expression of TBSV CVPs in plants was achieved by the genetic engineering of the 
TBSV-P plasmid. This vector carries the whole cDNA of TBSV genome (Szittya et al., 
2000) and a multi-cloning site (MCS) was inserted by transforming the CP stop codon. 
The resulting pTBSV-vector (figure 8), harbouring the promoter for T7 RNA polymerase, 
is essential for in vitro cDNA transcription in order to obtain infectious RNA. Accordingly, 
the production of TBSV CVPs is firstly obtained by direct infection of N. benthamiana 
leaves with infectious transcribed RNA and subsequent infection can be propagated using 
sap from primary infected leaves (Grasso et al., 2013). 
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Figure 8 Schematic representation of TBSV features. A. Diagram of TBSV 
genome; B. Tridimensional representation of TBSV particle. T7: T7 viral promoter; 
RdRP: RNA-dependent RNA Polymerase; CP: Coat Protein; MP: movement 
protein; p19: silencing inhibitor. Red arrows indicate the multi-cloning site within 
the CP gene in which the foreign peptide sequence is cloned.  (Adapted from Grasso 
et al., 2013).  
In order to avoid the critical step of in vitro retro-transcription, some other vectors were 
developed by the replacement of T7 promoter with the Cauliflower mosaic virus (CaMV) 
35S promoter (Odell et al., 1985). Finally, the A. tumefaciens nopaline synthase (NOS) 
termination sequence (Depicker et al., 1982) was introduced downstream of the 3’ viral 
end. For plant infection, these vectors harbouring the TBSV cDNA fused to the foreign 
peptide sequence, are directly inoculated on N. benthamiana leaves. Re-infections were 
performed using saps from infected leaves as well. 
Finally, another interesting facet of TBSV is that it can be adopted to load cargo inside its 
CVPs. The inner TBSV CVP core can be easily reached by switchable pH-dependent 
gating (Aramayo et al., 2005; Kruse et al., 1982). 
 
4.4. Turnip Mosaic Virus (TuMV) 
Turnip Mosaic Virus (TuMV) belongs to the genus of Potyvirus of the family Potyviridae. 
TuMV is a positive-single strand RNA virus (approximately 10 kb long) forming flexuous 
and filamentous particles with an average length of 720 nm and a diameter of 12-15 nm 
(Sánchez et al., 1998). TuMV virions are characterized by 2000 copies of the same CP that 
has a molecular weight of approximately 32-33 kDa. 
The viral genome encodes for a single polyprotein that is processed into at least eight 
mature proteins by three viral proteinases (Richmann et al., 1992; Verchot et al., 1992). 
TuMV was an attractive candidate as expression vector because it infects most of the 
species in the family Brassicaceae, including some of the largest plants in terms of 
biomass.  
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A biosafe viral vector was developed from the original TuMV infectious cDNA clone 
(p35Tunos), modified by introducing a restriction site by substitution of third-base 
nucleotides in the codons of the first two amino acids of the CP (Ala e Gly). The resulting 
plasmid was named p35Tunos-vec01 (Touriño et al.,2008). Moreover, the non-aphid-
trasmissible (NAT) mutation was introduced in a particular motif located at residues 6-8 
of the CP which was mutated by PCR site-directed mutagenesis. The resulting p35-Tunos-
vec01-NAT1 is not transmitted through seeds or by contact between plants. 
With this system up to 2000 peptide copies can be expressed on the TuMV particles’ 
surface.  
The sequence encoding the foreign peptide of interest is cloned into the p35-Tunos-vec01-
NAT that is then used for N. benthamiana inoculation. The presence and integrity of the 
exogenous sequence is analysed by immunocapture-RT-PCR (IC-RT-PCR) from extracts 
of infected plants (Nolasco et al., 1993) using a monoclonal antibody antiPoty to capture 
the virus. Extracts of infected N. benthamiana leaf are used to inoculate Brassica juncea 
plants and  TuMV CVPs particles are then purified from the subsequent infected leaves. 
A new expression system has been developed to produce TuMV eVLPs in N. benthamiana 
(personal communication of Fernando Ponz). This virus system lacks the RNA inner 
skeleton, consequently the CPs to form TuMV eVLPs are assembled randomly, and 
particles are expressed at different lengths. 
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AIM OF THE PROJECT 
The advantages of the expression of proteins in plants combined with the high yield and 
the short production time achieved with the expression platforms based on plant viruses, 
allow to consider this approach interesting for several applications.  
This project is focused on the exploitation of plant virus nanoparticles, either CVPs or 
eVLPs, for different applications. 
First of all, for therapy and diagnosis our approach was focused on autoimmune diseases; 
the target diseases are Type 1 Diabetes (T1D), Rheumatoid Arthritis (RA) and Sjögren’s 
Syndrome (SjS).  
The therapeutic application, in the first part of this PhD thesis, is focused on the prevention 
of T1D and on the treatment of RA; 
In the second chapter, the diagnostic application has been explored for SjS and RA. 
Finally, the last part of this project regards other applications of eVLPs; these uses include 
the set up of system for internalization of peptide inside the cell and the development of 
eco-pesticides. 
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TARGET AUTOIMMUNE DISEASES  
1. Type 1 Diabetes (T1D) 
Type 1 Diabetes (T1D) is a chronic autoimmune disease characterised by the loss of self-
tolerance to insulin-producing β-cells in the islets of Langerhans within the pancreas. The 
destruction of these pancreatic cells engaged to the insulin production results in plasma 
glucose deregulation leading to a chronic hyperglicemia.  
The incidence peak is in children aged less than 15 years; after the pubertal years, the 
incidence rate significantly drops in young women, but remains relatively high in young adult 
males up to the age of 29-35 (Soltesz et al., 2007). 
According to the latest edition of Diabetes Atlas (7th edition, 2015) 542 000 children around 
the world have T1D and there is an increase of around 86 000 new cases per year. Europe 
has the higher (140 000) number of children with T1D. 
Up to now there are not therapies able to prevent or revert the onset of T1D and people 
affected by this disorder need daily insulin injection in order to control blood glucose level. 
Without insulin, a person affected by T1D will die. 
Despite the insulin replacement therapies, long-term complications affecting eye, 
cardiovascular system, foot, oral cavity, kidney and nervous system can appear. 
T1D develops as a consequence of a combination of genetic predisposition, environmental 
factor and stochastic events (Bluestone et al., 2010). 
Considering that human pancreas it is not easily accessible, most of the knowledge about the 
T1D pathogenesis comes from studies done in the last 30 years in animal model, first of all 
non-obese diabetic (NOD) mice. T1D developed in this animal share with human many 
aspects including the disease pathogenesis.  
The studies in NOD-mice have demonstrated that the T1D occurs as a consequence of a 
breakdown in the immune regulation, resulting in the destruction of insulin producing β-cells 
through the expansion of autoreactive CD4+ and CD8+ T cells, autoantibody-producing B 
lymphocytes and the activation of the innate immune system. 
Although, the presence of autoantibodies in sera from T1D patients is the first diagnostic 
evidence of autoimmunity, autoreactive T cells play a dominant role in disease initiation and 
progression. T cells CD4+ CD8+ are present in the surrounding area of the β-cells islets in 3-
4 weeks old NOD mice (Anderson et al., 2005) together with dendritic cells and 
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macrophages. These cells are the first infiltrates and have been shown to recognize islet 
autoantigens similar to those binded by autoantibodies (e.g. Insulin B chain, Glutamic acid 
decarboxylase (GAD) and zinc transporter 8 (ZnT8)) presumably resulting from the β-cells 
turnover (Turley et al., 2003; Nakayama et al., 2005). These effector T cells generally exhibit 
a type 1 phenotype characterized by the secretion of pro-inflammatory cytokines such as 
IFNγ and TNFα (Wang et Tisch, 2008). Although the molecular events that initiate the loss 
of tolerance in this setting are still speculative, several studies suggest that a limited number 
of primary islet autoantigens recognized by these infiltrating cells may be responsible for 
disease initiation (Lennon et al., 2009), that can be explained with a defect in thymic T-cell 
negative selection. 
To corroborate this hypothesis, 20% of individuals with spontaneous mutations of the 
autoimmune regulator gene AIRE developed T1D; indeed, insulin is an AIRE-regulated islet 
protein expressed in thymic medullary epithelial cells where autoreactive T-cells can come 
into contact for the first time with the autoantigen (Gardner et al., 2009). 
This is not the only genetic variation linked to the development of T1D, indeed the most 
important genetic association in T1D is found within HLA-DR class II genes, encoding major 
histocompatibility complex (MHC) class II molecules (Erlich et al., 2008). Other established 
common variants include Insulin, CTLA-4, PTPN22 and CD25 genes (Sgouroudis et Ciriaco, 
2009). 
Moreover, number of reports demonstrate that the frequency and/or function of various 
immunoregulatory effectors such as FoxP3-expressing CD4+CD25+ Tregs and IL-4 secreting 
Th2 cells are reduced in NOD mice and diabetic patients (Wang et Tisch, 2008). 
Finally, the environment is likely to have a strong effect on the development and progression 
of T1D. In NOD mice the incidence of T1D decreases dramatically when they are exposed 
to microbial stimuli (Qin et al., 1997; Wen et al., 2008). Similar observation has been noted 
in humans as the incidence of T1D is higher in the industrialized societies with reduced 
exposure to parasites (Weintrob et al., 2001). The influence of other environmental factors 
has been demonstrated ranging from cows’ milk/bovine serum albumin, meat 
preservatives/N-nitroso compounds, vitamin D and analogues, omega-3 fatty acids, 
environmental stress and toxins (Virtanen et al., 2006; Akerblom et al., 2005; Norris et al., 
2007; Jun et al., 2004). Finally, recent evidences suggested a potential role for viruses in 
T1D pathogenesis (Richardson et al., 2009; Nejentsev et al., 2009). 
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2. Rheumatoid Arthritis (RA) 
Rheumatoid Arthritis (RA) is a common chronic, inflammatory autoimmune disease 
affecting approximately 1% of the world population, increasing with age and peaking 
between the ages of 35 and 50 years. The annual incidence of RA is approximately 3 cases 
per 10,000 individuals in the general population (http://emedicine.medscape.com).  
This disease is characterized by synovial inflammation and hyperplasia, rheumatoid factor 
(RF) and anti-citrullinated protein antibody production (ACPA), cartilage and bone 
destruction and systemic feature, including cardiovascular, pulmonary, psychological and 
skeletal disorders. 
The quality of life of RA patients is reduced by pain, fatigue and loss of body function. 
Moreover, a number of extra-articular manifestation and comorbidities are present in RA 
patients, resulting in increased mortality (Gonzalez et al., 2008). Even if the cause of RA is 
unknown, it is demonstrated that this disease involves a complex interplay among genotype, 
environmental factor and chance. 
Citrullination is a normal process in which dying cells, that normally do not come in contact 
with the immune system, incur. The interaction between environmental factor (e.g. smoking, 
bronchial stress as exposure to silicia) and genetic susceptibility (e.g. HLA-DR4 alleles) 
(Symmons et al., 1997) lead to altered post-trascriptional regulation and self-protein 
citrullination. In particular, peptodylarginine deiminase (PAD) enzyme and citrullinated 
protein leak out of the dying cells and contact the immune system. PAD cittrulinate 
extracellular protein containing arginine, generating citrullinate antigens that are not 
recognized as self and consequently develop ACPA and the loss of tolerance. Also the 
presence of RF is indicative of autoantibody production.  
The production of ACPA and RF usually precedes inflammation and adhesion molecule 
formation in the synovium and the clinical RA (Van de Sande et al., 2011).  
The relationship between the loss of tolerance and the synovitis is unclear, but synovial 
involvement occurs when various inflammatory cell types infiltrate the synovium and 
ultimately work together to cause joint destruction. In particular, dendritic cells express 
cytokines, HLA class II molecules and costimulatory molecules and are involved in antigen-
presentation and T-cell activation. The latter causes recruiting of T helper cells such as Th17 
cell that, with the collaboration of dendritic cells and macrophages, created an inflammatory 
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environment. Th17 also triggers humoral adaptive immunity mediated by synovial B-cells 
that secrete antibodies, present antigen to T-cell and secrete cytokines stimulating synovial 
fibroblasts (Isaacs et al., 2010). 
Also cells of the innate immune system (e.g. macrophages and neutrophils) are involved in 
the pathophysiology of synovial inflammation in RA.  
Finally, intracellular signal transduction pathway may be also involved, since cytokines 
release reflects the way cells respond to environmental stress (Rasheed et al., 2008). 
This complex pathophysiology leads to synovial hyperplasia that results in the loss of 
normally protective effects of synovium and cartilage demage (Rhee et al., 2005); bone 
erosion occurs rapidly affecting 80% of the patients within 1 year after diagnosis (van der 
Heijde et al., 1995). 
Despite RF and ACPA are crucial in RA pathophysiology, the presence of these two 
autoantibodies is no longer considered necessary for the diagnosis; indeed, when RF and 
ACPA are negative, but there are symptoms similar to those of RA, seronegative RA can be 
diagnosed.  
In particular, 38 % of RA patient are diagnosed with seronegative RA (De Winter et al., 
2016). However, often within the first two years of diagnosis around 80% of seronegative 
RA cases could become seropositive or develop into other autoimmune disease as well 
(http://www.everydayhealth.com).  
In a study done by Nordberg et al. (2016) on a total of 234 European patients it has been 
demonstrated that patients with seronegative RA have more inflammatory activity compared 
with those with RA seropositive. 
 
3. Sjögren’s Syndrome (SjS) 
Sjögren’s Syndrome (SjS) is a chronic autoimmune systemic disease, characterized by a 
lymphoplasmocytic infiltration and a progressive salivary a lachrymal glands destruction, 
leading to ocular and mouth dryness. 
Beyond these first sicca symptoms manifestations, half of SjS patients develop 
extraglandular complications, including lung interstitial disease, nervous system 
involvement and tubular nephrophaty (Cornec et al., 2012). 
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There are two forms of SjS: 1. primary SjS occurs without other autoimmune and rheumatic 
disorders; 2. secondary SjS is associated with another rheumatic disease such as systemic 
lupus erythematosus (SLE), RA or scleroderma. 
The geo-epidemiological distribution of SjS in the global population is extremely variable 
according to study design and geographic area.  
A meta-analysis of studies, published between 1993 and 2013, allows to evaluate the SjS 
incidence and prevalence. The data, emerged comparing six studies reporting heterogeneous 
data, estimates 6.92 cases per 100 000 person-years with an incidence ratio between female 
and males of 9.29. On the other hand, prevalence data coming from a meta-analysis of 18 
studies elaborated a prevalence of 60.82 cases per 100 000 inhabitants and an incidence ratio 
between females and males of 10.72 (Qin et al., 2015). 
Regarding SjS pathogenesis, both genetic and non-genetic factors are involved in disease 
susceptibility and initiation of disease process. 
Regarding the genetic factor, some HLA class II loci have been demonstrated to be associated 
to SjS (Huang et al., 2015); moreover, Markeljevic et al. (2015) reported an association 
between low platelet serotonin level in SjS patients and polymorphism in the serotonin 
transporter gene (5-HTT). 
Also the epigenetic alterations, in particular those related to DNA methylation mainly present 
in B cells, have been shown to play a central role in the pathogenesis of SjS (Miceli-Richard 
et al., 2016).  
Beyond genetics and epigenetics, alteration in the cytokines networks seem to be crucial in 
the onset of SjS. In particular, it as been demonstrated that an up-regulation of IFN activity 
in labial salivary gland is associated with a more severe disease phenotype (Hall et al., 2015).  
An important point in the role of cytokines in SjS are the over-expression of IL-18 (that 
induce and aberrant expression of IL-22 receptor) (Ciccia et al., 2015) and/or IL-33 (Jung et 
al., 2015). 
Another two important protagonists in the pathogenesis of SjS are B-cell Activation Factor 
(BAFF) which rescue B cells from apoptosis, and APRIL (proliferation-inducing ligand) 
which participate in B-cell activation (Mackay et al., 2003). Deregulation in this pathway 
could be involved in the onset of SjS. 
Another aspect that need to be considered is the role of salivary gland epithelium; in 
particular, the loss of apical-basolateral acinar-cell polarity could lead to the presence of 
	 																																																																				TARGET AUTOIMMUNE DISEASES  
	30 
salivary mucins in the extracellular matrix of salivary gland resulting in the expression of 
proinflammatory cytokines (Barrera et al., 2015). 
Finally, the acquired immunity plays a central role in the SjS pathogenesis. The main player 
in this contest results to be the thymic seletion of Treg cells (Yaciuk et al., 2015), a different 
distribution of lymphocytes in the peripheral blood (PB) in comparison to healthy individuals 
(Sudzius et al., 2015), the number of Th17 cells that seems to be a central role as initiators 
of the inflammatory process in SjS (Lin et al., 2015) and the activation of various Signal 
Transducer and Activator of transcription (STAT) proteins in PB monuclear cells that have 
a role in signal transduction induce by inflammatory cytokines (Pertovaara et al., 2015). 
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MATERIALS AND METHODS 
 
1. Materials and methods for microbiology 
 
1.1. Bacterial strains 
 
1.1.1. Escherichia coli strains 
• DH5α 
The Escherichia coli DH5α strain carries the mutations recA1, endA1, the gene lacZΔM15, 
and shows high transformation efficiency. Moreover, it carries no antibiotic resistance 
genes. 
• TOP10 
Competent One Shot® TOP10 E. coli provided by Invitrogen (C4040-03) were used. 
Strain features are reported in the product information provided by the manufacturer. 
• XL1-blue 
The E. coli XL1-blue derived from the E. coli K12 strain and carries the mutations recA1, 
endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lacZΔM15. Moreover, it carriers antibiotic 
resistance to tetracycline. 
1.1.2. Agrobacterium tumefaciens strains 
• LBA4404 
This is an octopine strain with a disarmed octopine vir plasmid. Cells are selected on 
medium containing 50 mg/l of rifampicin and 100 mg/l of streptinomycin. 
1.2. Culture media 
 
• LB (Luria-Bertani) broth, pH 7.5. 
• SOC (Super Optimal broth with Catabolite repression) broth, pH 7.0: it is obtained by 
the addition of 20 mM glucose and 10 mM MgCl2 to the SOB broth. 
For solid medium preparation, 15 g/l of bacteriological agar were added. 
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1.3. Competent cell preparation 
 
1.3.1. E. coli competent cells 
Competent cells were prepared using the simple and efficient method (SEM), as described 
in Inoue et al. (1990). 
1.3.2. A. tumefaciens competent cells 
In order to obtain electro-competent cells of EHA105 and LBA4404 strains, a single 
colony was inoculated in 5 ml of rifampicin-containing LB broth (50 mg/l). After 24 hours, 
an aliquot of 1.5 ml of culture was centrifuged at 14000 rpm for 1 minute at room 
temperature (RT). In order to completely eliminate antibiotic, pellet was washed three 
times in 500 µl of cold and sterile glycerol 10% (v/v) and finally resuspended in 40 µl of 
glycerol 10% (v/v). 
To obtain electro-competent cells of GV3101, the same procedure was followed but each 
final aliquot was derived from 20 ml of saturated o/n culture, instead of 1.5 ml. 
 
1.4. Bacterial transformation 
 
1.4.1. Heat-shock 
Plasmid DNA or ligation reaction product were added to a vial of E. coli competent cells. 
The vial(s) was incubated on ice for 15-30 minutes, then heat-shocked at 42°C for 30 
seconds and placed on ice for 1-2 additional minute(s). 250 µl of pre-warmed SOC medium 
were added and the vial was shaken at 37°C for 1 hour at 200 rpm. After incubation 
different amounts of cell suspension were spread on LB agar plates containing antibiotics 
for the selection. For E. coli transformation with plasmid containing the lazZ gene α 
fragment 100 µl of 100 mM IPTG and 20 µl of 50 mg/ml X-Gal were spread on the plate 
surface approximately 30 minutes before bacteria spreading. Plates were incubating at 
37°C overnight (o/n).  
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1.4.2. Electroporation 
This protocol was used for transformation of electro-competent A. tumefaciens cells. 
Bacterial transformation was performed using Bio-Rad electroporation instrument, at 25 
µF, 200 Ω and 2.5 kV. 10-20 ng of DNA plasmid for EHA105 and LBA4404 strains and 
600-900 ng for GV3101 strain in a maximum volume of 5 µl of a low ionic buffer (such 
as TE or water) were added to 40 µl aliquots of electro-competent cells. The solution was 
subjected to the electric pulse and then rapidly 1 ml of LB broth without antibiotics was 
added. After 30-60 minutes of growth at 28°C by vigorous shaking, different amounts of 
cell culture were spread on selective medium. Plates were incubated at 28°C for 2-3 days. 
1.4.3. Plasmid DNA extraction 
For mini- and maxi preparation of plasmid DNA “QIAprep Spin Miniprep kit” (QIAGEN, 
27106) and “HiSpeed Plasmid Maxi kit” (QIAGEN, 12663) were used respectively. 
Extraction was performed by following the procedure described in the Handbook provided 
by the company. 
 
2. Materials and methods for molecular biology 
2.1. Nucleic acid agar gel electrophoresis 
 
The gel was obtained by boiling a solution of agar (a purified polysaccharidic linear 
polymer) and TAE buffer 1X (40 mM Tris-acetate, 1 mM EDTA, pH 8.0). Gels of 1% w/v 
agar were usually employed as they allow separating neatly fragments between 0.5 and 10 
kbp; 0.7% w/v agar gels were used to improve the separation of longer fragments; for DNA 
molecules of length inferior to 1.5 kbp, gels with 2% w/v agar were employed. Before the 
gel became solid and while its temperature was higher than 50° C, the intercalator 
“SYBR® safe DNA gel stain” (Invitrogen) was added to the solution, at a final 
concentration 10 000 times lower than the stock solution. One volume of the solution “6X 
Blue/orange loading dye” (Promega) was added to each sample prior to the loading, to 
reach a final concentration of 1X. The electrophoresis was performed at room temperature, 
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applying a constant voltage of 80-100V to the gel for 15-30 minutes, depending on the 
desired degree of separation between DNA bands. 
2.2. RNA extraction and reverse transcription  
 
Total RNA extraction was performed by using TRIzol® Reagent (Invitrogen), according 
to the procedure provided by the company. RNA samples were quantified with the 
NanoDrop spectrophotometer (NanoDrop Thermo Scientific Technologies). 1 µg of RNA 
was treated with 1 unit (U) of DNase (Promega) for 30 min at 37°C in 1X DNase Buffer. 
DNase-treated RNA was used for cDNA synthesis using the enzyme SuperScriptIII 
(Promega) through a reaction protocol provided by the producing company. In order to 
assess if the cDNA was produced properly, an amplification step using primers (Act1 - 
Act2) designed on the 3’-UTR of the gene transcript which codify for a member of the 
Nicotiana actin family was performed. 
2.3. Polymerare chain reaction (PCR) 
 
PCR analyses were performed by using the GoTaq®DNA polymerase (Promega) and the 
5X buffer provided with the enzyme. Reaction mix and cycle were set-up following the 
protocol of the producing company. Extension time was calculated on the basis of the 
length of each target amplicon, considering an amplification rate of 1000 bp/min for the 
enzyme used. The annealing temperature (Ta) was calculated as the mean Ta of the two 
primers used for each reaction. For the amplification of gene that had to be cloned, the 
enzyme AccuPrime™ Pfx DNA Polymerase (Invitrogen) was used; reaction mix was 
assembled as described in the product information, using the buffer provided with the 
enzyme. Reaction cycle was set-up following Invitrogen indications, considering that the 
enzyme has an extension temperature of 68°C and an amplification rate of 1000 bp/min. 
Also in this case the Ta was calculated as the mean Ta of the two primers used for each 
reaction. The complete list of primers used is reported in the table 1, where Tm is referred 
as the melting temperature of each primer. 
 
 
	                                                           MATERIAL AND METHODS 
	 35 
Table 1 List of primers used in PCR. 
Primer name Sequence Tm °C 
ACT1 TCTCGAGTTCCTGTTCATAGTC 64 
ACT2 GGCCCGCCATACTGGTGTGAT 68 
pCP for AGGTCAGCACCAGCTAGC 58 
CP rev AGTTCCATACCACTGGAGC 58 
RT-PCR1for TGACATTTCGTGCAACTTGG 58 
TBSV-2Back AAGATCCAAGGACTCTGTGC 56 
CPMV Seq for TCTAATCCGGGTATTGATGG 56 
CPMV Seq rev CAGATTTCCAAGCAGCAGTA 56 
 
Different quantities of different DNA templates were employed, considering a volume of 
50 µl for each reaction tube: 1-10 ng for plasmid DNA, 1 µl for cDNA or genomic DNA 
obtained as described above. 
To detect E. coli recombinant clones carrying a vector with a fragment of interest, bacterial 
colonies were directly screened by PCR: a sterile tip was used to sample colony from the 
plate and dissolve it in the reaction mix. For A. tumefaciens transformed cells, the colony 
was previously dissolved in 5 µl of sterile water and warmed at 95°C for 10 minutes; this 
product was then used as template for PCR in a reaction volume of 50 µl.  
 
 
 
 
 
	                                                           MATERIAL AND METHODS 
	36 
2.4. Vectors and cloning procedure 
2.4.1. PVX CVPs peptide display system 
• pPVX201 
This vector contains the cDNA encoding the complete Potato Virus X (PVX) genome 
(Chapman et al., 1992). A schematic representation of the vector is reported in figure 9. 
Viral genome transcription is controlled by CaMV 35S promoter and nos terminator. 8k-, 
12k- and 25k-protein are viral movement proteins. Viral genome replication is conducted 
by RNA-dependent RNA polymerase (RdRp). Coat protein CP gene is preceded by a sub-
genomic (sg) promoter. At 5’- and 3’-ends of the viral genome cDNA, PVX 5’- and 3’-
untraslated region (UTR) are present. Β-lactamase gene allows the selection of transformed 
cloned on ampicillin-containing medium (100 mg/l). 
 
Figure 1 Schematic representation of pPVX201 vector. 
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• pPVXSma 
This vector (Lico et al., 2006) has the same features of pPVX201 vector, but it encodes for 
a 21 aminoacids (aa) N-terminal truncated version of the CP. Its map is reported in figure 
2. 
 
Figure 2 Schematic rappresentation of pPVXSma vector. 
To insert the sequences encoding the heterologous peptides as fusions with the CP gene 
into pPVXSma, oligonucleotide pairs were designed to obtain NheI-compatible 5’- and 
XmaI-compatible 3’-end DNA fragments, that were ligated into the NheI-XmaI-digested 
vector. Sequences encoding the peptides were preceded by an ATG codon. The complete 
list of oligonucleotide (oligo) sequences used with the PVX CVPs peptide display system 
is reported in the table 2. The autoantigen protein from which the peptide sequences derive 
are also reported. 
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Table 2 Oligonucleotids cloned with the PVX CVPs peptide display system. 
Autoantigen Oligo Sequence 
Lipocalin Lipo for 
CTAGCCTCGAGATGTCTTTTGAAAA
GGCTGCTGGTGCTAGAGGTTTGTCT
ACT 
Lipocalin Lipo rev 
CCGGGAGTAGACAAACCTCTAGCA
CCAGCAGCCTTTTCAAAGACATCTC
GAGG 
Liprin LIP1 for 
CTAGCCTCGAGATGGCTTCTGTTCT
TGCTAATGTTGCTCAAGCTTTTGAA
AAGTCTACTC 
Liprin LIP1 rev 
CCGGGAGTAGACTTTTCAAAAGCTT
GAGCAACATTAGCAAGAACAGAAG
CCATCTCGAGG 
FADK2 FADK2 for 
CTAGCCTCGAGATGTCTGAAGCT 
AAGGTTCTTGCTAATCTTGCTCAT 
CCTCCTGCTACTC 
FADK2 FADK2 rev 
CCGGGAGTAGCAGGAGGATGAGC 
AAGATTAGCAAGAACCTTAGCTTC 
AGACATCTCGAGG 
BANK1 BANK1 for 
CTAGCCTCGAGATGTCTGATATG 
ATTCTTGCTAATCTTTCTATTAAG 
AAGAAAACTGAAC 
BANK1 BANK1 rev 
CCGGGTTCAGTTTTCTTCTTAAT 
AGAAAGATTAGCAAGAATCATATC 
AGACATCTCGAGG 
 
	                                                           MATERIAL AND METHODS 
	 39 
2.4.2. CPMV eVLPs peptide display system 
This system is based on the use of two vectors, sharing a common backbone: pEAQ-HT-
24K and pEAQ-HT-VP60 (Sainsbury et Lomonossoff, 2008; Sainsbury et al., 2009; 
Saunders et al., 2009). The two vectors were kindly provided by professor Lomonossoff 
(John Innes Centre, Norwich, UK). Target gene transcription is regulated by CaMV 35S 
promoter and terminator. Cowpea mosaic virus (CPMV) 5’-UTR and 3’-UTR function as 
translation enhancer; P19 gene encodes for a viral suppressor of silencing. Transformed 
clones are selected on kanamycin-containing medium (50 mg/l). 
• pEAQ-HT-24K 
In this vector the gene encoding CPMV 24K proteinase was cloned (Saunders et al., 2009). 
A schematic representation of the vector map is reported in figure 3. 
 
Figure 3 Shematic rappresentation of pEAQ-HT.CPMV/24K vector. 
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• pEAQ-HT-VP60 
In this vector the gene encoding CPMV VP60 (precursor of viral small and large coat 
protein) was cloned (Saunders et al., 2009). A schematic representation of the vector map 
is reported in figure 4. 
 
 
Figure 4 Schematic rappresentation of pEAQ-HT-VP60 vector. 
To insert the sequences encoding the heterologous peptides as fusions with the small CP 
gene, oligonucleotide pairs were designed to obtain NheI-compatible 5’- and AatII-
compatible 3’-end DNA fragments that were ligated into the NheI-AatII-digested vector. 
The complete list of oligonucleotide (oligo) sequences used with the CPMV eVLPs peptide 
display system is reported in the table 3. 
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Table 3 Oligonucleotids cloned with the CPMV eVLPs peptide display system. Bold letters 
correspond to the nucleotids added in order to restor the pEAQ-HT-VP60 vector. 
Autoantigen Oligo Sequence 
Lipocalin Lipo for 
CTAGCACTCCTCCTGCTTTTGAAAAGGCTGCTGGT
GCTAGAGGTTTGTCTACTCCATTTTCAGACGT 
Lipocalin Lipo rev 
CTGAAAATGGAGTAGACAAACCTCTAGCACCAGC
AGCCTTTTCAAAAGCAGGAGGAGTG 
GAD65 p524 for 
CTAGCACTCCTCCTGCTGATTCTCGTCTTTCTAAG
GTTGCTCCTGTTATTAAGGCTAGAATGATGGAAGA
TCCATTTTCAGACGT 
GAD65 p524 rev 
CTGAAAATGGATCTTCCATCATTCTAGCCTTAATA
ACAGGAGCAACCTTAGAAAGACGAGAATCAGCAG
GAGGAGTG 
   
Protein Oligo Sequence 
BP100 BP100 for 
CTAGCACTCCTGCTGATAAGAAACTTTTTAAGAA
AATTCTTAAGTATCTTGAAGATCCATTTTCAGACG
T 
BP100 BP100  rev 
CTTGAAAATGGATCTTCAAGATACTTAAGAATTTT
CTTAAAAAGTTTCTTATCAGCAGGAGGAGTG 
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2.4.3. TBSV CVPs peptide display system 
The cloning steps in the pTBSV vector have been conduced by the research group of the 
professor Luca Santi at the Department of Agriculture and Forestry Science (DAFNE) of 
the University of Tuscia following the procedures reported in Grasso et al. 2013. 
A schematic representation of the pTBSV vector map is reported in figure 5. 
 
Figure 5 Schematic rappresentation of pTBSV vector. 
 
The complete list of oligonucleotide (oligo) sequences used with the TBSV CVPs peptide 
display system is reported in the table 4. 
 
 
pTBSV
peptide
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 Table 4 Oligonucleotides cloned with TBSV CVPs peptide display system. 
Autoantigen Oligo Sequence 
FADK2 FADK2 for 
TGGAGGAGCTAAGGTTCTTGCTAATCTTGCACAT
CCACCTGCTTGATTGAT 
FADK2 FADK2 rev 
CAATCAAGCAGGTGGATGTGCAAGATTAGCAAG
AACCTTAGCTCCTCCAGGCC 
Liprin LIP1 for 
CGGAGGAGCTTCTGTTCTTGCTAATGTTGCACAA
GCATTTGAATGATTGAT 
Liprin LIP1  rev 
CAATCATTCAAATGCTTGTGCAACATTAGCAAG
AACAGAAGCTCCTCCGGGCC 
 
2.4.4. TuMV CVPs peptide display system 
The cloning steps in the vector p35Tunos-vec01-NAT have been conduced by the research 
group of the professor Fernando Ponz Ascaso (Centro de Biotecnología Y Genómica de 
plantas – Madrid – Spain) following the procedure reported in Sánchez et al. 2013.  
A schematic representation of the p35Tunos-vec01-NAT vector map is reported in figure 
6. 
 
Figure 6 Schematic rappresentation of p35Tunos-vec01-NAT vector. 
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3. Plant materials and methods 
	
3.1. Plant material 
Nicotiana benthamiana plants were grown from seeds in heat-sterilized soil and cultivated 
in a growth camber at 25°C with a light/dark cycle of 16 h/8 h and a relative humidity 20-
40%. 
Brassica juncea plants were grown from seeds in heat-sterilized soil and cultivated in a 
greenhouse with temperature between 30°C and 21°C, relative humidity of approximately 
32-50% and a 15 h/9 h light/dark cycle. 
3.2. Expression of PVX CVPs in N. benthamiana 
N. benthamiana plants were inoculated with the different pPVXSma constructs or with 
pPVX201 as described previously (Marusic et al., 2001). To verify the genomic stability 
and infectivity of virus particles that cause systemic infection, repeated cycles of re-
infection were performed using leaf sap, prepared by homogenizing infected tissue in 1X 
PBS pH 7.2 (3 g/l Na2HPO4·12H2O, 0.256 g/l NaH2PO4·H2O, 8.8 g/l NaCl) and 
centrifuging the sample for 3 min at 20 000 g and 4°C. The supernatant was used directly 
to infect the plants. Briefly, sap obtained from symptomatic systemic leaves of the plants 
inoculated with the construct of interest (#1) was used to inoculate a second group of plants 
(#2). Afterwards, a third group of plants (#3) was infected by using the sap of the 
symptomatic systemic leaves from #2 plants. 
3.3. Expression of CPMV eVLPs in N. benthamiana 
For CPMV eVLPs expression, pEAQ-HT-24K and pEAQ-HT-VP60 vectors were 
transformed into A. tumefaciens LBA4404 strain. Bacterial cultures carrying the two 
vectors were grown separately to stable phase in LB medium supplemented with the 
appropriate antibiotics and then pelleted by centrifugation at 4 000 g and resuspended in 
MMA (10 mM MES, pH 5.6, 10 mM MgCl2, 100 mM acetosyringone) to an OD600 of 0.8. 
After 1- to 4-h incubation at room temperature, equal volumes of the two bacterial 
suspensions were mixed and used for syringe infiltration of 4-5 weeks-old N. benthamiana 
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leaves; 4 expanded leaves were infiltrated in each plant. Infiltrated leaves were sampled 6 
days post infection (dpi). 
3.4. Expression of TBSV CVPs in N. benthamiana 
The expression of TBSV CVPs in N. benthamiana has been conduced as reported 
in Grasso et al. 2013.  
3.5. Expression of TuMV in N. benthamiana and B. juncea 
The expression of TuMV CVPs in N. benthamiana and the following propagation of them 
in B. juncea have been conduced as reported in Sánchez et al. (2013). 
 
4. Biochemical materials and methods 
4.1. Protein extraction from leaf material 
Leaf samples were ground to fine powder with liquid nitrogen, homogenized in extraction 
buffer supplemented with Protease Inhibitor Cocktail (cOmplete TM EDTA-free Protease 
Inhibitor-Roche) and then centrifuged at 13 000 g	for 20 minutes at 4°C. The selected ratio 
between plant tissue weight (g) and buffer volume (ml) was 1:3. Supernatant was collected 
and conserved at -80°C for further analyses. Buffers used for protein extraction are listed 
below. 
• Sodium phosphate buffer 0.1 M pH 7.0 
- Solution A: 0.1 M NaH2PO4 
- Solution B: 0.1 M di Na2HPO4.  
Final solution at pH 7.0 was obtained by mixing 39 ml of solution A and 61 ml of solution 
B. This buffer was used for protein extraction from N. benthamiana leaves expressing 
CPMV eVLPs. 
• Boric acid 0.5 M pH 7.8. 
	                                                           MATERIAL AND METHODS 
	46 
This buffer was used for protein extraction from N. benthamiana leaves expressing PVX 
CVPs. 
4.2. SDS-PAGE 
For SDS-PAGE, protein samples were supplemented with 0.5 volume of R buffer (0.1 M 
Tris-HCl, 3% SDS, 1% w/v Bromophenol blue, 15% glycerol, pH 6.8) and boiled for 10 
minutes. Samples were loaded on gel with different percentage of polyacrylamide: 
- 12% for protein extracts of plant leaves expressing CPMV eVLPs; 
- 14% for protein extracts of plant leaves expressing PVX CVPs and TuMV CVPs. 
For the TBSV CVPs samples were supplemented with 0.5 volume of R buffer (for 10 ml: 
3 ml 0.1 M Tris-HCl 0.5 M pH 6.8, 2.4 ml glycerol 100%, 1.6 ml SDS 10%, 1 ml 
Bromophenol blue in TE, 300 µl EDTA, 1.7 ml H2O; every 160 µl add 10 µl of 2- 
mercaptoethanol). The sample were treated as follow: 3 minutes room temperature, mixed 
with vortex, 1 minute at 60 °C, mixed with vortex, 1 minute room temperature and stored 
in ice. 
Running buffer used for electrophoresis was Tris-glycine 1X pH 8.3 (3 g/l Tris-base, 18.8 
g/l glycine) supplemented with 0.1% SDS. The electrophoresis was performed at room 
temperature, applying a constant voltage of 150V to the gel for approximately 1 hour. 
4.2.1. Gel Coomassie staining 
After electrophoresis, gel was washed with water and stained by heating it in the presence 
of Coomassie staining solution A in a microwave oven for about two minutes, until boiling 
point. After that, it was cooled down at room temperature and gentle shaken. Solution A 
was discarded and gel was distained by subsequent heating and cooling in the presence of 
solution B, C and D, following the same protocol described for staining solution A. The 
compositions of the solutions are following described. 
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•  Staining solution A 
 
 
 
 
 
• Distaining solution B 
 
 
 
 
• Distaining solution C 
 
 
 
 
• Distaining solution D: acetic acid 10% 
4.2.2. Gel Silver staining 
For silver staining of gels, after electrophoresis the procedure described in Mortz et al. 
(2001) was applied. 
 
4.3. Western blot analysis 
• Tris-glycine 5X pH 8.3: 15.1 g/l Tris-base, 94 g/l glycine. 
• Blotting buffer: 1X Tris-glycine pH 8.3, 20% methanol.  
Component Concentration 
Coomassie R-250 0.05% 
Isopropanol 25% 
Acid acid 10% 
Component Concentration 
Coomassie R-250 0.05% 
Isopropanol 25% 
Component Concentration 
Coomassie R-250 0.002% 
Acetic acid 10% 
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• PBS 10X pH 7.4: 80 g/l NaCl, 2 g/l KCl, 14.4 g/l Na2HPO4, 2.4 g/l KH2PO4. 
• Blocking solution: 1X PBS pH 7.4, 4% powder milk, 0.05% Tween-20. 
• Washing solution: 1X PBS pH 7.4, 0.1% Tween-20. 
After electrophoresis, proteins were transferred to a nitrocellulose membrane by 
electroblotting in the presence of blotting buffer. To decrease non specific antibody 
binding, membrane was incubated in blocking solution for 1 hour at room temperature. 
Different detection antibodies and protocol were employed for the different kinds of 
sample analyzed, as following described. 
- For the detection of CPMV coat proteins, the same protocol described for 
GAD65-containing samples was used, but membrane was probed with a primary 
polyclonal antibody (G49) specific to CPMV particles (Saunders et al., 2009) 
used at a concentration of 1:2 000. 
- For the detection of PVX coat protein, an alkaline phosphatase conjugated anti-
PVX antibody (Agdia, PSA10000/0288) was used. It was diluted 1:200 in 1X 
PBS and the membrane was incubated for 2 hours at room temperature. The 
detection was performed with the NBT/BCIP System. NBT (Sigma-Aldrich, 
N6659) and BCIP (Sigma-Aldrich, B1026) were prepared according to 
manufacturer’s information and the procedure provided by the company was used 
for signal detection. 
 
4.4. CVPs and eVLPs purification 
4.4.1. PVX CVPs purification from leaf material 
For large scale purification of PVX particles, approximately 50 g of symptomatic N. 
benthamiana leaves were used. The process was carried out as described in Uhde et al. 
(2004). 
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4.4.2. CPMV eVLPs purification from leaf material 
4.4.2.1. PEG 6000 precipitation 
Large scale CPMV eVLPS purification was carried out starting from 15-20 g of N. 
benthamiana infiltrated leaf material. Leaf tissue was homogenized with 3 volumes (i.e. 3 
ml of buffer for 1 g of tissue) of 0.1 M Sodium phosphate buffer, pH 7.0 using a blender. 
Polyvinyl-polypyrrolidone (PVPP) was added to the buffer to a final concentration of 2%. 
Homogenate was squeezed through three layers of muslin cloth and spin at 30 000 g for 
60 minutes at 4 ⁰C to remove cell debris. To the supernatant, polyethylene glycol 6 000 
(PEG 6000) to a final concentration of 4% and NaCl to 0.2 M were added. Sample was 
stirred o/n at 4 ⁰C to precipitate the virus particles. Then it was spinned at 13 000 g for 20 
minutes at 4 ⁰C to pellet the PEG precipitate. The pellet was dissolved in 0.01 M sodium 
phosphate buffer, pH 7 (0.5 ml/g leaf tissue) and resuspended thoroughly by vortexing. 
Sample was spinned at 27 000 g for 20 minutes at 4 ⁰C. The supernatant was transferred 
to ultracentrifuge tubes and spin at 118 700 g for 150 minutes at 4 ⁰C in an ultracentrifuge. 
The pellet was resuspended in 200 µl of 0.01 M phosphate buffer o/n at 4°C. The day after, 
the sample was spinned again at 10 000 g for 15 minutes on a bench-top centrifuge to 
remove aggregates and remaining plant contaminants. The supernatant containing purified 
CPMV eVLPs was conserved at 4°C. 
4.4.2.2. Protocol based on anion-exchange and size exclusion 
chromatography 
Large scale CPMV eVLPS purification was carried out starting from 15-20 g of N. 
benthamiana infiltrated leaf material. Leaf tissue was homogenized with 3 volumes (i.e. 3 
ml of buffer for 1 g of tissue) of 0.1 M Sodium phosphate buffer, pH 7.0 using a blender. 
Polyvinyl-polypyrrolidone (PVPP) was added to the buffer to a final concentration of 2%. 
Homogenate was squeezed through three layers of muslin cloth and spin at 30 000 g for 
60 minutes at 4 ⁰C to remove cell debris. The DEAE SephadexTM A-50 (GE Healthcare) 
(regenerated in sodium phosphate buffer 0.1 M pH 7, 0.02% Tween 20) were used in 
sample:resin ratio 1:4, the flow through was concentrated to 4-5 ml and loaded of size 
exclusion chromatography. For the size exclusion chromatography HiPrepTM 16/60 
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Sephacryl S-500 HR was used with a flow rate of 0.9 ml/min. This column has a resolution 
of 4 x 104- 2 x 107. 
4.4.2.3. Protocol based of double sucrose cushion and Nycodenz gradient 
Large scale CPMV eVLPS purification was carried out starting from 15-20 g of N. 
benthamiana infiltrated leaf material following the procedure reported in Peyret et al. 
(2015). 
4.5. CVPs and eVLPs characterization  
4.5.1. Dynamic Light Scattering (DLS) 
The DLS analyzing the Brownian motion of the particles present in solution, allows to 
analyze the CPMV eVLPs conformation to gain their diameter. 
The sample was centrifuged at 10 000 rcf for 10 minutes in order to eliminate aggregated 
particles. The sample must to be at the concentration 0.4-0.5 mg/ml. 3 measurements was 
done and each measurement was the results of the mean of 12 repetitions. 
4.5.2. Limulus Amebocyte Lysate-test (LAL-test) 
LAL-test was conducetd following the product sheet instruction (International Pbi s.p.a.). 
the acceptable limits of endotoxins for injectable is 0.25 UE/ml. 
4.6. ELISA test 
Indirect ELISA for the set up of diagnostic kits were done following the procedure reported 
in Tinazzi et al. (2015). 
 
5. Human Cell Culture 
5.1. SH-SY5Y neuroblastoma cells 
SH-SY5Y (ATCC® CRL-2266TM) were propagated and subculture as reported in the 
product sheet and the Cell culture guideline (abcam ®). 
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The compositions of the DMEM culture medium are following described. 
Component Concentration 
Non essential aminoacids 1% 
Glu-T 1% 
Penicillin-streptomycin 1% 
FBS 15% 
 
6. Animal models 
6.1.  NOD mice 
NOD mice are the animal model of T1D. The characteristics of this animal models are 
reported in Kachapati et al., 2012. 
The treatments were done as reported in the following scheme. 
 
 
6.2. DBA-1/CIA mice 
DBA-1 (Dilute Brown Non-Agouti) mice are immunized with type II collagen (CII) as 
reported in Bran et al. 2007 in order to obtained CIA (collagen-induced arthritis) mice, the 
animal model of RA. 
CII immunization and treatment were done as reported in the following schema. 
0 2 4 5 10
Sacrifice for	
hystopathological
analysis
Treatment
24
End	of	experiment
and	sacrifice
days
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7. T1D cytokines analysis 
The cytokines analysis was conducted using the Luminex xMAP technology Bio-Plex 
Pro™ Mouse Cytokine 23-plex following the product sheet instruction. 
 
8. RA cytokines analysis 
To quantify cytokines from mouse joints, tissues were pulverized, resuspended in 1 ml of 
lysis medium/100 mg of joint weight for 60 min at 37°C, and centrifuged. To assess 
cytokine production from lymph nodes, these were removed, homogenized, and 
centrifuged. Supernatant fluids from joints and lymph nodes were sterilized through a 
Millipore filter (0.45 µm pore size) and stored at -80°C until analysis. TNF-α, IL-17A, IL-
1β, IFN-γ, TGF-β1, and IL-10 concentrations were determined in serum and supernatant 
fluids from joints and lymph nodes by using commercial ELISA kits (eBioscience) 
according to manufacturer’s recommended.
Sacrifice 
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CHAPTER 1: THERAPY 
INTRODUCTION 
1. Immunological tolerance and autoimmune disease 
The immune system is a network of cellular, chemical, and soluble protein components 
that interact with each other in a sequential and regulated manner and are charged with 
protecting the body against foreign substances. Foreign or self-molecules that evoke a 
specific immune response are referred as antigens. The immune system components are 
located throughout the body, either inside specific organs (e.g. spleen and thymus) or as 
accumulations of lymphoid and myeloid cells placed in strategic sites (e.g. associated with 
the skin and gut) to monitor the entry of foreign substances.  
The distinction between self and non-self occurs through complex mechanisms depending 
either on non-specific effectors that act as first line of defence against pathogens (e.g. 
macrophages, natural killer cells and polymorphonuclear leukocytes and cytokines) or on 
specific recognition molecules present on the surface of T and B lymphocytes (Smith et 
Germolec, 1999). 
Despite the fact that lymphocytes with the ability to recognise self antigens are constantly 
being generated during the normal process of lymphocyte maturation, there are a complex 
series of mechanisms, generally referred as immunological tolerance, that impair the 
immune system to mount responses against self antigens.  
In particular, immunological tolerance is the failure of a lymphocyte clone to respond to 
an antigen, due to a prior exposure to the same antigen.  
Tolerance can occur by two main mechanisms named central or peripheral tolerance. 
central tolerance occurs when immature lymphocytes encounter the antigen in the primary 
lymphocytes organ, and consequently they die or become unreactive. 
The peripheral tolerance occurs when mature lymphocytes, escape from negative selection 
during ontogeny, encounter the antigen in peripheral or secondary lymphoid tissues and 
undergo to one of the following mechanism to prevent self-response: 
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1) clonal deletion, which requires the physical elimination of autoreactive 
lymphocytes; 
2) clonal anergy, which requires the functional elimination of autoreactive 
lymphocytes via downregulation of responsiveness; 
3) suppression or inhibition of autoreactive lymphocyte via interaction with other 
cell type or cytotoxic T lymphocytes of Natural Killer cells. 
 
Finally, a heterogeneous family of T regulatory cells (Tregs) have been discovered to play 
an important role in suppressing immune responses against self. 
The breakdown in the network of this mechanism results in an immune response against 
self-molecules leading to the establishment of an autoimmune disease (Romagnani, 2006).  
Autoimmune diseases (AD) are a spectrum of diseases ranging from organ specific to 
systemic. In organ specific, antibodies and T cells react to self-antigens in a define tissue 
(e.g. Hashimoto thyroiditis and type 1 diabetes), whereas systemic AD are characterized 
by reactivity against a specific antigen spread throughout various tissues in the body (e.g. 
systemic lupus erythematosus and rheumatoid arthritis). 
The American Autoimmune Related Diseases Association reported the identification of 
80-100 different autoimmune diseases with annual direct health care costs in the range of 
$ 100 billion. 
Direct costs are costs paid to health service by patients and insurance companies. 
Epidemiological studies have indicated ADs to be the 10th most common cause of 
mortality in developing countries. The incidence is estimated to be around 10% (Cooper 
et al., 2009). 
 
2. Current strategies and ongoing studies for the treatment of 
autoimmune diseases 
The current AD therapeutic approach can be categorized into two groups: the symptomatic 
or replacement therapy (conservative approach) and the immunosuppressive therapy 
(aggressive therapy).  
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T1D could be an example of disease managed by replacing the hormone insulin once 
pancreatic β-cells are damaged. However, this kind of therapy could only stem the disease 
effect without preventing the organ damage. Moreover, the replacement therapy must be 
adopted all life long with consequent side-effects and high-costs associated. 
Furthermore, the symptomatic therapy is often associated to the immunosuppressive one. 
For example, in RA the symptoms are treated with non-steroidal anti-inflammatory drug 
(NSAIDS) associated with corticosteroid hormones (and other immunosuppresor).  
The immunosuppressive therapy is used for dampen the immune response to prevent 
further organ damage and considering that is highly effective for many patients remain the 
current “gold standard” of care.  
The response to immunosuppression in AD is initially in 60-70% of the cases, and 
subsequently the disease may progress or stop responding to the drug used. 
On the other hand, the use of immunosuppressive agents causes several side-effects. 
Indeed, long-term treatments with high doses are often needed to maintain diseases control, 
leaving the patient susceptible to life-threatening opportunistic infections and long-term 
risk malignancy. 
Considering that immunosuppressive drugs are non-specific, they interfere in non-target 
pathways and cells. Moreover, some of the ADs may go for clinical remission to relapse 
sometime (van der Kooij et al., 2007).  
In recent years, more experimental studies were focused on the development of new 
target-specific drugs that decrease the risk of systemic immune suppression and improve 
tolerability. 
In particular, the optimal ADs therapy should fit these four goals:  
- specifically target the pathogenic cells leaving the rest of the immune system 
unaltered; 
- reestablished immune tolerance that is stable over time; 
- have low toxicity and few side effects 
- its associated costs low when compared to alternative approach. 
In literature there are many examples of ongoing studies aimed to the development of 
biological molecules that could meet the abovementioned criteria.  
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One of the most promising one is the costimulatory blockade. This approach is based on 
the evidence that the achievement of a total T cells activation requires two signals: the first 
is the antigen recognized by T-cell receptor (TCR) and the second is a costimulatory signal 
provided by the cell presenting the antigen (APC); without the second signal the T cell 
become suboptimally stimulated, resulting unresponsive in a state of anergy (Mueller et 
al., 2010). On the basis of this, the greatest success up to now is the development of a 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin (Ig) which is 
able to prevent costimulation by interacting with the costimulatory receptor CD28 on T 
cells. Treatment with CTLA-4-Ig results to be effective in RA (Maxwell et al., 2010; 
Mease et al., 2011).  
However, despite monthly administration of this drug over 24 months the beneficial effects 
were observed only within the first 6 months of therapy (Orban et al., 2011). Moreover, 
blocking the costimulation may be unable to suppress the pathogenicity of T cells and for 
this reason this approach could be better exploited in the prevention of the disease. 
Furthermore, this approach is not target-specific for autoreactive T cells and can cause 
patient susceptibility to pathogens. Finally, this approach does not induce self-tolerance 
and needs continuous treatments. 
Another strategy relies on the exploitation of the potential of regulatory T cell (Tregs). 
Tregs are a subset of CD4+ T cells that express high levels of the IL-2 receptor α chain CD25 
and the transcription factor FoxP3. It has been broadly demonstrated that Tregs play a central 
role in suppressing auto-immunity (Sakaguchi et al., 2010). The strategy consists in the 
isolation of Tregs cell, activation and expansion ex-vivo to high number, and adoptively 
transfer of them to AD patient in an attempt to suppress the ongoing autoimmune response. 
Unfortunately, this strategy is highly hampered by the inability to isolate an appropriate 
pure Tregs and the suppression function of this cell may not be stable over time (Roncarolo 
et al., 2006). 
Another approach that has been explored is the manipulation of the IL-2 pathway. This 
interleukin is a T cell growth factor with opposing role in the immune system. On one 
hand, IL-2 triggers the immune response by promoting the proliferation and generation of 
effector T cell. On the other hand, IL-2 can promote the survival and function of Treg 
suppressing the immune response. It has been demonstrated that the use of a particular 
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cytokine/anti-cytokine complex built up by recombinant-IL-2 bound to anti-IL-2 antibody 
preferentially enhances Treg numbers (Boyman et al., 2006). A similar strategy with IL-2 
noncomplex (without the anti-IL-2 antobody) has also been attempted and demonstrated 
to be successful (Koreth et al., 2011). However, as the previous strategies described, also 
the manipulation of IL-2 pathway leads to a non-specific immune system suppression that 
results in important side effects. 
 
3. Antigen-specific immunotherapy (ASI) 
The antigen-specific immunotherapy (ASI) meets on the major goal for the treatment of 
autoimmune disease, which is acting upon the relevant autoimmune response without 
inducing a state of generalized immunosuppression. 
ASI consists in the delivery of autoantigenic protein or specific immunodominat peptides 
derived from them, administrated at different disease stages via a variety of routes 
(Peakmen et von Herrath, 2010). 
It was noted, several decades ago, that the administration of autoantigenic proteins or 
peptides derived from them could inhibit the subsequent immune response against the same 
antigen. The effect of the treatment with autoantigens has been widely explored in antigen-
induced and spontaneous animal models and it has been demonstrated that this strategy 
resulted in protection from disease (Myers et al., 1989; Gaur at al., 1992; Mukasa et al., 
1992; Sasamoto et al., 1992; Fuller et al., 1993).  
The immune response obtained with ASI strongly depends on the molecule chosen for 
immunization, the dose, the frequency, and route of administration but also on the precise 
context, in which the use of suitable adjuvants and inflammation can profoundly influence 
the resulting immune response (Peakman et von Herrath, 2010). 
The administration of autoantigens seems to act through two different mechanisms; indeed, 
recent full genome transcriptional analysis of T cells exposed to a dose escalation of 
peptide suggests that ASI shifts T cells towards production of IL-10, a regulatory cytokine 
(Burton et al., 2014); while a single dose of ASI can drive T cells to apoptosis (Konkel et 
al., 2014). 
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As mentioned in the introduction, peptides derived from autoantigens have attracted 
attentions as potential ASI agents. Peptides offer several advantages over whole protein, 
being the smaller functional part of the protein, they ensure greater efficacy, selectivity and 
specificity than antigenic protein. Moreover, they minimized drug-drug interaction 
because peptide degradation products are aminoacids that are not toxic.   
 
ASI can be applied at different disease stages:  
- before the development of autoimmunity in at-risk subjects (primary prevention) 
or when autoimmunity is present but not disease (secondary prevention), to 
suppress the response and prevent the development of autoimmune disease 
blocking the organ damage; 
- after diagnosis when the autoimmune disease is established (tertiary prevention 
or intervention) to prevent complications. 
 
This thesis is focused on the development of immunodominat peptide-ASI for the therapy 
of T1D and RA. 
In particular, in order to stabilize and cost-effectively produce the peptide of interest, 
expression systems based on plant viruses are exploited. Plant viruses are used for the 
display of several copies of selected immunodominant peptide associated either to T1D or 
RA. In this approach, the viral structure not only acts as scaffold in order to increase 
peptide stabilization but works as an adjuvant able to boost the regulative immune response 
enhanced by the peptide displayed on viral surface. 
Finally, two different therapeutic approaches were chosen for T1D and RA. Regarding 
T1D pre-clinical studies treatments of NOD mice were done before the onset of the disease 
in order to find a preventive therapy.  
On the other hand, for the RA pre-clinical studies, the disease was induced in DBA mice 
by two immunizations with type II collagens and 7 therapeutic treatments were started at 
the arthritis onset in order to find a potential RA cure. 
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RESULTS AND DISCUSSION 
TYPE 1 DIABETES PREVENTION 
 
1. Experimental design 
Non-obese diabetic (NOD) mice spontaneously develop autoimmune diabetes with clinical 
manifestations and a disease pattern comparable with those of human T1D, including 
lymphocytic infiltration of the islet of Langherhans (insulitis). Consequently, NOD mice 
became the elite animal model for studying human T1D (Saï et al., 1996). 
The major autoantigens associated to T1D are the 65 kDa human isoform of glutamate 
decarboxylase (GAD65), the heat shock protein 60 (HSP60), the zinc transporter 8 (ZnT8), 
the insulinoma associated antigen 2 (IA-2c) and insulin (Ins). 
   Graph 1 T1D autoantigens tested in pre-clinical studies 
 
Studies over the past 35 years on NOD mice showed that a number of T1D autoantigen-
derived peptides can prevent or even reverse T1D (Elias et Cohen, 1995; Tian et al., 1996; 
Daniel et Wegmann 1996; Tisch et al., 1999; Ogino et al., 2000; Quinn et al., 2001; 
Martinez et al., 2003; Carter et al., 2006; Lie et al., 2009; Chen et al., 2009; Gong et, 2010; 
Lianget et al., 2010; Arai et al., 2010) when are used alone or together with other peptides. 
Among the autoantigens associated to T1D, peptides derived from GAD65 are the most 
widely used in pre-clinical studies for immulogical tolerance induction.  
   Graph 2 GAD65 derived immunodominant peptide 
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Dose and administration route are crucial parameters to be considered in the set up of a 
pre-clinical study in animal models. In table 1, the details of pre-clinical studies for 
prevention or suppression of T1D done with peptides derived from GAD65 showed in 
graph 2 are summarized. 
In a previous PhD thesis (Merlin, 2013) the GAD65-derived peptides p217, p290 and p524, 
the insulin and pro-insulin derived peptides InsB9 and L7 and the HSP60 derived 
DiaPep277 were selected for their expression in N. benthamiana plants using the PVX 
CVPs system. None of them was successfully expressed either because of the 
incompatibility between the selected peptide and the PVX replication and/or assembly or 
the instability of the peptide sequence on the viral surface. 
In order to avoid the abovementioned issues, the CPMV eVLP system was tested for the 
expression of p217, p290, InsB9, L7 and DiaPep277 peptides but even with this platform 
none of them was expressed.  
Vectors used in this part of the work were kindly provided by Professor George P. 
Lomonossoff from the Department of Biological Chemistry of the John Innes Centre, 
(Norwich, UK).  
None of the selected peptides was successfully express with the CPMV eVLPs based 
system. Different results were reached with the p524 peptide which was correctly express 
on the surface of CPMV eVLPs. 
eVLPs are produced only in infiltrated tissues and cannot spread systemically because 
they lack viral genome. This can be considered an additional advantage in terms of bio-
containment, because eVLPs preparation do not retain the ability to infect plants 
(Montague et al., 2011). 
After cloning the p524 peptide sequence in the expression vector pEAQ-HT-VP60, a small 
scale agroinfection of 1-2 N. benthamiana plant (4 leaves/plants) was carried on to check 
the expression of CPMV eVLPs displaying p524 peptide (CPMV eVLPs.p524). 
The unmodified CPMV eVLPs (i.e. lacking heterologous peptides on their surface) were 
expressed and purified following the same procedure of the CPMV eVLPs.p524, in order 
to be used as negative controls in animal model studies. 
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After purification and characterization to confirm the correct assembly and shape, the 
capability of the CPMV eVLPs.p524 (and the unmodified CPMV eVLPs) in induction of 
immunological tolerance in autoimmune diabetes was in vivo tested in NOD mice.  
In particular, mice treatments were scheduled at 4 weeks of age in order to precede the 
onset of insulitis and to assess the preventive effect of the CPMV eVLPs.p524 in the 
development of the disease. 
Dose, administration route and timing are crucial parameters to be considered in the set up 
of a pre-clinical study in animal model. In table 1, the details of pre-clinical studies for the 
prevention or the suppression of T1D done with peptides derived from GAD65 showed in 
graph 2 are summarized. 
The intra-peritoneal administration route was chosen and, on the basis of  evidences present 
in literature and reported in table 1, a dose of 50 µg of CPMV eVLPs.p524 without any 
adjuvant was used per each injection. In the immunological tolerance induction study, the 
use of an adjuvant (e.g. Incomplete Freund Adjuvant, IFA) is usually adopted mixed to an 
immunodominat peptide in order to boost the immune response; it has been demonstrated 
that the use of a viral structure as a scaffold for peptide display can boost the immune 
system without the need of any other agents (Lico et al., 2012). 
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Table 1: T1D studies done with GAD65 derived immunodominant peptides. 
Peptide Prevention	(P) Suppression	(S) Studies Administration Dose Note Ref
p217
Yes
Yes
co-administered
with	p290
P (in	vivo	trials):	4	weeks	old female NOD
mice;	 					
S (in	vivo	trials):	12	weeks	old female NOD	
mice.
Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA;
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA
- Tisch	et	al.,	1999
- Yes S (in	vivo	trials):	12	weeks	old female NOD	mice Intravenous
1	injection a	day for	3	days with	50	
μg of	p217-sMHCII-Ig	(correspondig
to	~1.1	μg of	peptide)	in	200	μl of	
PBS	without IFA.	After 3	weeks	
repetition of	the	same treatment.
Peptide	fused to	
sMHCII-Ig
Li	et	al.,	2009;	
Arnold	et	al.,	2002
p247
Yes
co-administered with	
p524
No
co-administer
with	p524	
P (in	vivo	trials):	4	weeks	old female NOD	
mice;	 							
S (in	vivo	trials): 12	weeks	old female NOD	
mice.
Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA;	
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA.
p247-265 Tisch	et	al.,	1999
Yes
co-administered with	
p509	and	p524
- P (in	vivo	trials):	2-3	weeks	old femaleNOD	mice	 Intranasal
Single	dose	of	a	mix	of	50	μg of	each
peptide	in	50	μl of	PBS	without IFA. p247-266 Tian	et	al.,	1996
p290
Yes
No
administered alone;														
Yes
co-administered with	
p217
P (in vivo	trials):	4	weeks	old female NOD	
mice;	 							S (in	vivo	trials):	12	weeks	old
female NOD	mice.
Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA ;	
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA.
Peptide	fused to	
sMHCII-Ig Tisch	et	al.,	1999
- Yes S (in	vivo	trials):	12	weeks	old female NOD	mice. Intravenous
1	injection a	day for	3	days with	50	
μg of	p290-sMHCII-Ig	(correspondig
to	~1.1	μg of	peptide)	in	200	μl of	
PBS	without IFA. After 3	weeks	
repetition of	the	same treatment.
- Li	et	al.,	2009;	Arnold	et	al.,	2002
p316
Yes
co-administered with	
p531
- P (in	vivo	trials):	4	weeks	old female NOD	mice Intravenous
1	injection	wuth	50	μg		of	each	
peptide	in	RPMI	1640 - Ogino	et	al.,	2000
p509
Yes
co-administered
with	p247	and	p524
- P (in	vivo	trials):	2-3	weeks	old femaleNOD	mice Intranasal
Single	dose	of	a	mix	of	50	μg of	each
peptide	in	50	μl of	PBS	without IFA. - Tian	et	al.,	1996
Yes No P (in	vitro	trials):	expansion of	CD4+CD25+Foxp3+	T	lymphocyte Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA;	
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA.
- Chen	et	al.,	2009
Yes -
P (in	vitro	trials):		proliferation test	of	T	
lymphocytes derived from	rAAV/GAD500-
585	treated mice
- - Han	et	al.,	2005
p524
Yes Yes
P (in vitro trials): expansion of	
CD4+CD25+Foxp3+	T lymphocyte;                                                                 
S (in vivo test): Adoptive transfer in 4-8 
weeks old NOD.scid mice
Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA;	
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA
- Chen	et	al.,	2009
Yes
co-administered with	
p247	and	p509
- P (in	vivo	trials):	2-3	weeks	old femaleNOD	mice Intranasal
Single	dose	of	a	mix	of	50	μg of	each
peptide	in	50	μl of	PBS	without IFA. - Tian	et	al.,	1996
Yes
co-administered with	
p247
No
co-administered
with	p247
P (in	vivo	trials):	4	weeks	old female NOD	
mice;	 							S (in	vivo	trials):	12	weeks	old
female NOD	mice.
Intra-peritoneal
P:	2	injection (2	weeks	a	part)	of	50	
μg of	peptide	mixed with	0.05	ml	of	
IFA;	
S:	3	injection (every 7-10	days)	of	200	
μg of	peptide	mixed 0.10	ml	of	IFA.
- Tisch	et	al.,	1999
p531
Yes No P (in	vitro	trials):	expansion of	CD4+CD25+Foxp3+	T	lymphocyte - p530-543 Chen	et	al.,	2009
Yes
co-administered with	
p316
- P (in	vivo	trials):	4	weeks	old female NOD	mice Intravenous
1	injection	wuth	50	μg		of	each	
peptide	in	RPMI	1640 p532-543 Ogino	et	al.,	2000
Yes -
P (in	vivo	trials):	5	weeks	old femalemice	
(peptide	administration up	to	10	or	35	
weeks)
Direct	administration	
into	esophgus/gut
1	injection	of	20	μg		of	recombinat	
protein	every	other	day	for	5	
(insulite	analysis)	or	30	(desease	
incidence	study)	weeks.
Fusion	protein	
between	cholera	
toxin	B	subunit	
and	p531-545	
peptide	triple	
tandem	(CTB-
GAD(531-545)3)	;	
conjugated	CTB		
works	as	carrier	
and	adjuvant
Gong	et	al.,	2009
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2. Cloning of GAD65 derived peptide p524 
 
As mentioned in the introduction, to be expressed with the system based on CPMV peptide 
should meet the criteria reported in the Cowpea Mosaic Virus (CPMV) section on page 15. 
Because of that, the p524 amminoacidic sequence was optimized (table 2) by the addition 
of one acid aminoacid at the peptide N-terminus and two at the C-terminous in order to 
decrease the peptide pI that is too high for the expression with this platform. 
Table 2 Optimization of GAD65 p524 peptides for its expression with CPMV eVLPs system 
Aminoacids sequence SRLSKVAPVIKARMM 
Nucleotidic sequence TCT CGT CTT TCT AAG GTT GCT CCT GTT ATT AAG GCT 
AGA ATG ATG 
Peptide length 
(aminoacids) 
pI 
15 12.02 
Optimazed aminoacids 
sequence 
DSRLSKVAPVIKARMMED 
Optimazed nucleotidic 
sequence 
GAT TCT CGT CTT TCT AAG GTT GCT CCT GTT ATT AAG 
GCT AGA ATG ATG GAA GAT 
Peptide length 
(aminoacids) 
pI 
18 8.59 
 
For the expression with the CPMV eVLPs system the nucleotidic optimized sequence 
encoding for the p524 peptide was cloned in the pEAQ-HT-VP60 vector within the 
sequence of the S CP located into the VP60 precursor sequence. 
Oligonucleotide pairs were designed to obtain NheI-compatible 5’- and AatII-compatible 
3’-end DNA fragments that were ligated into the NheI-AatII-digested vector. 
After ligation of the DNA fragments encoding p524 peptide into pEAQ-HT-VP60 vector, 
the resulting pEAQ-HT-VP60.p524 plasmid was trasformated in E. coli DH5α strain 
competent cells by heat-shock. E. coli cells were plated on kanamycin containing medium 
(50 µg/ml) and PCR selected using vector-specific primers CPMV Seq-for and CPMV Seq 
rev, annealing respectively upstream and downstream of the insertion site. The length of 
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the amplification fragments obtained is 200 bp plus the length of the p524 inserted 
sequence, making a total of 254 bp. 
Results of the PCR analysis on the colonies growth on selection medium after 
transformation with pEAQ-HT-VP60.p524 vector are reported in figure 1. 
 
 
Figure 1 PCR analysis of E. coli colonies transformed with pEAQ-HT-VP60 vector 
after ligation with p524 oligonucleotide. PCR amplification products obtained with 
two vector-specific primers (CPMV Seq for – CPMV Seq rev) were loaded on a 2% 
agarose gel. M: molecular marker (Benchtop 100bp DNA ladder - Promega); 1-7: 
number of E. coli DH5α colonies tested; P: positive control (using pEAQ-HT-VP60 
vector as template); N: negative control. 
The PCR results showed that among the seven colonies tested six of them were presumably 
correctly transformed; indeed, the resulting bands correspond to an amplicon of 
approximately 254 bp as expected. As opposed, the colony number 4 shows a band 
corresponding to an amplicon of 200 bp comparable with that of positive control (P) 
obtained using as template the unmodified pEAQ-HT-VP60 vector. Positive bacterial 
colonies were propagated in selective broth and plasmids were extracted, PCR analysed 
and sequenced to assess that the insert was correct.  
Selected pEAQ-HT-VP60.p524 resulting suitable from the PCR and sequencing analysis 
was transformed in competent cells of A. tumefaciens LBA4404 strain by electroporation 
and plated on kanamycin (50 µg/ml), rifampicin (50 µg/ml) and streptomycin (100 µg/ml) 
containing medium. After three days at 28 °C incubation, colonies were PCR selected 
using vector-specific primers CPMV Seq-for and CPMV Seq rev to assess their effective 
transformation. Positive A. tumefaciens LBA4404 colonies were propagated in selective 
broth and used for the next expression step. 
RESULTS AND DISCUSSION               THERAPY 
	 65 
3. Analysis of the expression in plant of CPMV eVLPs displaying 
p524 
 
For the assessment of the in planta expression of CPMV eVLPs.p524 a small scale first 
trial was carried out. 
4 leaves of N. benthamiana were infiltrated with a mixed suspension of A. tumefaciens 
carrying pEAQ-HT-24K or pEAQ-HT-VP60.p524 plasmid.  
At the same time, 4 leaves of N. benthamiana were infiltrated with a mixed suspension of 
A. tumefaciens carrying pEAQ-HT-24K or pEAQ-HT-VP60 plasmid in order to express in 
plant unmodified CPMV eVLPs to be used as positive control. 
Finally, as negative control, 4 leaves of N. benthamiana were infiltrated with the 
infiltration buffer used for the resuspension of bacterial cells (MMA) 
The agroinfiltrated leaves sampled at 6 days post infection (dpi) did not showed viral 
symptoms, as expected. 
Indeed, CPMV eVLPs systems leads to the expression of empty viral particles that being 
deprived of the viral genome are not infective and therefore cannot cause viral symptoms 
as reported in figure 2. 
 
Figure 2 N. benthamiana leaf agroinfiltrated for the expression of CPMV 
eVLPs.p524 (D) and unmodified CPMV eVLPs (C) in comparison with a control 
leaf infiltrated only with infiltration buffer (B), wild type non infiltrated leaf (A) and 
Vigna unguiculata leaf with typical CPMV symptoms (E). 
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Total soluble proteins (TSP) were extracted from infiltrated leaves and analysed by 
western blot, using a polyclonal antibody (G49) specific to CPMV particles for the 
detection of specific signals. Results of this analysis are reported in figure3.  
 
Figure 3. SDS-PAGE, western blot analysis (A) and Commassie staining (B) of 
TSP extracted from agroinfiltrated leaves expressing CPMV eVLPs.p524 (1), 
unmodified CPMV eVLPs (2) and as a negative control protein extract from leaves 
infiltrated with infiltration buffer (3). Extracts were obtained using PBS buffer pH 
7.2 and loaded on 12% polyacrylamide gels then blot was probed with a polyclonal 
antibody (G49) specific to CPMV particles used at a concentration of 1:2000. The 
position of L and S coat proteins are indicated with the red arrows. Equal volumes 
of protein extracts were loaded for each sample: 10 µl for western blot analysis and 
6 µl for gel Commassie staining. 1: molecular marker (PageRuler™ Plus Prestained 
Protein Ladder, Thermo Scientific). 
 
In the gel stained with Commassie blue (figure 3-B) a signal corresponding to 35 kDa and 
two signals corresponding to 25-27 kDa are clearly visible in the lanes of extracts of leaves 
infiltrated for the expression of either CPMV eVLPs.p524 or unmodified CPMV eVLPs. 
Considering that these signals are not present in the lane corresponding to the negative 
control, they could be specific signal of the CPMV CPs.  The western blot analysis (figure 
3-A) highlight the presence of two specific bands in lane 1, but absent in the negative 
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control sample (lane 3). These two bands being in the position expected for the L and S 
CPMV CPs confirm the hypothesis and highlighted that the expression of CPMV 
eVLPs.p524 (1) appeared to be similar to that of unmodified eVLPs (2). The shift between 
the signals of the S CPs in this two samples indicates the presence of the fused peptide in 
CPMV eVLPs.p524 sample. 
 
4. Purification of CMPV eVLPs.p524 and unmodified CPMV 
eVLPs for T1D peptide display 
 
4.1. CPMV eVLPs.p524 
 
A large-scale infection of N. benthamiana plants was carried out, to obtain infected tissue 
for particle purification. 20-30 plants (4 leaves per plant) were agroinfiltrated with a mixed 
suspension of agrobacteria carrying pEAQ-HT-24K or pEAQ-HT-VP60.p524 vector. 
Agroinfiltrated leaves (~25-30 g) were sampled 6 dpi and used for CPMV eVLPs.p524 
purification. 
TSP were extracted and clarified through filtration and centrifugation in order to remove 
cellular debris. An anion-exchange chromatography using the DEAE SephadexTM A-50 
resin was performed in order to remove a large part of plant contaminant proteins present 
in the extract, first of all the Ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) 
that is one of the major contaminant. 
In particular, DEAE SephadexTM A-50 is a resin containing the positively charged group 
diethyl-aminoethyl groups that allows the absorption of protein with smaller pI than the 
pH of the extraction buffer (pH 7) which are therefore proteins negatively charged. 
The resin/sample ratio was optimized at ¼ and a NaCl gradient starting from 50 mM to 1 
M was used for the elutions. 
In figure 4 the results of the chromatography steps analysed by SDS-PAGE and 
Commassie staining are reported.  
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Figure 4 SDS-PAGE and Commassie staining on 12% polyacrylamide gel of 14 µl 
of the following samples: total protein extract (E), sample loaded on anion-exchange 
chromatography (clarified sample) (L), Flow through (FT), wash (W), elution steps 
(1-6) done with NaCl gradients from 50 mM to 1 M, 4 µg of purified unmodified 
CPMV eVLPs as positive control (P). The Rubisco’s subunit molecular weight (55 
kDa), the CPMV large and small coat proteins molecular weight (respectively 35 and 
25 kDa) are indicated. M: molecular marker (PageRuler™ Plus Prestained Protein 
Ladder, Thermo Scientific). 
The peptide p524 has a pI of 8.59 that makes the CPMV eVLPs.p524 positively-charged 
at pH 7 and therefore these particles do not interact with the chromatographic resin. 
Indeed, only in the sample corresponding to the flow through (lane FT, figure 4) are visible 
two bands attributable to CPMV eVLPs.p524 large and small coat proteins that are 
completely absent in the sample derived from elution steps (lane 1-6, figure 4).  
The FT (~ 120 ml) was concentrated 30 times (~4 ml) using a 100 kDa cut off Centricon® 
tube and, according with Alaa et al. (2013), injected into the HiPrepTM 16/60 SephacrylTM 
S-500 HR (Akta Prime plus) size exclusion chromatography column. 
The resulting chromatogram is characterized by six elution peaks (figura 5). 
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Figure 5 Elution chromatogram of the CPMV eVLPs.p524 purification process done 
through HiPrepTM 16/60 SephacrylTM S-500 HR (Akta Prime plus) size exclusion 
chromatography column. The A280 (mAu) and the elution volume (ml) are reported 
respectively on the y and x-axis. The arrows indicate the peak obtained from this analysis 
and in red the number of the collected fraction is indicated; the volume of the fraction from 
the number 1 to 67 is 1 ml, the following fractions are 5 ml. 
A sample (20 µl) of the central fraction of each peak was analysed by SDS-PAGE and 
silver staining in order to identify the CPMV eVLPs.p524 elution peak, the results of the 
size exclusion chromatography analysis are showed in the following figure 6. 
 
Figure 6 Elution chromatogram of the CPMV eVLPs.p524 purification process (A) in 
which the number of the selected fraction of each peak is reported. The A280 (mAu) and the 
elution volume (ml) are reported respectively on the y and x-axis. In panel B SDS-PAGE 
and silver staining of the selected fraction corresponding to the central one of each peak (3, 
34, 45, 56, 71 and 75) is shows. Thermo Scientific); 20 µl of each selected fractions were 
loaded on 12% polyacrylamide gel. P: 1.5 µg of unmodified purified CPMV eVLPs as 
positive control; L: 3µl of a dilution 1:10 of the protein extract leaded on size exclusion 
chromatography column. M: molecular marker (PageRuler™ Plus Prestained Protein 
Ladder); the expected molecular weight of the CPMV L and S CP are reported on the side 
of the gel. 
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In fraction 34 (figure 6) there are two bands corresponding to CPMV eVLPs L and S CPs 
expected sizes, therefore the peak containing the CPMV eVLPs.p524 particles is the 
number 2, corresponding to an elution volume from 65 to 80 ml. Considering that this 
region of the elution chromatogram it is not a well-define peak but there is a partial 
overlapping of peaks 2 and 3, samples from fractions of the peak 2 were analysed by SDS-
PAGE and silver staining in order to remove possible contaminated fractions.  
In the following figure 7 the results of peaks 2 fractions SDS-PAGE and silver staining 
analysis is reported. 
 
Figure 7 Elution chromatogram of the CPMV eVLPs.p524 purification process (A) 
in which the peak 2 is indicated with the red circles. In the panel B the SDS-PAGE 
and silver staining shows the analysis on the peak 2 fractions. 36-51: 20 µl of each 
fraction were loaded on 12% polyacrylamide gel; P: 1.5 µg of unmodified purified 
CPMV eVLPs as positive control; L: 3µl of a diluition 1:10 of the protein extract 
leaded on size exclusion chromatography column. M: molecular marker 
(PageRuler™ Plus Prestained Protein Ladder); the expected molecular weight of the 
CPMV L and S CP are reported on the side of the gel. 
 
The results show that all the fractions are pure, therefore they were mixed and 
concentrated 10 times (~0.4 ml) using a 100 kDa cut off Centricon® tube. 
Purified CPMV eVLPs.p524 were stored at -80 °C because there were some evidences of 
peptide loss when particles are stored at 4 °C after purification. In order to assess the 
M				P L					36					37				38				39					40	 41		 42 M	 43			 44					45				46				47		 48					49	 50					51
35	kDa
25	kDa
L	CP
S	CP
A
B C
RESULTS AND DISCUSSION               THERAPY 
	 71 
suitability of the storage method an aliquot of the sample was analysed after 6 days at -80 
°C.  
The result of the SDS-PAGE and silver staining of CPMV eVLPs.p524 purified and stored 
at -80°C for 6 days is showed in figure 8. 
 
Figure 8 SDS-PAGE and silver staining analysis on 12% polyacrylamide gel of the 
purified CPMV eVLPs.p524 stored 6 days at -80°C. After thawing, 1,5 µ of the 
CPMV eVLPs.p524 (p524) purified through gel filtration (figure 7) are loaded on 
the gel. P: 1.8 µg of unmodified purified CPMV eVLPs as positive control; M: 
molecular marker (PageRuler™ Plus Prestained Protein Ladder. The expected 
molecular weight of the CPMV L and S CP are reported on the side of the gel. 
The effective absence of proteolytic activity is confirmed as showed in figure 8. 
Indeed, the S CP of the CPMV eVLPs.p525 shows a higher molecular weight in 
comparison to that of the unmodified CPMV eVLPs used as positive control, confirming 
the presence of p524 peptide fused on the small coat protein. 
This analysis shows that the storage at -80 °C result to be a appropriate storage methods 
for CPMV eVLPs.p524. 
Finally, the CPMV eVLPs.p524 sample do not have contaminant protein and particles 
result to have a higher level of purity.  
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4.2. Unmodified CPMV eVLPs 
 
The procedure above-described was used also for the purification of unmodified CPMV 
eVLPs to be used afterwards as negative control in the tolerance induction studies in 
animal model. 
The same results of CPMV eVLPs.p524 were obtained for unmodified CPMV eVLPs in 
the anion-exchange chromatography step, confirming the presence of CPMV eVLPs 
particles in the flow through (data not shown). 
On the other hand, the size exclusion chromatography showed an elution pattern slightly 
different in comparison to that of particles displaying peptide p524. 
The elution chromatogram is reported in figure 9. 
 
Figure 9 Elution chromatogram of the unmodified CPMV eVLPs purification 
process done through HiPrepTM 16/60 SephacrylTM S-500 HR (Akta Prime plus) 
size exclusion chromatography column. The A280 (mAu) and the elution volume 
(ml) are reported respectively on the y and x-axis. The peak relative of the 
Unmodified CPMV eVLPs is indicated with the red circle and correspond to an 
elution volume from 65 to 80 ml. 
Differently from CPMV eVLPs.p524, a well define peak is clearly visible in the region 
corresponding to unmodified CPMV eVLPs elution volume (65-80 ml). In order to 
confirm the effective presence of the particles of interest in these peaks and for the 
assessment of the purity level of the sample, an aliquot (20 µl) of 7 random fractions which 
Unmodified CPMV	eVLPs	
elution region
mAu
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are part of the peaks were analysed by SDS-PAGE and silver staining. The results are 
reported in figure 10. 
 
Figure 10 SDS-PAGE and silver staining of the analysis of the unmodified CPMV 
elution peak. 20 µl of the selected fraction were loaded on 12% polyacrylamide gel; 
P: 1.5 µg of unmodified purified CPMV eVLPs as positive control; L: 3µl of a 
diluition 1:10 of the protein extract leaded on size exclusion chromatography 
column . M: molecular marker (PageRuler™ Plus Prestained Protein Ladder). The 
expected molecular weight of the CPMV L and S CP are reported on the side of the 
gel. 
The selected fractions did not show any contaminant protein (figure 10) and considering 
these fractions representative of the entire peak, all the fractions (from the number 28 to 
46) which are part of it were mixed and concentrated at ~1 ml and then stored at – 80 °C. 
The difference between the elution pattern of the unmodified CPMV eVLPs and the 
CPMV eVLPs.p524 can be explained with the presence in the latter of the p524 peptide 
fused to the CP. 
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5. Characterization of purified CPMV eVLPs.p524 and 
unmodified CPMV eVLPs  
 
The purified CPMV eVLPs.p524 and the unmodified CPMV eVLPs were quantified and 
then characterized by Dynamic Light Scattering (DLS) and LAL-test.  
 
5.1. Quantification and yields 
Purified CPMV eVLPs.p524 and unmodified CPMV eVLPs were quantified by reading 
of the 280 nm absorbance. Using the Lambert Beer law 
 
A280 = ε x L x C 
ε: molar extinction coefficient (m2 mol-1); 
L: path leght (cm); 
C: concentration (mg/ml). 
 
and considering the CPMV eVLPs molar extinction coefficient (1.28 m2 mol-1) the 
concentration (mg/ml) of the particle preparations was obtained. 
The amount of purified CPMV eVLPs.p524 and unmodified CPMV eVLPs needed for the 
tolerance induction studies in NOD mice was respectively 3 mg and 2 mg. 
320 g and 25 g of infiltrated leaves were necessary to purify respectively 3 mg of CPMV 
eVLPs.p524 and 2.4 mg of unmodified CPMV eVLPs.  Thus, the final yields are 0.01 
g/kg LFW for the CPMV eVLPs.p524 and 0.1 g/kg LFW for the unmodified CPMV 
eVLPs purification. 
The CPMV eVLPs.p524 10-fold lower purification yield could be due to the presence of 
p524 peptide on particles surface that might interfere with their stability causing particles 
aggregation and subsequent precipitation. 
 
5.2. Structural particles evaluation 
In literature, a CPMV eVLPs diameter of 28 nm is reported (Montague et al., 2011); 
knowing this data and exploiting DLS analysis, the appropriate assembly of the CPMV 
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eVLPs.p524 and the unmodified CPMV eVLPs and the absence of any aggregates was 
assessed.  
For each sample, 3 measurements were done. Every measurement corresponds to the 
means of 12 analysis repetitions. 
The DLS results regarding either the purified CPMV eVLPs.p524 or the unmodified 
CPMV eVLPs are reported in figure 11. 
 
Figure 11 Dynamic light scattering analysis of the unmodified CPMV eVLPs (A), 
CPMS eVLPs.p524 (B) purified as described. The marge of the graphs A and B is 
reported in the panel C. For each sample, 3 measurements were done and every 
measurement corresponds to the means of 12 analysis repetitions. The intensity (%) 
and the diameter size (nm) are reported respectively on the y and x axis. 
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Figure 11-panel A demonstrates that purified unmodified CPMV eVLPs have the expected 
diameter (30 nm), indicating the proper assembly of the unmodified CPMV eVLPs sample 
and the absence of aggregates. 
Figure 11-B reports DLS analysis of purified CPMV eVLPs.p524 displaying 2 peaks 
corresponding approximately to a diameter of 30 nm and 100 nm respectively. This 
sample is polydisperse and seems to be characterized by either well-assembled particles 
and particle aggregates. However, when the Intensity distribution is reported, the peak 
height is not indicative of the particles’ quantity because more light scattered is produced 
by bigger particles. On the basis of this assumption, in order to understand which particles’ 
species is the most representative of the sample, the data has to be reported as volume 
distribution. 
The Intensity distribution can be converted, using Mie theory, to a volume distribution 
(figure 12) describing the relative proportion of multiple components in the same sample 
based on their volume rather than based on their scattering (Intensity).  
 
Figure 12 Dynamic light scattering analysis results from the marge of the 
measurements of CPMV eVLPs.p524 and unmodified CPMV eVLPs purified by 
gel filtration. For each sample 3 measurements were done and every measurement 
corresponds to the means of 12 analysis repetitions. The intensity (%) and the 
diameter size (nm) are reposted respectively on the y and x axis. 
The Volume distribution (figure 12) confirmed the prevalent presence of well-assembled 
CPMV eVLPs.p524 in the purified sample, and the peaks representing these particles are 
overlapping those representing the unmodified CPMV eVLPs. 
Vo
lu
m
e	
(%
)
Size (d.	nm)
Unmodified CPMV	eVLPs
CPMV	eVLPs.p524
1 2 3
1 2 3
RESULTS AND DISCUSSION               THERAPY 
	 77 
So, in conclusion, the conformation of the purified CPMV eVLPs.p524 and unmodified 
CPMV eVLPs is correct, thus they are structurally suitable for the pre-clinical trials in 
animal models. 
 
5.3. Qualitative analysis 
The LAL-test is a technique commonly used to ensure that a therapeutic product is 
endotoxins-free.  
Diluted or undiluted CPMV eVLPs.p524 and unmodified CPMV eVLPs preparation have 
been subjected to this test. 
The gel clot method was used with a sensitivity of 0.125 UE (endotoxin unit)/ml. Equal 
volumes of LAL reagents were mixed with diluted or undiluted samples and observed for 
gel clot formation, if the endotoxin concentration in the sample tested is higher than the 
test sensitivity, a gel clot is formed in the tube. 
None of the samples showed any gel clot formation, including the undiluted sample. The 
endotoxin concentration in either CPMV eVLPs.p524 or unmodified CPMV eVLPs 
sample is lower than 0.125 UE/ml thereby confirming the suitability of the preparation to 
be used in pre-clinical studies. 
 
6. Pre-clinical trials in T1D animal model  
 
Administration of p524 synthetic peptide and CPMV eVLPs.p524 to NOD female mice 
Groups of twenty female of NOD/SHILTJ mice were treated before the onset of insulitis 
(4-week-old). When 2 doses were planned treatments were administered 2 weeks apart. 
The schedule of treatments was as follows: 
 
- CPMV eVLPs.p524 50 µg (1 dose); 
- CPMV eVLPs.p524 50 µg (2 doses); 
- Unmodified CPMV eVLPs (2 doses); 
- Original 15 aminoacids p524 synthetic peptide with IFA (table 2); 
- Optimased 18 aminoacids p524 synthetic peptide with IFA (table 2). 
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GAD65 derived peptide p524 was first report to elicit T cell-proliferation responses in 
spleen cell colture prepared from NOD mice (Kaufman et al., 1993) and prevent diabetes 
when it was administrated to NOD mice mixed with another GAD65 derived peptide (Tian 
et al., 1996). Subsequently some evidence, showed that p524 peptide reduces 
cyclophosphamide-accelerated diabetes in NOD-mice. 
In this work, for the first time, the p524 peptide was tested alone for the prevention of 
T1D in NOD-mice. 
The survival curves obtained by weekly glycaemia measurements of the treated NOD-
mice are shown in figure 13. 
 
Figure 13  Overall survival curve for mice treated with the original 15 aminoacids 
(orange) and the optimased 18 aminoacids (blue) p524 synthetic peptides mixed 
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with IFA (p=0.364) (A), Overall survival curve for all mice groups of the T1D pre-
clinical study (B), mice treated with 2 doses (blue) and 1 dose (orange) of CPMV 
eVLPs.p524, mice treated with unmodified CPMV eVLPs (green), mice treated with 
the original 15 aminoacids (red) and the optimased 18 aminoacids (grey) p524 
synthetic peptides mixed with IFA (p=0.01). The probability of no disease and the 
Time (days) are reported respectively on the y and x axis. 
The figure 13-A demonstrated that more than the 70% of the mice in both groups shows 
diabetic symptoms and have developed the disease; moreovere, there are not significative 
differences in the use of the original p524 synthetic peptide upon the other (p=0.364). 
Indeed, the original 15 aminoacids nor the optimased 18 aminoacids p524 synthetic 
peptide showed a immunoregolative activity able to prevent the onset of T1D when they 
are injected alone mixed with IFA.  
Instead, the use of CPMV eVLPs.p524 enhances the peptide immunological activity 
(p=0.001 and p=0.008 respectively for 18 and 15 aminoacids syntethic peptide) as shown 
in figure 13-B. It is important to underline that the CPMV eVLPs.p524 were injected 
without any adjuvant and the results obtained confirm the capability of the eVLPs to act 
as an adjuvant itself as reported in Jegerlehner et al. (2002). In conclusion, the results 
shown in figure 13 demonstrate that, compared to the treatment with the unmodified 
CPMV eVLPs, CPMV eVLPs.p524 partially protect mice from T1D onset. Finally, as 
expected, the treatment with two doses of CPMV eVLPs.p524 showed a partial protection 
higher (p=0.04) than the one obtained with the single dose (p=0.398). 
 
6.1. Histopathological analysis of the pancreatic Langerhans islets 
At 5 and 10 weeks after the treatments two mice per group were sacrificed and pancreatic 
sections were microscopically examined in order to assess the presence of lymphocytic 
infiltrates into the Langerhans islets indicating the presence of an insulitis process. 
A pancreatitis score from 0 to 3 indicates the levels of lymphocytic infiltrates, with higher 
scores assigned to stronger infiltration; this score was used to evaluate mouse pancreatic 
sections.  
Figure 14 shows the insulitis score and the analysis of the pancreatic section.  
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Figure 14 Histopathological analysis of lymphocyte infiltration in the pancreatic 
Langerhans islets of mice of the pre-clinical T1D study. Analysis of different 
sections of the pancreas of two mice per group at 5, 10 (A) and 27 weeks (C) from 
the second treatment are shown. The analysis were done considering the mice groups 
treated with the original 15 aminoacid p524 synthetic peptide mixed with IFA, with 
2 doses of CPMV eVLPs.p524, with the unmodified CPMV eVLPs and as negative 
control an untreated mouse. In the table under the graph the number of pancreatic 
sections and the Langerhans islets observed is reported. Panel B shows the insulitis 
score used for the evaluation of pancreatic sections. 
At 5, 10 weeks and at the end of the experiments, the pancreata of the mice injected with 
the CPMV eVLPs.p524 have a pancreatitis score lower than the other sample confirming 
the results showed in the survival curve (figure 13-B).    
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6.2. Cytokines analysis in serum 
All the Sera derived from mice were analysed in order to quantify 23 different cytokines 
using a commercial immunoassay method. 
The cytokines analysed were:  
Eotaxin 
G-CSF 
GM-CSF 
IFN-γ 
IL-1α 
IL-1β 
 
IL-2 
IL-3 
IL-4 
IL-5 
IL-6 
IL-9 
 
IL-10 
IL-12 (p40) 
IL-12 (p70) 
IL-13 
IL-17A  
KC 
 
MCP-1 (MCAF) 
MIP-1α 
MIP-1β 
RANTES 
TNF-α 
 
The data set regarding the quantification of the cytokines in sera of mice that did not 
developed T1D symptoms was explored in order to evaluate the presence of  cytokine 
patterns in the sera analysed.  
A Principal Component Analysis (PCA) was performed on data derived from 18 samples 
of the immune-analysis. In particular, 7 and 5 sera derived from mice treated respectively 
twice and once with CPMV eVLPs.p524, 6 sera derived from the mice group injected with 
optimased 18 aminoacids synthetic peptide p524 (+IFA) and 5 sera from mice treated with 
unmodified CPMV eVLPs.  
The PCA was then used to supervise the best Orthogonal Bidirectional Projections to 
Latent Structures-Discriminant Analysis (O2PLS-DA). OPLS-DA is a discriminant 
analysis based on OPLS and employed to examine the difference between groups while 
neglecting the systemic variation. 
A four-class O2PLS-DA model (3+7+0, UV, R2cum:0.944, Q2cum:0.764) corresponding 
to the four mice group analysed, was obtained (figure 14-A). 
The first two principal components (PC) explained 44.7 % of the total variance of the 
model. The graph clearly showed a good clusterization of the four mice groups receiving 
different treatments. The second component could explain the immunoregolative action 
of the peptide. Figure 14-B shows the loading scatter plot relating to figure 14.  
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Figure 14 Plot of the O2PLS-DA (A) (3+7+0, UV, R2cum:0.944, Q2cum:0.764) of 
the mice treated with 2 doses (dark green square) and 1 dose (light green dot) of 
CPMV eVLPs.p524, with the unmodified CPMV eVLPs (blue triangle) and the 
original 15 aminoacids p524 synthetic peptide (red diamond) showing the first two 
principal component t[1]=35.5% and t[2]=10.2%. In the panel B the corresponding 
loading scatter plot is reported. The yellow starts indicate the average position on 
the plot of the analysed mice groups; the purple dots show the contribution of each 
cytokines. 
A
B
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The loading scatter plot (figure 14-B) demonstrated that the group of mice treated with 2 
doses of CPMV eVLPs.p524 that did not develop T1D is characterized by a strong 
activation of different cytokines. 
Also in mice injected with unmodified CPMV eVLPs there seems to be a cytokines 
activation, this data it is not all that surprisingly because, miming a viral structure, particles 
injected are immunoactivators themselves. 
Considering this overall results, more focused analyses were done.  
The following figure 15 shows the two-classes O2PLS-DA (A) (1+3+0, UV, 
R2cum:0.702, Q2cum:0.954) corresponding to the mice groups treated with CPMV 
eVLPs.p524 and synthetic p524 peptide. 
 
 
Figure15 Plot of the two classes O2PLS-DA (A) (1+3+0, UV, R2cum:0.702, 
Q2cum:0.954) of the mice treated with 2 doses (green square) and the original 15 
aminoacids p524 synthetic peptide (red diamond) showing the first two principal 
component t[1]=28.6% and to[1]=16.8%. In the panel B the corresponding loading 
scatter plot is reported. The yellow starts indicate the average position on the plot of 
the analysed mice groups; the purple dots show the contribution of each cytokines. 
The first two PC explained 45.4 % of the total variance of the model. The graph clearly 
showed a strong clusterization of the two mice groups receiving different treatments. 
The corresponding loading scatter plot (figure 15-B) underlines that the use of CPMV 
eVLPs for the p524 display allows to induce a strong activation of cytokines and the two 
groups analysed result to be separated only on the basis of the first component that is the 
one explaining the major variance (28.6%) of the model. In further detail, the 
immunological activation effects of CPMV eVLPs.p524 seem to be particularly due to 
A B
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some cytokines IL-12(p40), IL-13 and IL-3. The role of the IL-12(p40) in the prevention 
of T1D result to be ambiguous because, on the contrary, in literature there are evidences 
of its involvement in the onset of the disease. In particular, IL-12 is the key cytokine 
driving Th1 cell development which is critical to the pathogenesis of T1D (Hsieh et al., 
1993). IL-12 stimulates the differentiation of CD4+ helper T lymphocytes into Th1 type, 
which themselves trigger IL-12 secretion by dentritic cells; Th1 usually produce high 
levels of INF-g and IL-2 which activate macrophages and CD8+ cytotoxic T lymphocyte. 
Upon activation, these cells secrete cytokines such as IL-1b and TNF-a that are potentially 
responsible of the pancreatic β cells destruction (Adorini, 2001). 
In the light of above and considering the loading scatter plot of O2PLS-DA (figure 15-B), 
it is possible to assume that this mechanism is partially active in mice group treated with 
CPMV eVLPs.p524. Indeed, it is visible a strong activation of IL-12 (p40), that could lead 
to an activation of INF-g and IL-2 that are more activated in the mice group treated with 
CPMV eVLPs.p524 in comparison to the mice group treated with p524 synthetic peptide. 
On the other hand, even if IL-1b result to be again more activated in the mice group treated 
with CPMV eVLPs.p524 in comparison to the mice group treated with p524 synthetic 
peptide, the latter result to be characterised by a strong activation of TNF-a which is the 
only cytokine representing this group.  
One possible explanation of the mechanism at the basis of this strong IL-12 activation is 
reported in Rabinovitch et al. (2007) in which is described the Th1 cytokines activate, but 
also downregulate immune responses. In other word, paradoxally the administration of 
IL-2 and INF-g actually prevent T1D, at least in animal models. A mechanism for the 
preventive effect of INF-g may be activation/induced cell death of pathogenic CD4+ Th1 
cells (Raefaeliy et al., 2002). Similary, IL-2 has been recognized to be crucial for induction 
of immunological tolerance (Mallek et al., 2004). In conclusion, the Th1 cytokines, IFNg 
and IL-2, have dual roles in the immune response, first activating and then downregulating 
autoimmune responses.  
Regarding the IL-3, Akihiko et al. (1997) demonstrated that this cytokine plays an 
important role in delay the onset of T1D. In particular, the administration of IL-3 twice 
weekly starting at 2–4 weeks of age delayed the onset and reduced the overall incidence 
of diabetes. 
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In figure 16-A the O2PLS-DA model (1+2+0, UV, R2cum:0.884, Q2cum:0.682) explores 
the CPMV eVLPs.p524 effect of the two different doses used. 
The first two PC explained 67.6 % of the total variance of the model. The graph clearly 
shows a clusterization of the two mice groups receiving different CPMV eVLPs.p524 
doses. 
 
Figure 16 Plot of the two classes O2PLS-DA (A) (1+2+0, UV, R2cum:0.884, 
Q2cum:0.682) of the mice treated with 1 dose (light green dot) or 2 doses (dark green 
square) and the original 15 aminoacids p524 synthetic peptide (red diamond) 
showing the first two principal component t[1]=54.7% and to[1]=12.9%. In the 
panel B the corresponding loading scatter plot is reported. The yellow starts indicate 
the average position on the plot of the analysed mice groups; the purple dots show 
the contribution of each cytokines. 
The corresponding loading scatter plot (figure 16-B) highlights that there is a stronger 
activation of cytokines when mice were treated twice. Indeed, the two groups analysed 
result to be separated only on the basis of the first component that explains the major 
variance (54.7%) of the model and could represent the dose effects. 
Finally, a two-class O2PLS-DA model (1+3+0, UV, R2cum:0.626, Q2cum:0.757) 
corresponding to mice treated twice with CPMV eVLPs.p524 that showed or not T1D 
symptoms was obtained (figure 16-A). 
This analysis confirmed the strong activation of IL-12 as reported in the previous plot 
(figure 15), but the double doses seem to trigger the anti-inflammatory cytokines IL-4, IL-
10 and IL-13. Numerous studies have revealed that treatment of NOD mice with these 
cytokines delays the onset of T1D and reduce its incidences (Rapoport et al., 1993; 
Pennline et al., 1991; Cameron et al., 1997; Papaccio et al., 2002). Moreover, in Rusell et 
A B
RESULTS AND DISCUSSION               THERAPY 
	86 
Morgan (2014) is reported the possible role of IL-4, IL-10 and IL-13 as citoprotective 
agents in the Langerhans pancreatic β-cell. 
 
 
Figure 17 Plot of the two classes O2PLS-DA (A) (1+3+0, UV, R2cum:0.626, 
Q2cum:0.757) of the mice treated 2 doses of CPMV eVLPs.p524 that at the end of 
the pre-clinical trials result to be healthy (green square) or ill (red dot) showing the 
first two principal component t[1]=17.4% and to[1]=22.4%. In the panel B the 
corresponding loading scatter plot is reported. The yellow starts indicate the average 
position on the plot of the analysed mice groups; the purple dots show the 
contribution of each cytokines. 
The first two PC explained 39.8 % of the total variance of the model. The clusterization 
of the healthy and ill mice results to be less strong in comparison to the other O2PLS but 
the corresponding loading scatter plot (figure 17-B) confirms a strong cytokines activation 
in the healthy mice with a stronger contribute of IL-12(p40), IL-13 and IL-10. These 
cytokines result to be the most implicated in the preventive effects of CPMV eVLPs.p524 
thus supporting the results showed in figures 15-B and 16-B. 
 
6.3. Analysis of Treg cells 
The population of regulative T cell (Treg) CD4+CD25+ having the phenotype FoxP3 have 
been characterised in the Langerhans islets of treated mice.  
This analysis was performed since evidence in literature have been associated the Treg 
CD4+CD25+ FoxP3+ with T1D disease resistance. In particular, Foxp3 seems to act as a 
master regulator transcription factor for the induction of a regulatory differentiation 
program in T cells (Jaeckel et al., 2008).  
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In figure 18 the results of the Treg CD4+CD25+ FoxP3+ analysis done in the Langerhans 
islets of mice treated with CPMV eVLPs.p524 in comparison with the ones treated with 
the unmodified CPMV eVLPs are reported. 
 
Figure 18 Cells count of the Treg CD4+CD25+ positive to the FoxP3 phenotype in 
the Langerhans islets of the pancreatic β-cell of mice treated with CPMV 
eVLPs.p524 or unmodified CPMV eVLPs. In the y axis the number of FoxP3 
positive cells/islets is reported. 
Figure 18 shows that the preventive effect of CPMV eVLPs.p524 seems not to involve 
changes in Foxp3 levels. On the other hand, mice treated with the unmodified CPMV 
eVLPs became diabetic despite increases in Foxp3 levels.  
A similar result has been demonstrated in Lau et al. (2011) in which they demonstrated an 
Foxp3-indipendent inhibition of T1D correlated to a GAD-expressing lactobacillus. It 
could be concluded that that Foxp3 induction was not the primary mechanism mediated by 
CPMV eVLPs.p524. 
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EXPRESSION OF CPMV eVLPs.p524 IN EDIBLE PLANTS 
1. Experimental design 
Edible plants represent optimal biofactories for recombinant protein production. This 
strategy allows the production of oral biomolecule that can be assimilated in the diet, thus 
inducing immunological oral tolerance. The expression of eVLPs or CVPs in edible plants 
has never been reported in literature thus, in this work, the expression of CPMV 
eVLPs.p524 has been tested.  
8 spinach and red beet plants 6 weeks old were infiltrated with a mix of A. tumefaciens 
LBA4404 stains carring one the vector pEAQ-HT-VP60.p524 and the other the plasmid 
pEAQ-HT-24K. Starting from 3 dpi to 7 dpi the infiltrated leaves of one plant per species 
per day were collected. The CPMV eVLPs.p524 expression was assessed by SDS-PAGE, 
Commassie staining and western blot analysis. 
 
2. Analysis of the expression in Spinach and Red beet of CPMV 
eVLPs displaying p524 
 
4 leaves of 7 plants of either spinach or red beet were infiltrated with a mixed suspension 
of A. tumefaciens carrying pEAQ-HT-24K or pEAQ-HT-VP60.p524 plasmids.  
As negative control, 4 leaves of either spinach or red beet were infiltrated with the 
infiltration buffer used for the resuspension of bacterial cells (MMA) 
The agroinfiltrated leaves of one plant per species per day were collected and the TSP 
were extracted from them and analysed by western blot, using a polyclonal antibody 
specific to CPMV particles for the detection of specific signals. Results of this analysis 
are reported in figure 19. 
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Figure 19 SDS-PAGE and western blot analysis of the analysis of the expression of 
CPMV eVLPs.p524 in spinach (A) and red beet (B). 20 µl of the total protein extract of 
each sample were obtained using PBS buffer pH 7.2 and loaded on 12% polyacrylamide 
gels then blot was probed with a polyclonal antibody (G49) specific to CPMV particles 
used at a concentration of 1:2000. M: molecular marker (PageRuler™ Plus Prestained 
Protein Ladder, Thermo Scientific); 1: negative control, protein extract from leaves 
infiltrated with infiltration buffer; 2: protein extract of infiltrated leaves for the expression 
of CPMV eVLPs.p524 at 3 dpi; 3: protein extract of infiltrated leaves for the expression 
of CPMV eVLPs.p524 at 4 dpi; 4: protein extract of infiltrated leaves for the expression 
of CPMV eVLPs.p524 at 5 dpi; 5: protein extract of infiltrated leaves for the expression 
of CPMV eVLPs.p524 at 6 dpi; 6: protein extract of infiltrated leaves for the expression 
of CPMV eVLPs.p524 at 7 dpi; 7: positive control, protein extract from N. benthamaina 
expressing CPMV eVLPs.p524; 8:- ; 9: positive  control, 1 µg of purified unmodified 
CPMV eVLPs. Commassie stained gels of Rubisco large subunit (C: spinach samples 
and D: red beet sample) are reported as loading control.  
The analysis reported in figure 18 shows that CPMV eVLPs.p524 are not expressed 
neither in spinach nor in red beet. Indeed, no specific signals is visible in the samples 
relative to the time course expression analysis (lanes 2-6 figure 19-A/B) but there are 
only some aspecific bands clearly visible also in the negative control protein extract 
(lane 1 figure 19-A/B). In conclusion, the CPMV eVLPs expression system, which was 
developed for the transient expression of these particles in N. benthamiana, is 
unsuitable for the expression of them in the tested edible plants. 
 	90 
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RHEUMATOID ARTHRITIS TREATMENT 
 
1. Experimental design 
There are several animal models of autoimmune arthritis that have proven to be valuable 
research tools for testing new therapies, including spontaneous models and those that 
require immunization. Among the latter, CIA (collagen-induced arthritis) mice has been 
the most widely studied model of rheumatoid arthritis (RA).  
In DBA-1 mice, RA is induced by immunization with an emulsion of complete Freund’s 
adjuvant (CFA) and type II collagen (CII). Typically, the first signs of arthritis appear 21-
28 days after immunization and identification of the arthritic limbs is not difficult (Brand 
et al., 2007). 
The identification of new putative immunodominant peptides involved in RA was 
performed in collaboration with Dr. Elisa Tinazzi’s research group of the Department of 
Medicine in the University of Verona. 
A FliTrx random dodecamer peptide library was used according to the manufacturer’s 
instruction (FliTrx Panning Kit Invitrogen) and following the methods reported in Navone 
et al (2005), three novel peptides (table 1) were identified to be putatively involved in 
seronegative RA. 
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Table 1: Novel peptide identified to be putatively involved in seronegative RA. 
Name Sequence Features of the protein at which belongs the peptide 
LIP1 ASVLANVAQAFE 
The Liprin-alpha-1 protein may regulate the disassembly 
of focal adhesions. It may localize receptor-like tyrosine 
phosphatases type 2A at specific sites on the plasma 
membranes, possibly regulating their interaction with the 
extracellular environment and their association with 
substrates. (Serra-Pags et al., 1995) 
FADK2 AKVLANLAHPPA 
The protein-tyrosine kinase 2-beta is a non-receptor 
protein-tyrosine kinase that regulates the reorganization of 
the actin cytoskeleton, cell polarization, cell migration, 
adhesion, spreading and bone remodelling. It plays a role 
in the regulation of the humoral immune response and it is 
required for normal levels of marginal B-cells in the 
spleen and normal migration of splenic B-cells. It is also 
required for normal macrophage polarization and 
migration towards inflammation sites. It regulates 
cytoskeleton rearrangement and cell spreading in T-cells, 
contributing to the regulation of T-cell responses. It 
promotes osteoclastic bone resorption and it may inhibit 
differentiation and activity of osteoprogenitor cells. It 
functions in signalling downstream of integrin and 
collagen receptors, immune receptors, G-protein coupled 
receptors (GPCR), cytokine, chemokine and growth factor 
receptors, mediating responses to cellular stress. 
Furthermore, it regulates numerous signalling pathways 
(Sun et al., 2008; Ruusala et al., 2008; Collins et al., 2010; 
Lipinski et al., 2010). 
BANK1 DMILANLSIKKK 
The B-cell scaffold protein with ankyrin repeats is 
involved in B-cell receptor (BCR)-induced Ca2+ 
mobilization from intracellular stores. It promotes Lyn-
mediated phosphorylation of IP3 receptors 1 and 2. It is 
involved in Systemic lupus erythematosus (SLE).  
(Yokoyama et al., 2002; Kozyrev et al., 2008)  
 
 
Among the 3 peptides identified, the former two, LIP1 and FADK2, were considered the 
most interesting ones from an immunological point of view, hence they were selected to 
be tested in pre-clinical studies in DBA-1/CIA mice. 
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The TBSV CVPs expression system was used for the expression of viral particles 
displaying either LIP1 or FADK2 peptides on their surface. 
Following the method reported in Grasso et al. (2013), a small scale infection 3 N. 
benthamiana plants (2 leaves/plants), with the infectious RNA in vitro synthetized from 
pTBSV vectors, was carried on to check the expression of TBSV particles displaying the 
two peptides of interest (TBSV CVPs.FADK2 and TBSV CVPs. LIP1). 
In order to assess the genetic stability of TBSV CVPs particles displaying the peptides of 
interest, for the following infections, sap from symptomatic leaves was used for other 2 
cycles. 6-10 days after each infection when the viral symptoms are clearly visible, 
symptomatic leaves (either local or systemic ones) of the infected plants were collected 
and analyzed: RNA was extracted, retro-transcribed and the cDNA was used for PCR and 
following sequencing to ensure that viral genome is stable. 
Since these particles were properly produced and TBSV CVPs.FADK2 and TBSV CVPs. 
LIP1 are genetically stable, a large scale infection was performed and, as reported by 
Grasso et al. (2013), extracted and purified from symptomatic leaves. 
The unmodified TBSV CVPs (i.e. lacking heterologous peptides on their surface) are 
essential in the perspective of animal trials as negative control and they were expressed 
and purified as well. 
After purification and characterization to confirm the correct assembly and shape, the 
TBSV CVPs.FADK2 and TBSV CVPs. LIP1 were used in pre-clinical studies in DBA-
1/CIA mice in order to assess the potential of these particles to be used for the treatment 
RA. 
 
2. Cloning of LIP1 and FADK2 
The expression vectors for the production of pTBSV.LIP1, pTBSV.FADK2 and pTBSV 
were generously provided by the Prof. Luca Santi (Department of Agriculture and Forestry 
Science (DAFNE) of the University of Tuscia).  
The sequence of the two peptide of interest are reported in table 2. 
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Table 2: LIP1 and FADK2 sequence for their expression with the TBSV CVPs system 
LIP1 
Aminoacid sequence  ASVLANVAQAFE 
Nucleotidic sequence GCT TCT GTT CTT GCT AAT GTT GCA 
CAA GCA TTT GAA 
Length (aminoacids) 12 
FADK2 
Aminoacid sequence  AKVLANLAHPPA 
Nucleotidic sequence GCT AAG GTT CTT GCT AAT CTT GCA 
CAT CCA CCT GCT 
Length (aminoacids) 12 
 
Starting from the sequences reported in table 2 oligonucleotide pairs for both the peptides 
were designed to obtain DNA fagments ApaI and PacI compatible ends that were ligated 
in the pTBSV ApaI-PacI digested vector.  
After the ligation of the DNA fragments encoding for LIP1 or FADK2 peptide into the 
pTBSV vector, the resulting pTBSV.LIP1 and pTBSV.FADK2 plasmids were 
independently transformed in E. coli XL1-Blue strain competent cells by electroporation. 
E. coli were plated in ampicillin (100 µg/ml)  containing medium and PCR selected using 
vector- and peptide-specific primers (TBSV-2Back/LIP1-For and TBSV-2Back/FADK2-
For). 
All the colony tested result to be correctly transformed (data not shown). 
Selected pTBSV-LIP1 and pTBSV-FADK2 were propagated in selective broth and 
plasmids were extracted, PCR analysed and sequenced to assess that the inserts were 
correct.  
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3. Analysis of the expression in plant of TBSV CVPs.FADK2 and 
TBSV CVPs.LIP1 
A small scale infection of 3 plants per TBSV CVPs.FADK2 and TBSV CVPs.LIP1. was 
performed, in order to verify the expression of the modified particles. 
The vectors pTBSV.LIP1 and pTBSV.FADK2 were linearized and the infectious RNAs 
were in vitro transcribed. The RNA quality was assessed using BioAnalizer (data non 
shown) and the resulting infectious viral RNAs were used to infect 2 leaves per plants. 8 
dpi, when viral symptoms appeared, symptomatic leaves were collected and analysed by 
retrotrascription-PCR (RT-PCR). The cDNAs were then sequenced to verify the stability 
of the peptide expressed on the viral surface. 
After the first cycle of infection, another cycle was performed inoculating 2 leaves/plants 
using sap derived from symptomatic leaves of the first infection cycle. 6-10 dpi, the local 
and systemic symptomatic leaves were collected and analysed as describe before. 
- First infection cycle 
The symptomatology was constantly monitored; an example of a plant inoculated with the 
infectious RNA derived from pTBSV.FADK2 is shown in figure 1.  
 
 
Figure 1 N. bethamiana leaves showing clorotic symptoms 3-4 dpi after the infection 
with TBSV CVPs.FADK2 (B)and their effects on the whole plant 8 dpi (D). In panels 
A and C a respectively wild type leaf and plant is showed.   
A B
C D
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Plants infected showed the characteristic chlorotic lesion onto inoculated leaves at 3-4 dpi 
(figure 1-A). At 5-6 dpi symptoms appeared systemically showing mottling, distortions 
and stunting leaves (figure 1-B and 1-D).  
Symptomatology of plants inoculated with infectious TBSV RNAs harbouring LIP1 
peptide showed the same behaviour of the ones shown in figure 1. 
At 8 dpi local and systemic leaves were collected in order to avoid the coming necrosis of 
the apical shoots. 
RT-PCR analysis was done on the latter being the viral concentration higher than in the 
local one. 
The RT-PCR reactions were performed using the SuperScript III (Promega) and 2 PCR 
analysis were performed. The first was carried out with primers specific for the actin 
constitutive gene (ACT1 and ACT2) in order to assess cDNA synthesis. The latter, was 
done using TBSV specific primers (RTPCR1For and TBSV-2back) to amplify the 3’ CP 
region, in which the peptide sequence was cloned.  
The results of the PCR are reported in figure 2. 
 
Figure 2 RT-PCR analysis of the symptomatic leaves collected from plant infected 
with the infectious RNA derived from pTBSV.LIP1 (1-3) and pTBSV.FADK2 (4-6). 
The PCR analysis done on the cDNAs using primers for a constitutive gene (ACT1 
and ACT2) (A) and TBSV specific primers (RTPCR1For and TBSV-2back) (B) are 
reported. PCR amplification products obtained were loaded on a 2% agarose gel. M: 
molecular marker (BenchTop 1Kb DNA ladder – Promega); N: negative control of 
the PCR; N*: negative control (using cDNA derived from a wild type N. bethamiana 
as template); P: positive control (using a pTBSV vector display a well-know peptide 
as template).  
 
An amplicon of approximatly 700 bp is clearly visible in all cDNA samples (figure 2–B) 
confirming the specific presence of the viral TBSV RNA in analysed plants.  
1	Kb
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The fragments resulting from the PCR with TBSV specific primers, were sequenced and 
the resulting sequence was aligned with the expected one; the results are summarized in 
table 3. 
Table 3: Genetic stability results for the primary infection of N bethamiana plants with 
infectious RNA derived from pTBSV.LIP1 and pTBSV.FADK2. V: the genetid stability is 
confermed. 
Primary infection TBSV CVPs.LIP1 TBSV CVPs.FADK2 
N. benthamiana 1 V V 
N. benthamiana 2 V V 
N. benthamiana 3 V Problems in the sequencing 
  
5 of the 6 samples analysed resulted to have the expected sequence and no mutations were 
present. 
- Second infection cycle 
Sap obtained from the systemic symptomatic primary infection leaves was used for 
inoculating 5 plants, either for the expression of TBSV CVPs.LIP1 or TBSV CVPs.FADK2. 
When the infection is performed with a plant extract containing TBSV particles, viral 
symptoms appear faster than when the primary infection is carried out with infectious 
TBSV RNA, hence 6 dpi the symptomatic leaves were collected in order to avoid necrosis 
and plant death. 
RT-PCRs were conducted on the symptomatic systemic leaves and the results confirmed 
the presence of TBSV particles in infected plants, either for TBSV CVPs.LIP1 or TBSV 
CVPs.K (data not shown). The PCR products obtained with TBSV specific primers, were 
sequenced and the resulting sequences were aligned with the expected one. 
All the resulting sequences, TBSV CVPs.LIP1 and TBSV CVPs.FADK2 had a 100% 
identity with the reference one.  
In conclusion, TBSV CVPs.LIP1 and TBSV CVPs.FADK2 are correctly expressed in N. 
benthamiana plants and they resulted to be genetically stable.  
For the purpose of the production of TBSV CVPs.LIP1 and TBSV CVPs.FADK2 in view 
of pre-clinical trials, in literature there are many evidences (Grasso et al., 2013) of higher 
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particles yields in the second infection cycle than the primary, thus allowing to avoid the 
need of third infection cycles 
4. Purification of TBSV CVPs.LIP1, TBSV CVPs.FADK2 and 
unmodified TBSV CVPs 
 
4.1. TBSV CVPs.LIP1 and TBSV CVPs.FADK2 
The TBSV CVPs displaying either LIP1 or FADK2 peptides were purified following the 
method reported in Grasso et al. (2013) starting from 30-40 g of mixed symptomatic and 
local infected leaves derived from the second infection cycle. 
An aliquot of every purification step was collected in order to monitor the process. Purified 
particles were eventually resuspended in 0.7% NaCl buffer. 
SDS-PAGE and silver staining analysis were performed on the final purified particles 
TBSV CVPs.LIP1, TBSV CVPs.FADK2 and aliquots were collected during the purification 
in order to confirm particles purification; in figure 3 the results of these analysis are 
reported. 
 
Figure 3 SDS-PAGE and silver staining analysis of the purified TBSV CVPs.FADK2 
(A) and TBSV CVPs.LIP1 (B). 1: 2.5 µl of total protein extract derived from 
symptomatic leaves; 2-3: 2.5 µl of sample from  progressive purification steps; 4: - ; 
5: 2.5 µl of a diluition 1:100 (A) and 1:50 (B); 6: 5.0 µl of a diluition 1:100 (A) and 
1:50 (B); 7: 7.5 µl of a diluition 1:100 (A) and 1:50 (B); 8: - ; 9: 0.25 µl of the purified 
TBSV CVPs.FADK2 (A) and TBSV CVPs.LIP1 (B). The samples were loaded on 
14% polyacrylamide gel. The TBSV CP molecular weight (40 kDa), is indicated. M: 
molecular marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). 
This analysis highlighted the progressive purification of TBSV CVPs.LIP1 (A) TBSV 
CVPs.FADK2 (B) particles. Lanes 5-7 show pure viral particles, corresponding to a band 
of approximately 40 kDa. In both lane 6 and 7 there is also a signal at approximately 90 
kDa corresponding to a dimer of TBSV CP that was probably not denatured during the 
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treatment before electrophoresis, probably due to high TBSV CVPs particles 
concentration. The purity of the samples was confirmed in lane 9 corresponding to the non-
diluted purified TBSV CVPs.LIP1 (figure 3-A) and TBSV CVPs.FADK2 (figure 3-B). 
 
4.2.  Unmodified TBSV CVPs 
Following the same procedure, unmodified TBSV CVPs from infected N. benthamiana 
leaves were successfully purified. SDS-PAGE and silver staining analysis were performed 
on the final pure unmodified TBSV CVPs in order to confirm the particles purification; in 
figure 4 the results of these analysis are reported. 
 
Figure 4 SDS-PAGE and silver staining analysis of the purified unmodified TBSV 
CVPs 1: 7.5 µl of 1: 50 diluited TSP derived from 40 g of symptomatic leaves. The 
samples were loaded on 14% polyacrylamide gel. The TBSV CP molecular weight 
(40 kDa), is indicated. M: molecular marker (PageRuler™ Plus Prestained Protein 
Ladder, Thermo Scientific). 
Figure 4 underlines that the unmodified TBSV CVPs were successfully purified and they 
will be used as negative control in the subsequent pre-clinical studies.  
 
5. Characterization of purified TBSV CVPs.LIP1, TBSV 
CVPs.FADK2 and unmodified TBSV CVPs 
Purified TBSV CVPs.LIP1, TBSV CVPs.FADK2 and unmodified TBSV CVPs were 
quantified, analysed by Dynamic Light Scattering and subjected to a LAL test in order to 
exclude the presence of any endotoxin in the purified particle preparations and to assess 
their suitability to be used in pre-clinical studies. 
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5.1. Quantification of purified TBSV CVPs.LIP1, TBSV 
CVPs.FADK2 and unmodified TBSV CVPs 
The Bradford protein assay with known quantities of bovine serum albumin (BSA) as 
standards was used for the quantification of purified TBSV CVPs.LIP1, TBSV 
CVPs.FADK2 and unmodified TBSV CVPs.  
1.750 mg of each purified TBSV CVPs particles were necessary for pre-clinical study and 
twice of the amount (3.5 mg) were prepared.  
The amount of symptomatic leaves (leaf fresh weight; LFW) needed to achieve 3.5 mg of 
TBSV CVPs displaying the peptide of interest were specific for each sample and yields are 
reported in table 4. 
Table 4: TBSV CVPs.FAK2, TBSV CVPs.LIP1 and unmodified TBSV CVPs purification yields.  
 LFW (g) to achieve 3.5 mg Yields (µg/g) 
TBSV CVPs.FADK2 31 114 
TBSV CVPs.LIP1 49 72 
Unmodified TBSV CVPs  54 65 
 
5.2. Limulus Amebocyte Lysate-test (LAL-test)  
Purified TBSV CVPs.LIP1, TBSV CVPs.FADK2 and unmodified TBSV CVPs were 
subjected to a LAL-test. 
The gel clot method was used and LAL-test showed a sensitivity of 0.125 UE (endotoxin 
units)/ml.  
None of the samples of TBSV CVPs.LIP1 and TBSV CVPs.FADK2 showed any gel clot 
formation indicating that endotoxin concentration in these samples is lower than 0.125 
UE/ml. As a consequence, particles were suitable to be injected in animal models. 
On the other hand, the undiluted unmodified TBSV CVPs formed a gel clot indicating an 
endotoxin concentration higher than 0.125.  A resin for the endotoxin removal (EndoTrap® 
HD) was then used. After the treatment with EndoTrap, the resulting unmodified TBSV 
CVPs sample was subjected again to LAL-test resulting negative, thereby indicating 
particles suitability to be used in pre-clinical study. 
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6. Pre-clinical trials in RA animal model 
 
6.1. Induction of autoimmune arthritis in mice with type II collagen 
(CII) 
Collagen-induced arthritis (CIA) mouse model is the most commonly studied autoimmune 
model of rheumatoid arthritis. The original “gold standard” of the CIA model are DBA-1 
(Dilute Brown Non-Agouti) mice that have to be immunized using type II collagene. 
DBA-1 mice were immunized or not with an emulsion of complete Freund’s adjuvant 
(CFA) and type II collagen (CII) at day 0 and 21 in order to develop arthritis. 
The immunization was done as reported in scheme 1: 
 
Scheme 1 CIA induction  
 
 
Results showing the kinetics of arthritics development in DBA-1 mice immunized with 
CII are reported in figure 5. 
 
Figure 5 Kinetics of arthritics development in DBA-1 mice immunized with CII. The 
percentage of arthritic mice and the time (days) are respectively reported on y and x 
axis. 
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Figure 5 shows that 28 days post-immunization 60 % of immunized mice were arthritic 
and 33 days post-immunization 100% of immunized mice showed signs of RA. 
 
6.2. Injection of LIP1 and FADK synthetic peptides, TBSV CVPs.LIP1, 
TBSV CVPs.FADK2 and unmodified TBSV CVPs in CIA mice 
The pre-clinical study was scheduled as reported in scheme 2: 
Scheme 2 RA pre-clinical study in CIA mice. 
 
Each experimental group was treated 7 time, 5 days apart, starting from day 28 after the 
first immunization.  
The experimental groups of the pre-clinical study were: 
- No CIA mice; 
- CIA mice treated with 50 µg of TBSV CVPs.LIP1; 
- CIA mice treated with 50 µg of TBSV CVPs.FADK2; 
- CIA mice treated with 50 µg of synthetic peptide LIP1 mixed with IFA; 
- CIA mice treated with 50 µg of synthetic peptide FADK2 mixed with IFA; 
- CIA mice treated with 50 µg of unmodified TBSV CVPs; 
- CIA mice treated with saline buffer as negative control; 
- CIA mice treated with Dexamethasone as positive control. 
Each experimental group was composed by 5 mice.  
Sacrifice
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Clinical assessment of CIA was done using a macroscopic score system based on visual 
identification of arthritic limbs; the RA index for each mouse was expressed as the mean 
of the four scores of individual paws. 
The clinical score, reported in the vertical axis, was constructed by dividing the total score 
by the number of animals used for each experimental group. 
Therapeutic effects of different treatments are reported in figure 6. 
 
Figure 6 Clinical score of the pre-clinical RA study. The results of the treatments done with 
the TBSV CVPs.FADK2 (green circle- A) and TBSV CVPs.LIP1 (blu cross - B) and the 
corresponding synthetic peptides mixed with IFA (FADK2: purple dot - A and LIP1dark 
blue cross - B) are reported respectively in panel A and B in comparison with the negative 
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control CIA mice group (orange square) and mice treated with dexamethasone as positive 
control (grey triangle). The panel C shows the clinical score of mice treated with TBSV 
CVP.LIP1 (dark blue cross) and TBSV CVP.FADK2 (light blue cross) in comparison with 
the negative control CIA mice group (orange square) and mice group treated with the 
unmodified TBSV CVPs. On the bottom of the figure the clinical score used for the 
evaluation of mice clinical symptoms is reported. The clinical score and the time (days) are 
showed in each graph respectively on the y and x axis. The red starts under the x axis 
indicate the mice treatments that were started at day 28 as indicated by the blu dotted line. 
Results in figure 6-panel A shows that the mice group treated with TBSV CVPs.FADK2 
has a similar behaviour of the positive control group injected with dexamethasone. It is 
important to underline that at the end of the immunization (day 28; dotted black line in 
figure 6) the mice group treated with TBSV CVPs.FADK2 had a higher clinical score then 
the positive control group, so the therapeutic effects of the TBSV CVPs.FADK2 is relevant. 
Moreover, at day 28 the clinical score of the mice group treated with TBSV CVPs.FADK2 
is exactly the same of the one injected with the synthetic FADK2 peptide (+IFA) but, at the 
end of experiment, the clinical score of the group injected with TBSV CVPs.FADK2 is 
lower then the one treated with the synthetic peptide confirming a higher therapeutic effect 
of TBSV CVPs.FADK2.  
The results were more robust in the treatments made with TBSV CVPs.LIP1. Results in 
panel B of figure 6 showed that synthetic peptide LIP1 had a similar behaviour of the 
positive control group (dexamethasone-treated mice) and, notably, at the end of the 
experiment the mice group injected with TBSV CVP.LIP1 did not show any arthritic 
symptoms. 
Finally, in figure 6-panel C it is shown the clinical score of the groups treated with TBSV 
CVPs.FADK2, TBSV CVPs.LIP1 and the unmodified TBSV CVPs; in comparison with the 
negative control group, the injection with the unmodified TBSV CVPs seems to induce a 
partial mice protection as reported even in the T1D clinical trials done using CPMV eVLPs 
expression system; it is clearly visible that the treatments with TBSV CVPs.LIP1 resulted 
to be the most effective; the injection with TSBV CVPs.FADK2 seems to have similar 
effects of those of the treatments with the unmodified TBSV CVPs but it is important to 
consider that at day 28 the mice group treated with TSBV CVPs.FADK2 had a clinical 
score higher than the group treated with unmodified TBSV CVPs.   
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These data clearly confirmed the effectiveness of the viral structure in boosting an 
immunoregolative activity of the novel discovered immunodominant peptides and the 
capability of the viral scaffold to work as an adjuvant itself. 
 
6.3. Treg determination in lymph nodes 
At the end of the experiment (day 60) Treg were determined in lymph nodes and the 
analysis results are reported in figure 7. 
 
Figure 7 Treg CD25+/FOXP3+ analysis in lymph nodes of the mice treated in the 
pre-clinical RA study. The CD25+/FOXP3+ percentage is reported on the y axis. 
 
Regulatory T cells (Tregs) are also considered suppressor T cells being responsible for 
immune system regulation retaining tolerance to auto-autoantigens and eliminating 
autoimmunity. CD4+ CD25+ suppressor T cells are well-known Tregs that express the 
transcription factor fork head box P3 (Foxp3); they are indispensable for the maintenance 
of immune self-tolerance and homeostasis by suppressing aberrant or excessive immune 
response (Haque et al., 2014).  
Figure 7 underlines a higher percentage of CD25+/FOXP3+ cells in lymph nodes of mice 
treated with TBSV CVPs.FADK2 and dexamethasone as well. These results suggest that 
the Treg mechanism could be at the basis of the therapeutic effect of TBSV CVPs.FADK2. 
Interestingly, the use of synthetic peptide FADK2 (+IFA) did not activated any Treg 
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response confirming a strong viral particle contribution in the immunoregolative action. 
On the other hand, the CD25+/FOXP3+ percentage in the lymph nodes of the mice injected 
with either TSBV CVPs.LIP1 or synthetic peptide LIP1 is similar to that of the negative 
control CIA-mice group treated with the saline buffer. 
 
6.4. Cytokines analysis in different sites 
The more important cytokines involved in the immune response associated to this 
treatment were determinate in lymph nodes, joints and serum. 
The following table 5 summarises the results of the treatment done with dexamethasone 
(positive control), TBSV CVPs.LIP1, TBSV CVPs.FADK2 and the synthetic peptide LIP1 
or FADK2 (both with IFA) in comparison with the negative control CIA-mice group treated 
with saline buffer. 
Results in table 5 shows a general decrease of the pro-inflammatory cytokines production 
(indicated as negative cytokines in table 5 –A) either in the groups of mice treated with 
TBSV particles displayed the peptides of interest or with the synthetic LIP1 and FADK2 
mixed with IFA. 
Table 5 Overview of the cytokines activation/repression in different tissue of mice group 
treated with dexamethasone as positive control, TBSV CVPs.LIP1, TBSV CVPs.FADK2 and 
synthetic peptide LIP1 or FADK2 mixed with IFA in relation to CIA mice control group treated 
with saline buffer. 
 
Negative	
citokines
TNF-α IL-17a IL-1β IFN-γ
LN J S LN J LN J S LN J
Dexamethasone
TBSV	CVPs.LIP1
TBSV	CVPs.FADK2
Synthetic	peptide	LIP1
Synthetic	peptide	FADK2
Positive	
citokines
TGF-β1 IL-10
Serum
Dexamethasone
TBSV	CVPs.LIP1
TBSV	CVPs.FADK2
Synthetic	peptide	LIP1
Synthetic	peptide	FADK2
A
B
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Table 5 underlines that the treatment with TBSV CVPs.LIP1 seems to be more effective 
in lymph nodes and serum; in particular, the viral structure seems to improve, in serum, 
the immunosuppression effect of the LIP1 peptide against the TNF-α, cytokines involved 
in the acute phase reaction of the systemic inflammation.  
On the other hand, by comparing the treatment with TBSV CVPs.LIP1 with the positive 
control (mice treated with dexamethasone) the former seems to have no effects in the joints. 
Conversely, looking at the results of the treatment performed with FADK2 synthetic 
peptide is more effective then the respective TBSV CVPs FADK2 in pro-inflammatory 
cytokines suppression. FADK2 synthetic peptide resulted to be very effective in dampen 
pro-inflammatory cytokines production in joints.  
Table 5-B highlights the activity in serum of either TBSV CVPs.LIP1 or TBSV 
CVPs.FADK2 in inducing the production of Interleukin-10 (IL-10) involved in the 
inhibition of the synthesis of pro-inflammatory cytokines. This activity has not been 
relived neither in treatments done with the synthetic peptides nor in the positive control 
mice.  
The treatment with dexamethasone and with the synthetic FADK2 peptide seem to activate 
a therapeutic effect driven by the transforming growth factor β (TGF-β), a pleiotropic 
cytokine with potent regulatory and inflammatory activity. Regarding the TGF-β 
regulatory activity, it has been demonstrated that it plays a central role in the induction of 
peripheral tolerance (Kronenberg et al., 2005). This cytokine is essential for the survival 
of naïve T cells and for inhibiting the proliferation and differentiation of self-reactive CD4+ 
and CD8+ T cells (Li et al., 2008; Lii et al., 2006). 
On the other hand, the treatment with TBSV CVPs.LIP1 and TBSV CVPs.FADK2 seems 
to activate the IL-10 mediated pathway. IL-10 is essential for homeostasis of the immune 
system by limiting the inflammatory response and has a particular role especially in the 
gastrointestinal tract following the action mechanism shown in the figure 8. 
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Figure 8 IL-10 mediated pathway in the gastrointestinal tract (Sanjabi et al., 2009). 
 
In figure 8 it is reported the IL-10 mediated pathway in the gut: in the gastrointestinal 
tract commensal bacteria/flora and food antigens are constantly sampled by intestinal 
dentritic cells (DCs). Tolerogenic CD103+ DCs produce retinoic acid which inhibits 
effector cytokine production by CD4+CD44+ T cells. In the absence of effector 
cytokines and in the presence of high concentrations of TGF-β, naïve CD4+ T cells are 
converted into Foxp3+ iTregs that produce TGF-β and IL-10. IL-10 produced by 
Intraepithelial lymphocytes (IEL) and iTregs regulates activation of intestinal 
lymphocytes, and reduces the expression of IL-12 and downregulates costimulatory 
molecules on macrophages.
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CHAPTER 2: DIAGNOSIS 
 
INTRODUCTION 
 
1. Autoimmune disease diagnosis 
There are 80-100 different autoimmune diseases (American Autoimmune Related Diseases 
Association) and many of them show similar symptoms, making their diagnosis 
challenging. 
An early and precise diagnosis is decisive for autoimmune diseases because it allows to 
manage and stem the negative effects of the disorders before they cause other 
complications and lead to a total tissue and/or organ target destruction. 
Most of autoimmune diseases cause fatigue, fever and general malaise affecting many parts 
of the body. The most common organs and tissues affected are joins and connective tissue, 
muscles, skin, red blood cells, blood vessels and endocrine glands. 
Diagnosis is often based on the investigation of the presence in the blood of either 
autoantibodies able to recognize specific tissues or organs that are involved in the 
autoimmune disease.  
Antinuclear antibodies (ANAs) are used as diagnostic marker for many autoimmune 
diseases. ANA are antibodies directed against structure within the nucleus of the cells 
found in many autoimmune, inflammatory and infective disorders such as Systemic Lupus 
Erythematosus (SLE), RA, SjS (Cervera et al., 2000), scleroderma (Barnett et al., 1993), 
polymyositis, dermatomytositis, primary biliary cirrhosis, autoimmune hepatitis 
(Obermayer-Straub et al., 2000), multiple sclerosis, discoid lupus, thyroid disease, 
antiphospholipid syndrome, juvenile idiopathic, psoriatic arthritis, juvenile 
dermatomyositis, idiopathic thrombocytopaenic purpurea and cancer. 
There are many prototype of ANAs, such as anti-La or anti-Ro antibodies which recognize 
different proteins or protein complexes within the nucleus.  
Moreover, there is a group of autoantigens called extractable nuclear antigens (ENA) 
associated to autoimmune disease. They are termed ENA because they can be extracted 
from cell nucleus with a saline buffer (Kavanaugh et al., 2000). They consist in 
ribonucleoproteins and non-histone proteins, called either with the name of the donor who 
INTRODUCTION	 	 	 DIAGNOSIS 
	110 
provides the prototype serum (La, Ro, Sm, Ja) or name of the disease setting in which they 
were found (SS-A, SS-B, Scl-70) (Wanzel et al., 2001). 
Other diagnostic procedure currently used in autoimmunity consists in red and white blood 
cells measurements because when an autoimmune disease is established the number of this 
blood cells varies compared to healthy individual. 
Also high level of C-reactive protein (CRP) in blood plasma may indicate the 
establishment of an autoimmune disease because CRP level rises in response to 
inflammation throughout the body and the indication of the inflammation rate can be 
obtained through the measurement of the erythrocyte sedimentation rate (ESR). 
 
1.1. Sjögren’s syndrome diagnosis 
The largest problem associated with SjS diagnosis is the absence of specific and unique 
diagnostic tools. At present, diagnosis consists of several steps based on classifying main 
SjS symptoms like ocular and oral dryness. Having symptoms common to most other 
widespread diseases, SjS is thus often underdiagnosed, and/or consequently diagnosed too 
late when the disease has already begun to damage the organism.  It has been estimated 
that on average it takes up to 4 years to diagnose SjS (The British Sjögren’s Syndrome 
Association). 
The current diagnostic criteria up to now used for SjS diagnosis is the one drawn up by the 
American European Consensus Group (AECG) and the American college of 
Rheumatology (ACR). 
In 2002 AECG proposed criteria for the classification of SjS: 
 I. Ocular Symptoms (dry eyes); 
 II. Oral Symptoms (dry mouth); 
 III. Ocular Signs (evaluated through Schirmer’s test); 
 IV. Histopathology: lip biopsy showing focal lymphocytic sialoadenitis; 
 V. Oral Signs (Unstimulated whole salivary flow (< 1.5 mL in 15 minutes); 
 VI. Autoantibodies ANA. 
INTRODUCTION	 	 	 DIAGNOSIS 
	 111 
Any 4 of the 6 criteria must be fit to diagnose SjS; but they must include either item IV 
(Hystopathology) or VI (Autoantibodies). Or any 3 of the 4 objective criteria (III, IV, V, 
VI). 
In 2012 ACR proposed simplified criteria for the classification of SjS: 
The classification of SjS, which applies to individuals with signs/symptoms that may 
suggest SjS, will be met in patients having at least 2 of the following 3 objective features: 
               1. positive serum anti-SSA/Ro and/or anti-SSb/La or (positive rheumatoid factor 
and ANA titer 1:320); 
               2. labial salivary-gland biopsy exhibiting focal lymphocytic sialoadenitis; 
               3. keratoconjunctivitis sicca with ocular staining score 3. 
  
Either on the basis of AECG or ACR criteria, one of the major diagnostic methods is the 
serological test for detecting antinuclear antibodies (ANA). However, 40-25% of SjS 
patients are ANA-negative (Nardi et al., 2006).  
Moreover, anti-SSA/Ro and Anti-SSA/La is found in 30–60% of Sjögren's syndrome; anti-
Ro antibodies alone are found in 50–70% of Sjögren's syndrome (Kumar et al., 2009; 
Hernández-Molina et al., 2011).  
For ANA-negative patients, labial salivary gland biopsy is needed.  This method is invasive 
and such an irreversible diagnostic technique can cause negative effects such as intolerance 
to anesthetics, bleeding and infection of damaged tissues.  
 
1.2. Rheumatoid arthritis diagnosis 
Rheumatoid arthritis can be difficult to diagnose because, especially early stage symptoms 
are common to other diseases or are typical manifestation of healthy elderly people. 
The current diagnostic procedure consists of several steps to evaluate physical and 
serological parameters. First of all, a physical evaluation of swelling, redness and warmth 
of joints allow to achieve a general valuation of the principal RA target. This analysis is 
in-depth verified using X-rays and magnetic resonance imaging (MRI) scan or ultrasound 
scan to assess the presence of damage in joints. 
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In order to evaluate the presence of inflammation, CRP and ESP blood tests are used linked 
with the investigation of autoantibodies typically present in sera of RA patient. These 
autoantibodies are rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA). 
RF is an antibody against the Fc portion of IgG (Falkenburg et al., 2015). 
However, about 4 out of 5 people with rheumatoid arthritis have positive tests for RF, but 
about 1 in 20 people without RA also have positive results. Only about half of all people 
with RA have a positive RF when the disease starts (Arthritis Research UK – 
arthritisresearchuk.org).  
Moreover, 38 % of RA patients are diagnosed with seronegative RA being negative to RF 
and ACPA serological tests (De Winter et al., 2016). 
 
The goal of this part of the PhD thesis work is the use of plant viruses for the display of 
new specific serological SjS and RA markers for the development of reagents to be used 
in an indirect ELISA test. These innovative diagnostic kits could avoid the current SjS and 
RA diagnostic obstacles due to the presence of a subgroup of seronegative patients. The 
development of these new tools could substantially reduce the time needs for a definitive 
diagnosis allowing a earlier disease identification thus avoiding further complications. 
RESULTS AND DISCUSSION    DIAGNOSIS 
 113 
RESULTS AND DISCUSSION 
SJÖGREN’S SYNDROME DIAGNOSIS 
 
Adapted from:  
Frontiers in Plant Science 2015. 6: 1080.  
Plant-derived chimeric virus particles for the diagnosis of primary Sjögren 
Syndrome. 
Tinazzi E., Merlin M., Bason C., Beri R., Zampieri R., Lico C., Bartoloni E., Puccetti A., Lunardi C., 
Pezzotti M., Avesani L. 
 
 
1. Experimental design 
The heterogeneity of Sjögren Syndrome (SjS) symptoms often delays diagnosis (Patel et 
Shahane, 2014) and many cases are overlooked due to the absence of sensitive and specific 
disease markers and other definitive criteria for classification. 
In Navone et al. (2005) a novel autoantigen target in SjS derived from tear lipocalin has 
been identified. This peptide, called lipo, is specifically recognized by the antibodies 
present in SjS patient sera and for this reason could be exploited for the development of a 
diagnostic kit. 
The sequence of lipo peptide is FEKAAGARGLST. 
The most widely used diagnostic immunoassays are based on the enzyme linked 
immunosorbent assay (ELISA), in which a passively adsorbed antigen is used to 
identify samples containing reactive antibodies. This is a simple and rapid technique 
which is routinely applied in many laboratories (Engvall et Perlmann, 1972).  
One major drawback of peptide ELISAs is the inefficient binding of peptides to solid 
substrates such as microtiter plates (Griesmann et al., 1991). Binding depends on the mass 
of the peptide and its amino acid composition, and if much of the peptide is involved in 
non-specific absorption then the relevant epitopes can be obscured (Sallberg et al., 1995; 
Gregorius et al., 1999; Gregorius et Theisen, 2001).  
To overcame this obstacle, lipo peptide were cloned in the pPVXSma, pTBSV and pEAQ-
HT-VP60 vectors in order to express in N. benthamiana plant PVX CVPs, TBSV CVPs 
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and CPMV eVLPs displaying lipo peptide. 
After purification from plant tissues these particles were used as coating reagent in ELISA 
and sensitivity, specificity, reproducibility and stability of diagnostic ELISAs building up 
with the different virus particle displaying lipo peptide were compared to each other and 
to the ELISAs based on the synthetic lipo peptide. The use of PVX CVPs-, TBSV CVPs- 
CPMV eVLPs-  based systems, characterized by different viral shapes, peptide display 
context and peptide position on the viral surface, allows to evaluate the influence of viral 
structures on ELISA performance.  
 
2. Production of PVX CVPs.lipo, CPMV eVLPs.lipo and TBSV 
CVPs.lipo 
2.1. PVX CVPs.lipo expression in plant and purification 
The PVX CVPs.lipo were produced by introducing the lipo synthetic peptide sequence into 
the vector pPVXSma to yield pPVXSma.lipo in which the peptide was fused to the N-
terminus of a truncated CP in order to be displayed on the particle surface. The peptide 
sequence was optimized for N. benthamiana codon usage, and virus movement was 
promoted by adding a serine residue between the initiator codon and the first native residue 
(Betti et al., 2012). The production of PVX CVPs particles depends on virus replication, 
so the genetic stability of the virus genome was verified after several reinfection cycles. 
The plants were infected using pPVXSma.lipo plasmid DNA to initiate the first cycle, 
followed thereafter by infection using sap from symptomatic leaves obtained 12 days after 
each round of infection. The chimeric CP gene remained stable through several passages 
as demonstrated by RT-PCR and sequencing (data not shown). The presence of PVX 
CVPs.lipo and unmodified PVX CVPs was verified by western blot analysis of infected 
leaf extracts as show in figure 1. 
	
Figure 1 Western blot of N. benthamiana leaf TSP extracts, 24 µl per lane separated 
by SDS-PAGE and detected with an alkaline phosphatase conjugated anti-PVX CP 
antibody. N: non-infected leaf extract, 1: PVX CVPs lipo leaf extract, and 2: 
unmodified PVX CVPs control leaf extract.  
25	kDa
N 1																								P
PVX	CP
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In figure 1 is evident a single band corresponding to the viral CP, with a molecular weight 
shift in the PVX CVPs.lipo sample in comparison to unmodified PVX CVPs, 
corresponding to the lipo peptide fused to the CP. 
A larger number of plants were infected to obtain sufficient leaf material for particle 
purification. A yield of 0.11 mg/g LFW of PVX CVPs.lipo and the purity of the particles 
was verified by SDS-PAGE and silver staining. The result of this analysis is shown in 
figure 2. 
	
Figure 2 Silver staining of 750 ng purified particles separated by SDS-PAGE. 1: PVX 
CVPs.lipo and 2: unmodified CVPs PVX as positive control. The position of the 25 
kDa molecular marker is indicated.  
N. benthamiana plants were also infected with pPVX201 to obtain leaf material for the 
production of unmodified PVX control particles (Figures 1 and 2). The yield was 0.62 
mg/g FLW.  
 
2.2. CPMV eVLPs.lipo expression in plant and purification 
The CPMV eVLPs.lipo were produced using the pEAQ-HT system. The VP60 CP 
precursor and the 24K protease were expressed on two separate pEAQ constructs allowing 
the production of eVLPs structurally identical to wild- type CPMV particles (Saunders et 
al., 2009). The sequence encoding the target peptide was inserted into vector pEAQ-HT- 
VP60, within the βB–βC loop of the small CP. N. benthamiana leaves were agroinfiltrated 
simultaneously with both vectors. Leaf extracts were prepared 6 dpi for analysis by western 
blot using anti-CPMV antibodies, revealing the presence of specific signals corresponding 
to the large and small and a molecular weight shift accounting for the modified small CP, 
thus confirming the insertion of the foreign peptide (figure 3).  
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Figure 3 Western blot of N. benthamiana leaf TSP extracts, 11 µl per lane separated 
by SDS-Page and detected with a polyclonal antibody (G49) specific to CPMV 
particles used at a concentration of 1:2000. N: non-infected leaf extract, 1: CPMV 
eVLPs.lipo leaf extract, and P: unmodified eVLPs CPMV control leaf extract.  
A larger number of plants were infiltrated to obtain leaf material for the purification of 
unmodified CPMV eVLPs and CPMV eVLPs.lipo. Clarified leaf protein extracts were 
processed by anion exchange chromatography column to remove phenolic compounds. 
The flow through fraction containing the eVLPs was concentrated and then purified by 
size-exclusion chromatography. A final yield of  0.04 mg/g and  0.05 mg/g FLW for 
respectively the modified and unmodified CPMV eVLPs was achieved. The purity of the 
eVLPs was confirmed by SDS-PAGE and silver staining as shown in figure 4. 
	
Figure 4 Silver staining of 2 µg purified particles separated by SDS-page. 1: CPMV 
eVLPs.lipo particles and 2: unmodified CPMV eVLPs as positive control. The 
position of the 25 and 35 kDa molecular markers is indicated. 
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2.3. TBSV CVPs.lipo expression in plant and purification 
The TBSV CVPs.lipo were produced by introducing the lipo synthetic peptide sequence 
into the vector pTBSV to yield pTBSV.lipo in which the peptide was fused to the C-
terminus of the TBSV CP in order to be display on the particle surface. The genetic stability 
of the TBSV CVPs.lipo genome was verified after several reinfection cycles. The plants 
were infected using pTBSV.lipo RNA infectious retrotranscribed from plasmid DNA to 
initiate the first cycle, followed thereafter by infection using sap from symptomatic leaves 
obtained 12 days after each round of infection. The chimeric CP gene remained stable 
through several passages as demonstrated by RT-PCR and sequencing (data not shown). 
TBSV CVPs.lipo and unmodified TBSV CVPs was purified from symptomatic leaves and 
analysed by SDS-PAGE and silver staining in order to assess the purity of particles. The 
result of this analysis is shown in figure 5. 
	
Figure 5 Silver staining of 1 µg purified particles separated by SDS-PAGE. 1: TBSV 
CVPs.lipo particles and P: unmodified TBSV CVPs as positive control; M: molecular 
marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). The 
position expected for the TBSV CP is indicated.  
Figure 5 confirms the correct purification of the TBSV CVPs.lipo particles and the shift in 
the molecular weight in comparison to the unmodified TBSV CVPs particles indicates the 
effective presence of lipo peptide fused to the CP. 
 
3. Development of an indirect ELISA using PVX CVPs.lipo, 
CPMV eVLPs.lipo and TBSV CVPs.lipo 
The suitability of modified viral particles for the diagnosis of SjS was tested by comparing 
ELISAs based on the free synthetic peptide to the different VNP formats, and also by 
M										P 1															
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comparing modified and unmodified CVPs and eVLPs, using sera from SjS patients, 
healthy controls and patients with other systemic autoimmune diseases. 
Preliminary comparative analysis of the modified and unmodified eVLPs allowed to 
discard the CPMV platform because the unmodified CPMV eVLPs generated a stronger 
signal than the CPMV eVLPs.lipo as shown in graph 1.  
 
Graph 1 OD value of ELISA based diagnostic kit set up with CPMV eVLPs.lipo.  
 
This result could be due either to the icosahedral viral structure or to the peptide position 
on the viral surface that is rigid into a loop. In order to understand which characteristic was 
the most important for the recognition between the lipo peptide and the antibodies present 
in SjS sera patient the TBSV CVPs-based expression platform was tested. This expression 
platform allows to express ichosaedral particles based on TBSV in which the peptide being 
fused on CP C-terminal is flexible on the viral surface. However, also with the TBSV CVPs 
expression system the unmodified TBSV CVPs generated a stronger signal than the TBSV 
CVPs.lipo (data not shown). 
The difference in performance between the three platforms may reflect their distinct 
structures. PVX particles comprise  1300 copies of identical CPs arranged in a helical  
configuration (Atabekov et al., 2007) whereas the icosahedral CPMV particle comprises 
60 copies each of the small and large CP subunits, only the former of which is modified, 
resulting in the display of 60 lipo peptides. The icosahedral TBSV particles comprise  180 
copies of identical CPs forming particles of 30 nm of diameter. 
The CPMV particles are 28 nm in diameter, compared to PVX with a diameter of 12 nm 
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but a length of  550 nm. This means that PVX and TBSV particles display approximately 
10 times as many peptides in the same unit of surface area (PVX = 6.2 × 10−2 peptides/nm2, 
and CPMV = 6.1 × 10−3 peptides/nm2 and TBSV = 6.4 × 10−2 peptides/nm2). Furthermore, 
the rigid icosahedral structure of CPMV and the position of the peptide within the β-loop 
of the small CP subunit may constrain its ability to be displayed whereas the peptides 
displayed on the surface of PVX and TBSV are fused respectively to the N- and C-terminus 
of the CP, leading to a more flexible and mobile structure maintaining the linear 
conformation, which correctly promotes antibody recognition.  
The flexible and filamentous PVX CVPs structure seem to be decisive for the diagnostic 
application of the particles in ELISA. 
The ELISA based on the PVX CVPs.lipo showed greater sensitivity than the corresponding 
assay with synthetic peptide. This may reflect the relatively flat nature of the synthetic 
peptide ELISA, with the synthetic peptide passively adsorbed to the two-dimensional 
polystyrene surface of the microtiter plate, compared to the three-dimensional nature of 
the PVX CVPs.lipo, which form a nanomolecular scaffold that increases the surface area 
of the plate available for peptide display.  
The ELISA based on PVX CVPs platform was compared with the one based synthetic 
peptide to evaluate the sensitivity and specificity of each ELISA.  90/91 patients with SjS 
were correctly shown to possess serum antibodies against lipo peptide using the PVX 
CVPs.lipo, whereas 79/91 were identified using the lipo peptide alone. These results 
corresponded to a sensitivity of 86.8% for the synthetic peptide and 98.8% for the PVX 
CVPs.lipo. 
Neither the synthetic peptide nor the PVX CVPs.lipo particles were recognized by sera 
from healthy donors. Autoimmune reactivity against the lipo peptide therefore appears to 
be largely confined to the SjS patient population. The specificity of quantitative analysis 
was 90% for both the PVX CVPs.lipo and synthetic lipo peptide ELISAs.  
Moreover, results showed that sera from the ANA-negative subgroup of SjS patients with 
diagnostic salivary gland histology (25/91 patients) reacted toward the PVX CVPs.lipo 
particles with a sensitivity of 98.7%, compared to 75% sensitivity in the peptide ELISA 
table 1). 
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Table 1 The sensitivity and specificity (expressed as a percentage) ELISAs based on the 
synthetic lipo peptide and PVX CVPs.lipo considering all SjS patients or the SjS 
subgroup without ANA as a diagnostic serological marker. 
 All SjS patients ANA-negative SjS patients 
Sensitivity Specificity Sensitivity Specificity 
Synthetic lipo peptide 86.8 90.0 75.0 90.0 
PVX CVPs.lipo 98.8 90.0 98.7 90.0 
 
The PVX CVPs.lipo based ELISA was more reproducible than the synthetic lipo peptide 
ELISA (data not shown), reflecting the nature of interaction between the binding reagent 
and the solid substrate. Synthetic lipo peptides are passively and non-covalently adsorbed 
to the solid substrate, an interaction which is weak due to the shortness of the peptide, and 
the structure of the peptide is randomly oriented with respect to the surface plane 
(Griesmann et al., 1991). In contrast, large and complex multimeric proteins such as PVX 
CVPs adsorb strongly to the surface, and regardless of orientation, there remain plenty of 
peptides projecting freely into solution to permit interactions with serum antibodies. This 
increases the robustness and reproducibility of the ELISA regardless of the chemical 
structure of the peptide. However, synthetic peptide-based ELISA can be improved by 
chemical modifications, such as biotinylation, that may help in maintaining peptide 
conformation and improve their adsorption to solid substrates. 
There was also a positive correlation between ANA titers and the ELISA outcome. Patients 
with an ANA titer exceeding 1:160 produced strong signals in the ELISA (p = 0.023), 
although there was no statistically significant relationship between ANA titers and the 
presence of anti Ro-SSA or anti La-SSB antibodies. Moreover, there was a strong 
correlation between the ELISA outcome and exocrine gland symptoms (p < 0.001) but not 
with the involvement of other organs, e.g., pulmonary fibrosis, neurological pathology, or 
vasculitis. This may reflect the small proportion of patients in our SjS cohort presenting 
with these symptoms.  
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4. Stability of ELISA test over the time 
To demonstrate the stability and reproducibility of the PVX CVPs.lipo-based ELISA, 
microtiter plates were coated with PVX CVPs.lipo, stored at 4◦C and then used after 1, 15, 
30, and 60 days to test the sera from 18 SjS patients.  
The results of these analysis are shown in figure 6. 
	
Figure 6 PVX CVPs.lipo ELISA results using sera from a subgroup of 18 SjS 
patients at four time points to determine assay stability. Each serum sample was 
tested three times at each time point; average values of optical density are graphed 
on the y axis. Blue: 24 h, red: 15 days, green: 30 days, and purple:60 days.  
The results of these tests did not change regardless of the duration of storage, confirming 
the stability of the PVX-based ELISA format and the reproducibility of the assay (figure 
6).  
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RHEUMATOID ATHRITIS DIAGNOSIS 
1. PVX CVPs expression system 
 
1.1. Experimental design 
RA is one of the most widespread autoimmune disease; although serological AR markers 
are well established (e.g. RF and ACPA), 38 % of RA patient are seronegative to these (De 
Winter et al., 2016) and for that difficult to diagnose. 
In Tinazzi et al. (2015) and as reported in the previous section (RESULTS – SJÖGREN’S 
SYNDROME DIAGNOSIS – page 115), filamentous and flexible viruses result to be 
excellent tools for the development of innovative diagnostic kit based on indirect ELISA. 
PVX CVPs and TuMV CVPs expression systems were selected for the expression of novel 
peptides identified to be putatively involved in seronegative RA (table 1 – page 92). 
The LIP1, FADK2 and BANK1 nucleotidic sequence were independently cloned in 
pPVXSma viral vector and purified through maxi purification from bacteriological culture. 
Once obtained a sufficient amount of pPVXSma.LIP1, pPVXSma.FADK2 and 
pPVXSma.BANK1, experimental procedure was divided in two infection phases: a small 
and large phase. The first phase consists in three infection cycle of 5 N. benthamiana 
plants: at the first cycle, plants are infected using plasmid DNA, while for the following 
infections, sap from symptomatic leaves is used. The aim of the small scale infection is to 
assess whether recombinant virus remains genetically stable despite the insertion of the 
peptide sequence in the CP gene.  
If PVX CVPs displaying peptide of interest result to be genetically stable a large phase 
infection (50 plants) was carried out for obtaining sufficient material for PVX CVPs.LIP1, 
PVX CVPs.FADK2 and PVX CVPs.BANK1 purification. 
In collaboration with the research group of professor Fernando Ponz Ascaso (Centro de 
Biotecnología Y Genómica de plantas – Madrid – Spain). LIP1 and FADK2 were selected 
to be expressed with the viral system based on TuMV. 
LIP1 and FADK2 were cloned in p35Tunos-vec01-NAT1 vector and used for N. 
benthamiana inoculation. The genetic stability of TuMV display peptides of interest were 
assessed by imunocapture-RT-PCR (IC-RT-PCR) and sequencing.  
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After the assessment of the TuMV CVPs.LIP1 and TuMV CVPs.FADK2 genetic stability, 
sap derived from symptomatic N. benthamiana leaves were used for the infection of 
Brassica juncea plants. This plant results to be more suitable for the expression of TuMV 
CVPs in comparison to N. benthamiana and it allows to reach higher biomass yield. 
TuMV CVPs.LIP1 and TuMV CVPs.FADK were purified from B. juncea infected plants. 
 
1.2. Cloning of LIP1, FADK2 and BANK1 with the PVX CVPs 
expression system 
The sequence of the novel peptides identified to be putatively involved in seronegative RA 
(table 1 – Results of RA therapy) were optimised as reported in table 1 in order to fit the 
parameters for the expressiom with the PVX CVPs expression system (rif introduzione 
PVX). 
Table 1 optimised sequence for the expression of novel peptides putatively 
associated with seronegative RA with the PVX CVPs system 
Peptide Sequence Length (aminoacids) pI 
W 
(%) 
S + T 
(%) 
LIP1 ASVLANVAQAFE 12 4.00 0 8.3 
Optimazed LIP1 MASVLANVAQAFEKST 16 5.75 0 18.8 
Nucleotidic 
sequence 
ATG GCT TCT GTT CTT GCT AAT GTT GCT CAA GCT TTT GAA 
AAG TCT ACT 
FADK2 AKVLANLAHPPA 12 8.80 0 0 
Optimazed FADK2 MSEAKVLANLAHPPAT 16 6.50 0 12.5 
Nucleotidic 
sequence 
ATG TCT GAA GCT AAG GTT CTT GCT AAT CTT GCT CAT CCT 
CCT GCT ACT 
BANK1 DMILANLSIKKK 12 9.70 0 8.3 
Optimazed BANK1  MSDMILANLSIKKKTE 16 8.25 0 18.8 
Nucleotidic 
sequence 
ATG TCT GAT ATG ATT CTT GCT AAT CTT TCT ATT AAG AAG 
AAA ACT GAA 
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The methionine (M) at the beginning of the sequence was added in order to introduce the 
translation start site. Moreover, serine (S) and threonine (T) residues were added because 
these phosphorylated residues promote virus disassembling and viral RNA replication. 
Finally, the absence of tryptophan was assessed because the presence of this aminoacid 
in peptide sequence could critically affect cell-to-cell and phloem movement of the 
virus. 
The peptide sequences reported in table 1 were used for the design of olinucleotide 
pairs NheI-compatible 5’- and XmaI-compatible 3’- end DNA fragments that were 
ligated into the NheI-XmaI digested vector. 
The resulting pPVXSma.LIP1, pPVXSma.FADK2 and pPVXSma.BANK1 were 
transformed in E. coli TOP10 strain competent cells by heat-shock, plated on 
ampicillin containing medium and PCR selected using vector-specific primers 
annealing respectively at the 5’ and at the 3’ of the insertion site (pCP for - CP rev). 
The length of the amplification fragments obtained is 360 bp plus the length of the 
inserted sequence. Results of this analysis on 4 colonies transformed with 
pPVXSma.LIP1, pPVXSma.FADK2 and pPVXSma.BANK1 are reported in figure 1. 
 
Figure 1  Colonies transformed with pPVXSma vector after ligation with LIP1, 
FADK2 and BANK1 oligonucleotides. PCR amplification products obtained with 
two vector-specific primers (pCP for – CP rev) were loaded on a 2% agarose gel. 
M: molecular marker (BenchTop 100bp DNA ladder - Promega); 1-4: number of E. 
coli TOP10 colonies trasformated with pPVXSma.LIP1 vector; 5-8: number of E. 
coli TOP10 colonies trasformated with pPVXSma.FADK2 vector; 9-12: number of 
E. coli TOP10 colonies trasformated with pPVXSma.BANK1 vector; P: positive 
control (using as template pPVXSma harboring a 12 aminoacid length peptide); N: 
negative control. 
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Figure 1 shows that all colonies analysed presumably contained the vector with peptides 
sequence insertion; indeed specific amplicons of approximately 380 bp were visible in all 
the samples loaded on the gel.  
Positive bacterial colonies were propagated in selective broth and plasmids were extracted, 
PCR analysed and sequenced to assess that the insert was correct. One colony for each 
insert type was selected and propagated in selective medium for the extraction of plasmid 
by maxi-preparation. Plasmids obtained were used for the small scale phase infection 
cycle. 
 
1.3. Analysis of the expression and genetic stability of PVX 
CVPs.LIP1, PVX CVPs.FADK2 and PVX CVPs.BANK1 
A small scale infection of 5 plants using vectors pPVXSma.LIP1, pPVXSma.FADK2 and 
pPVXSma.BANK1 was performed, in order to verify the expression of the modified 
particles. 
13 days post infection (dpi), local and systemic symptomatic leaves were collected and 
analysed by retrotrascription-PCR (RT-PCR). The cDNAs were then sequenced to verify 
the stability of the peptide expressed on the viral surface. 
After the first cycle of infection, other two cycles were performed inoculating 2 
leaves/plants using sap derived from symptomatic leaves of the first infection cycle. 10-13 
dpi, the local and systemic symptomatic leaves were collected and analysed as describe 
before. 
- First infection cycle 
A small scale infection of 5 plants for PVX CVPs.LIP1, PVX CVPs.FADK2 and PVX 
CVPs.BANK1 was performed, in order to verify the expression of the modified particles. 
The symptomatology was constantly monitored; an example of a plant inoculated with 
pPVXSma.LIP1 is shown in figure 2.  
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Figure 2 Inoculated (A) and systemic (B) leaves of a N. benthamiana plant infected 
with pPVXSma.LIP1 13 days post infection (dpi), in comparison with a wild type leaf 
(C). 
Figure 2 highlights the typical PVX chlorotic symptom on local leaves (A); after the 
mechanical inoculation on 2 leaves, the PVX CVPs moves from cell to cell in the infected 
tissue through the plasmodesmata and spreads systemically in the upper leaves through the 
phloem vein network. As shown in figure 2-B, PVX produces typical mosaic symptoms 
on systemic leaves.  
Either plants infected with PVX CVPs.LIP1 or PVX CVPs.BANK1 showed these typical 
symptoms, whereas plants infected with PVX CVPs.FADK2 did not developed neither 
chlorosis nor mosaic symptoms. 
RT-PCR analysis was done on systemic symptomatic leaves being the viral concentration 
higher than in the systemic one. 
The RT-PCR reactions were performed using the SuperScript III (Promega) and 2 PCR 
analysis were performed. The first was carried out with primers specific for the actin  
constitutive gene (ACT1 and ACT2) in order to assess cDNA synthesis. The latter, was 
done using PVX specific primers (pCP for – CP rev) to amplify the 3’ CP region, in which 
the peptide sequence was cloned.  
The results of the PCR are reported in figure 3. 
 
Figure 3 RT-PCR analysis of the symptomatic leaves collected from plant infected 
with pPVXSma.LIP1 (1-3) and pPVXSma.BANK1 (4-6). The PCR analysis done on 
the cDNAs using primers for a constitutive gene (ACT1 and ACT2) (A) and PVX 
A B C(a) (b) (c)
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specific primers (pCP for – CP rev) (B) are reported. PCR amplification products 
obtained were loaded on a 2% agarose gel. M: molecular marker (BenchTop 1Kb 
DNA ladder – Promega); N: negative control of the PCR; N*: negative control (using 
cDNA derived from a wild type N. bethamiana as template); P: positive control 
(using a pPVXSma vector display a well-know peptide as template).  
An amplicon of approximatively 700 bp is clearly visible in all cDNA samples (figure 2–
B) confirming the specific presence of the viral PVX RNA in the analysed plants.  
The fragments resulting from the PCR with PVX specific primers, were sequenced and the 
resulting sequence was aligned with the expected one; all the plants infected either with 
pPVXSma.LIP1 or pPVXSma.BANK1 expressed PVX CVPs in which the sequence of the 
peptide is genetically stable. 
- Second and third infection cycle 
Sap from symptomatic leaves of plants infected with pPVXSma.LIP1 and 
pPVXSma.BANK1 was used for the infection of 5 plants/peptide. 
At 10-12 dpi symptomatic leaves were collected and analysed by RT-PCR and 
sequencing in order to assess the genetic stability of the cloned peptide. 
The results of these analysis are summarized in table 2. 
 
Table 2 genetic stability of PVX CVPs.LIP1 and PVX CVPs.BANK1 in the 2nd and 
3th infection cycle. V: particles were expressed in plants and were genetically stable; 
X: particles were not expressed in plants or were not genetically stable. 
 2nd infection 3th infection 
PVX CVPs.LIP1 V X 
PVX CVPs.BANK1 V V 
 
PVX CVPs.BANK1 results to be stable among 3 infection cycle, whereas PVX 
CVPs.LIP1 in the 3rd infection cycle showed a mutation in a aminoacid that result in the 
shift of Leucine (L) in Proline (P). 
 
1.4. Purification of PVX CVPs.LIP1 and PVX CVPs.BANK1 
PVX CVPs.LIP1 and PVX CVPs.BANK1 were purified starting from 50 g of symptomatic 
local and systemic leaves respectively from the 2nd and 3th infection cycle. 
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The purification of particles was performed following the protocol described in Uhde et 
al. (2005). Purification fractions were analyzed by SDS-PAGE on a 14% polyacrylamide 
gel and the gel was silver stained. The results of this analysis are reported in figure 4. 
 
Figure 4 SDS-PAGE and silver staining analysis of the PVX CVPs.LIP1 (A) and 
PVX CVPs.BANK1 (B) purification steps. 1: 1.4 µl of total protein extract derived 
from symptomatic leaves; 2-3: 1.4 µl of sample from  progressive purification steps; 
4-5: 1.6 µl of sample from  progressive purification steps 6: - ; 7: 0.5 µl of the final 
purified PVX CVPs particles; P: 750 ng of unmodified PVX CVPs particles purified 
in a previuos PhD thesis work (Merlin, 2013) from N. benthmiana infected with 
pPVX201 vectors. The samples were loaded on 14% polyacrylamide gel. The PVX 
CP molecular weight (25 kDa), is indicated. M: molecular marker (PageRuler™ Plus 
Prestained Protein Ladder, Thermo Scientific). 
The silver staining analysis allows to confirm the correct purification of PVX CVPs.LIP1;  
indeed, in figure 4-A (lane 7) it is clearly visible a signal corresponding to the PVX CP 
protein without the presence of any other contaminant proteins. This signal is comparable 
to that of positive control, without any shift in the molecular weight. Positive control used 
in this analysis were unmodified PVX CVPs purified from N. benthamiana plants infected 
with pPVX201 vector during another PhD thesis work (Merlin, 2013). The resulting 
unmodified PVX CVPs are composed by CPs of 25 kDa. As reported in the previous 
sections, for the expression of PVX CVPs.LIP1 pPVXSma, which encodes for a 21 
aminoacids (aa) N-terminal truncated version of the CP, were used; however, the presence 
of 16 aminoacid LIP1 peptide cloned at the N-terminal of the CP sequence in the pPVXSma 
vector explained the same migration pattern of the unmodified PVX CVPs (figure 4-A, 
lane P) and the PVX CVPs.LIP1 (figure 4-A, lane 7) in the SDS-PAGE analysis. 
On the contrary, the PVX CVPs.BANK1 were not successfully purified because were lost 
during the purification steps. In particular, PVX CVPs.BANK1 seem to precipitate in the 
centrifugation step after the adding of silver nitrate, indeed no signal are present in the lane 
5 of the figure 4-B in which surnatant derived from this centrifugation step were loaded. 
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In order to find the suitable protocol for PVX CVPs.BANK1 purification, several 
procedures were tested changing centrifugation time and speed, using other published 
purification protocol (Leiser-Richter et al., 1978) or chromatography methods but none of 
them allowed to purified the PVX CVPs.BANK1 (data not shown). 
1.4.1. PVX CVPs.LIP1 purification yield 
Purified PVX CVPs.LIP1 were quantified by reading of the 280 nm absorbance.  
Using the Lambert Beer law: 
A280 = ε x L x C 
ε: molar extinction coefficient (m2 mol-1) 
L: path leght (cm) 
C: concentration (mg/ml) 
 
and considering the CPMV eVLPs molar extinction coefficient (1.25 m2 mol-1) the 
concentration (mg/ml) of the particle preparations was obtained. 
The PVX CVPs.LIP1 purification yield result to be 0.36 mg/g LFW. 
 
2. TuMV expression system 
2.1.  Cloning of LIP1 and FADK2 with the TuMV CVPs expression 
system 
Considering the results obtained with the expression system based on PVX, it was chosen 
to focus the attention on the expression of LIP1 and FADK2 using the expression system 
based on TuMV. 
This part of the work was carried out in collaboration with the research group of professor 
Fernando Ponz Ascaso (Centro de Biotecnología Y Genómica de plantas – Madrid – 
Spain). 
The sequence of optimised LIP1 and FADK2 reported in table 1 were successfully cloned 
in the p35Tunos-vec01-Nat1 vector following the procedure reported in Sánchez et al. 
(2013).  
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Nicotiana benthamaina plants inoculation with p35Tunos-vec01-Nat1.LIP1 and 
p35Tunos-vec01-Nat1.FADK2 
N. benthamiana plants were infected with p35Tunos-vec01-Nat1.LIP1 or p35Tunos-
vec01-Nat1.FADK2 when necrotic symptoms were visible leaves were collected, analyzed 
by IC-RT-PCR and sequenced in order to assess the genetic stability of the peptides 
displayed on TuMV surface. 
Either N. benthamiana infected with p35Tunos-vec01-Nat1.LIP1 or p35Tunos-vec01-
Nat1.FADK2 result to express genetically stable respectively TuMV CVPs.LIP1 and TuMV 
CVPs.FADK2 (data not shown). 
 
2.2. Expression of TuMV CVPs.LIP1 and TuMV CVPs.FADK2 in 
Brassica juncea 
Sap derived from N. benthamiana plants expressing TuMV CVPs.LIP1 and TuMV 
CVPs.FADK2 were used for inoculate B. juncea plants.  
B. juncea is the best model plant for TuMV CVPs production because allow to reach higher 
yield in comparison to the expression in N. benthamiana in which necrotic symptoms cause 
strong interference in the plant fitness. On the contrary, the first inoculation of plant with 
p35Tunos-vec01-Nat1.LIP1 or p35Tunos-vec01-Nat1.FADK2 were conduced in N. 
benthamiana because it is more susceptible. 
At 7-10 dpi B. juncea inoculated either for the expression of TuMV CVPs. LIP1 or TuMV 
CVPs.FADK2 plants showed typical clorotic and necrotic TuMV symptoms as shown in 
figure 5. 
 
Figure 5 Inoculated leaves expressing TuMV CVPs.FADK2 (A) and TuMV 
CVPs.LIP1 (B) of a (B). juncea plant 10 days post infection (dpi), in comparison with 
a wild type leaf (C). 
A B C
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A large scales infection of 30 plants for each peptide were carried out in order to obtained 
sufficient material for TuMV CVPs.FADK2 and TuMV CVPs.LIP1 purification. 
 
2.3. TuMV CVPs.LIP1 and TuMV CVPs.FADK2 purification 
The purifications of TuMV CVPs.LIP1 and TuMV CVPs.FADK2 were performed 
following the procedure reported in Sánchez et al. (2013). 
The last step of the purification protocols consists in a CsCl gradient that results in a thick 
white band forming in the tube below the green contaminant protein.  
The result of the CsCl gradient performed during the TuMV CVPs.LIP1 and TuMV 
CVPs.FADK2 purification steps is shown in figure 6. 
 
Figure 6 CsCl gradient step of the procedure for the purification of TuMV 
CVPs.FADK2 (A) and TuMV CVPs.LIP1 (B). 
The purification was successful only for the TuMV CVPs.FADK2 indeed the expected 
white band is visible only in figure 6-A as indicated with the red arrow. 
The band corresponding to the purified TuMV CVPs.FADK2 were picked up, whereas the 
CsCl gradient in which sample derived from the TuMV CVPs.LIP1 infection were loaded 
were fractionated and numerated from 1 to 27 from the bottom to the top. The resulting 
fraction were analyzed measuring the absorbance at 260 (A260); the results of this analysis 
is reported in the graph 1. 
Graph 1 A260 nm analysis of CsCl gradient fractions of the TuMV CVPs.LIP1 
purification experiment 
A B
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Beside the high value of A260 that characterise the first fraction that usually contain high 
molecular weight cantaminat (Rubisco, lipids, ..), graph 1 shows a peak in the A260 at the 
fraction number 12. 
This fraction and an aliquot derived from the white band of the TuMV CVPs.FADK2 
purification were loaded on 14 % polyacrylamide gel and silver stained in order to assess 
the effective presence of TuMV CVPs particles and their purification level. 
The result of this analysis is showed in figure 6. 
 
Figure 6 SDS-page and silver staining analysis of the TuMV CVPs.FADK2 (1) and 
TuMV CVPs.LIP1 (2). 10 µl of aliquots derived from white band of the TuMV 
CVPs.FADK2 (1) and fraction number 12 of CsCl gradient of TuMV CVPs.LIP1 the 
purification were loaded on 14% polyacrylamide gel. P: 800 ng of unmodified TuMV 
CVPs as positive control (gently provided by professor Fernando Ponz Ascaso). The 
TuMV CP molecular weight (33-35 kDa), is indicated. M: molecular marker 
(PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). 
Figure 6 underlines the presence of a signal (lane 1) corresponding to TuMV 
CVPs.FADK2. These particles were successfully purified indeed no other contaminant 
protein are present. The shift in the molecular weight of the TuMV CVPs.FADK2 (lane 1) 
in comparison to the unmodified TuMV CVPs used as positive control (lane 2) indicate 
the presence of FADK2 fused to the TuMV CP. 
On the other hand, no signal is visible in lane 2 indicating that fraction 12 did not contain 
TuMV CVPs.LIP1. The purification of these particle has failed. 
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CHAPTER 3: OTHER APPLICATIONS 
 
INTRODUCTION 
 
1. eVLPs internalization 
Cell-penetrating peptides (CPPs) have attracted attention due to their ability to deliver 
functionally cargo into cells in non-destructive manner (Langel et al., 2006; Seebach et al., 
2004). 
CPPs usually are short cationic sequences with amphiphilic nature that are attracted by the 
anionic cell surface and can eventually penetrate through the hydrophobic lipid bilayer. 
The exact mechanism is still poorly understood, but it seems to be independent of classical 
receptor-mediated intake and, in some cases, it might involve endocytosis as the initial step 
(Fonseca et al.,2009).  
A drawback of CPPs is their difficult synthesis and the fact that they are not accessible for 
recombinant expression.  
This peptide can be described as a cluster of arginine and lysine that provides the cationic 
nature to the peptide. 
 
1.1. Tat peptide 
Tat peptide is derived from the small nuclear protein of HIV. This protein is required for 
optimal HIV viability (Fisher et al., 1986) and transcription (Peterlin et al., 1986). Tat 
peptide is one of the most common used CPPs, indeed it has been successfully shown to 
deliver a large variety of cargos, from small particles to proteins, peptides and nucleic 
acids. 
Despite the high number of studies and biological application using this peptide, the precise 
mechanism of entry still appears controversy and requires further investigations. 
 
2. Antimicrobial Peptides (AMPs)  
Pesticides are widely used in agricultural production to reduce crop yield losses and 
maintain high product quality. However, serious concerns have been raised about health 
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risks and their impacts on environment. Thus there is a current need for alternative crop 
protection systems with improved safety propriety. 
A class of peptide called antimicrobial peptides (AMPs) is a key component of the innate 
immune system in almost all living organisms and has attracted attention as potential 
agents able to help plant species to fight microbial diseases. 
AMPs are sequence long less then 50 aminoacids with unique propriety in terms of 
biocompatibility, moderate biodegradability and low resistance developed on target 
microorganism (Badosa et al., 2013). 
Thanks to these characteristics they can be exploited in several fields: they can substitute 
or complement antibiotics in animal feed, they can be used as biopreservatives in food, 
cosmetics, biomaterials and antifouling (Cleveland et al., 2001). 
However, AMPs are produced at low concentration in living organisms and have low 
stability. 
 
2.1.  BP100 peptide 
BP100 peptide is a AMPs designed through combinatorial chemistry approaches. BP100 
is derived from a 125-member library of chimeric peptides, hybrids of two natural AMPs 
(cecropin and A-melittin). 
BP100 has a strong cationic charge and amphipathic arrangements that allow it to interact 
and destroy cell membranes of target microorganisms. 
Several studies have demonstrated that BP100 has significant in vitro activity against X. 
axonopodis pv. Vescicatoria, P. syringae pv syringae and E. amylovora  (MIC of 2.5-7.5 
µM) and low hemolysis showing a minimal cytotoxicity (22% at 150 µM) (Badosa et al., 
2007). 
Finally, its efficacy is comparable to standard antibiotics and it is highly biocompatible, as 
assessed by acute oral toxicity tests in mice (Montesinos and Bardaji, 2008). 
 
 
Besides the therapeutic and diagnostic applications, eVLPs displaying functional peptides 
can be useful reagents and tools in the industrial and biotechnological fields. 
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In particular, in this part of the work CPMV eVLPs have been used for the expression of 
CPP Tat peptide in order to develop eVLPs able to vehicle peptides inside the cell either 
for therapeutic purpose of for studying specific interaction.  
Finally, CPMV eVLPs system has been exploited for the expression of BP100 peptide in 
order to produce eco-friendly pesticides. 
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RESULTS AND DISCUSSION 
DEVELOPMENT OF A SYSTEM FOR CELLULAR PEPTIDE 
INTERNALIZATION 
 
1. Experimental design 
CPMV eVLPs expression system could be exploited as a biotechnological tool for peptide 
internalisation into the cells. This could be particularly useful in several fields, from 
targeting therapeutics or imaging agents to functional studies by targeting selected peptide 
inside specific cell types. 
In particular, the aim of this part of the work was the study of an interaction between a 
ligand and a receptor located inside the endothelial cell of the central nervous system. The 
strategy was to express the ligand on the surface on CPMV eVLPs, so the capability of 
these particle to penetrate the neuroblastoma cells had to be assess.  
The penetration capability of purified unmodified CPMV eVLPs was tested in vitro 
culture. In vitro culture of neuroblastoma cells were treated with unmodified CPMV 
eVLPs. At different times, unmodified CPMV eVLPs were removed and the 
neuroblastoma cells treated were lysate using a detergent. The cellular lysate was then 
analysed by SDS-PAGE and western blot using a polyclonal antibody specific for CPMV 
particles for the detection of specific signals. 
At the same time, the HIV-Tat derived peptide has been selected to be cloned into the 
pEAQ-HT-VP60 vector in correspondence of the ßB-ßC loop of the CPMV S CP which is 
the main exposed one. 
The pEAQ-HT-VP60 was engineered and two restriction sites were created at the ends of 
the sequence encoding for the second main exposed loop of the same CP (ßC’-ßC’’ loop) 
in order to obtain a new pEAQ-HT-VP60 whit an insertion site for peptide cloning into 
ßC’-ßC’’ loop.  
Tat sequence was modified in order to optimize the peptide pI to be expressed with the 
CPMV eVLPs expression system.  
The modified sequence was cloned into newpEAQ-HT-VP60 used for agroinfiltrated N. 
bethamiana plants. 
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The expression of CPMV eVLPs displaying Tat peptide (CPMV eVLPs.Tat) was assessed 
and the purification strategy was set up in order to test CPMV eVLPs.Tat penetration in 
neuroblastoma cells. 
 
2. Unmodified CPMV eVLPs internalisation experiments in 
neuroblastoma SH-SY5Y cells  
30-40% confluent neuroblastoma cells SH-SY5Y were transferred in plate wells and 
incubated at 37 °C until 70% confluency was reached. 
The treatments were done as reported in the following scheme in which every circle 
represent a wells with 70% confluent SH-SY5Y cells. 
 
Scheme 1 SH-SY5Y neuroblastoma cells treatment with unmodified CPMV eVLPs 
 
 
Some preliminary experiments showed that the sodium phosphate buffer (0.1 M + 0.15M 
NaCl), in which unmodified CPMV eVLPs were resuspended, could interfere with 
neuroblastoma cells stability; thus the unmodified CPMV eVLPs were concentrated and 
mixed with the DMEM colture medium without FBS (fetal bovine serum) to reach the 
particles concentration of 0.05 mg/ml in order to minimise the presence of that buffer. 350 
µl of the unmodified CPMV eVLPs prepared as described, were added to wells with 70% 
confluent SH-SY5Y neuroblastoma cells and incubated at 37 °C for different time points 
( 8 and 24 hours). 
As negative control, 4 wells containing 70% confluent SH-SY5Y neuroblastoma cells were 
treated with DMEM colture medium without FBS (fetal bovine serum) without the eVLPs 
and 4 empty wells (without neuroblastoma cells) were treated with DMEM colture medium 
1 3
3
1. SH-SY5Y	neuroblastoma	cells treated 24	hours	with	
unmodified CPMV	eVLPs;
2. SH-SY5Y	neuroblastoma	cellsnon-treated (24	hours);
3. Unmodified CPMV	eVLPs	without SH-SY5Y	
neuroblastoma	cells (24	hours);
4. SH-SY5Y	neuroblastoma	cells treated 8 hours	with	
unmodified CPMV	eVLPs;
5. SH-SY5Y	neuroblastoma	cellsnon-treated (8 hours);
6. Unmodified CPMV	eVLPs	without SH-SY5Y	
neuroblastoma	cells (8 hours);
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without FBS (fetal bovine serum) containing unmodified CPMV eVLPs at a final 
concentration of 0.05 mg/ml. 
After the incubation, the culture medium was picked up and the neuroblastoma cells 
attached on the bottom of the wells were washed in order to remove unmodified residual 
CPMV eVLPs and treated with SDS 1% to obtain a cellular lysate.  
Neuroblastoma cells incubated 24 hours with unmodified CPMV eVLPs, at the end of the 
experiment resulted to be in solution and not attached on the bottom of the well. The 
corresponding negative control, in which neuroblastoma cells were treated 24 hours with 
culture medium without unmodified CPMV eVLPs did not show any stress signal. 
This observation indicated that the presence of unmodified CPMV eVLPs end/or the 
residual of the sodium phosphate buffer (0.1 M + 0.15M NaCl) for this timeframe interfere 
with cell stability. Anyway, the cells were transferred into a tube pelleted and resuspended 
with SDS 1% as well. 
The resulting lysate was analysed by SDS-PAGE and western blot using a polyclonal 
antibody specific to CPMV particles for the detection of specific signals; results are 
reported in the figure 1. 
 
Figure 1 SDS-PAGE and western blot analysis of the cellular lysate obtained from 
the neuroblastoma cells internalization experiment done with the unmodified CPMV 
eVLPs. 1: negative control, cellular lysate obtained from non-treated SH-SY5Y 
neuroblastoma cells (24 hours); 2, 4, 5: cellular lysate obtained from SH-SY5Y 
neuroblastoma cell treated 24 hours with unmodified CPMV eVLPs; 3: negative 
control, unmodified CPMV eVLPs without SH-SY5Y neuroblastoma (24 hours); 6: 
negative control, unmodified CPMV eVLPs without SH-SY5Y neuroblastoma (8 
hours); 7: negative control, cellular lysate obtained from non-treated SH-SY5Y 
neuroblastoma cells (8 hours); 8: cellular lysate obtained from SH-SY5Y 
neuroblastoma cell treated 8 hours with unmodified CPMV eVLPs; P: 875 ng of 
purified unmodified CPMV eVLPs as positive control. 20 µl of each sample were 
loaded on 12% polyacrylamide gels then blot was probed with a polyclonal antibody 
(G49) specific to CPMV particles used at a concentration of 1:2000. The expected 
position of CPMV L and S CPs is indicated on the side of the figures. 
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Figure 1 showed no specific signals in the lane corresponding to the cellular lysates 
indicating that unmodified CPMV eVLPs are not able to penetrate neuroblastoma cells.  
 
3. Design of new insertion site in the pEAQ-HT-VP60 vector and 
development of newpEAQ-HT-VP60/Tat 
It is well known (Porta et al., 2003) that for the exposition in the ßC’-ßC’’ loop peptide 
sequence have to be inserted between the Val42 and Gly43 of the pEAQ-HT-VP60. Thus 
the sequence of this vector was studied in order to find possible sequences in the region 
above mentioned that, through silent mutation or by adding an aminoacid could be 
transformed into a unique restriction site.  
In  figure 2 the selected sequence and the mutations done are reported. 
 
Figure 2 pEAQ-HT-VP60 2451-2801 bp region. A: mutation done to obtained AgeI 
(red boxes), AseI (blue boxes) and SmaI (green boxes) retriction site. B: newpEAQ-
HT-VP60 final sequence. 
As explained in figure 2-A, new AgeI and SmaI unique restriction sites have been created 
by introducing two silent mutations and the AseI restriction site was obtained by the 
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addition of one aminoacid. These three new restriction sites were created to allow the 
insertion of the peptide of interest in the ßC’-ßC’’ loop located between the Val42 and 
Gly43. In particular, in this new vector sequence, the insertion can be obtained either 
through classic cloning procedure involving two oligonucleotides that are ligated between 
AgeI and AseI restriction sites or by designing a gene string to be inserted between AgeI 
and SmaI. 
In panel B-figure 2 the final newpEAQ-HT-VP60 vector sequence is reported. 
In order to express the Tat peptide with the CPMV eVLPs system its sequence has been 
optimized (table 1) to decrease its pI, too high for the expression with this platform. 
Table 1 Optimization of Tat peptides for its expression with CPMV eVLPs system 
Aminoacids sequence CGRKKRRQRRRPPQ 
Nucleotidic sequence TGT GGT AGA AAG AAG AGA CGA CAA AGA CGT AGA 
CCT CCA CAA 
Peptide length 
(aminoacids) 
pI 
14 12.30 
Optimazed aminoacids 
sequence 
DEDSCGRKKRRQRRRPPQTDEDD 
Optimazed nucleotidic 
sequence 
GAT GAA GAT TCT TGT GGT AGA AAG AAG AGA CGA 
CAA AGA CGT AGA CCT CCA CAA ACT GAT GAA GAT 
GAT 
Peptide length 
(aminoacids) 
pI 
23 8.20 
 
The modified Tat sequence reported in table 1 was inserted between the Ala22 and Pro23 
of the newpEAQ-HT-VP60, as reported in figure 3, in order to obtain a vector for the 
expression of CPMV eVLPs in which Tat peptide is exposed on the viral surface in  the 
small CP into the ßB-ßC loop. 
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Figure 3 newpEAQ-HT-VP60/Tat 2451-2801 bp region . In the purple box is 
reported the Tat sequence inserted between the Ala22 and Pro 23 into the sequence 
corresponding to the ßB-ßC loop of the CPMV small CP.  
In view of the above, a gene string started from the NheI until the StuI (restriction site not 
reported in figure 3 but present in pEAQ-HT-VP60 original vector approximatively 600 
bp downstream the NheI restriction site) was synthetized. Original pEAQ-HT-VP60 vector 
was restricted using NheI and StuI restriction enzymes and the new gene string harbouring 
all the modifications described was ligated resulting in the new vector called newpEAQ-
HT-VP60/Tat. 
 
4. CPMV eVLPs.Tat expression in N. benthamiana plants 
A small scale first trial was carried out in order to assess the expression in planta of CPMV 
eVLPs.Tat. 
4 leaves of N. benthamiana were infiltrated with a mixed suspension of A. tumefaciens 
carrying pEAQ-HT-24K or newpEAQ-HT-VP60/Tat plasmids.  
The agroinfiltrated leaves sampled at 6 days post infiltration (dpi) did not show viral 
symptoms as expected. 
DEDSCGRKKRRQRRRPPQTDEDD
Modified Tat sequence
GAT	GAA	GAT	TCT TGT	GGT	AGA	AAG	AAG	AGA	CGA	CAA	AGA	
CGT	AGA	CCT	CCA	CAA	ACT	GAT	GAA	GAT	GAT
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TSP were extracted from infiltrated leaves and analysed by SDS-PAGE and western blot, 
using a polyclonal antibody specific to CPMV particles for the detection of specific signals 
and the results confirmed the effective expression of CPMV eVLPs.Tat in plants.  
Afterwards a large scale infection of N. benthamiana plants was carried out, to obtain 
infected tissue for particles purification. 20-30 plants (4 leaves per plant) were 
agroinfected. Agroinfiltrated leaves (~25-30 g) were sampled 6 dpi and used for CPMV 
eVLPs.Tat purification experiments. 
 
5.    CPMV eVLPs.Tat purification 
5.1.  Chromatography based protocol 
Considering that CPMV eVLPs.Tat was meant to be used in sterile culture of 
neuroblastoma cells the purification procedure is very important and the first protocol 
chosen was the purification based on size exclusion chromatography. 
TSP were extracted from 25 g of agroinfiltrated leaves and clarified through filtration and 
centrifugation in order to remove cellular debris. An anion-exchange chromatography 
using DEAE SephadexTM A-50 resin was performed in order to remove a large part of plant 
contaminant proteins present in the extract before their injection into HiPrepTM 16/60 
SephacrylTM S-500 HR (Akta Prime plus). 
Considering the positive charge of the Tat peptide  an elution step with buffer containing 
1 M NaCl was performed in order to understand if particles interact with resin. 
The resin/sample ratio was optimized at ¼. 
Before injecting the sample into the HiPrepTM 16/60 SephacrylTM S-500 HR (Akta Prime 
plus) the aliquots collected in all purification steps were analysed by SDS-page and 
Coomassie staining (figure 4).  
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Figure 4 SDS-page, western blot (A) and coomassie staining of the purification step 
based on anion-exchange chromatography using DEAE SephadexTM A-50. 1: 10 µl 
of TSP extracted from leaves infiltrated with A. tumefaciens harbouring the 
newpEAQ-HT-VP60/Tat; 2: 10 µl of clarified extract; LOAD: 10 µl of  sample that 
has been loaded on the DEAE-chromatography; FT: 15 µl of the DEAE-
chromatography flow trough; W: 15 µl of the DEAE-chromatography wash step; E: 
15 µl of the DEAE-chromatography elution step done with sodium phosphate buffer 
0.1M NaCl 1 M; N: 10 µl of TSP extracted from wild type N. bethamiana leaves; P: 
purified unmodified CPMV eVLPs as positive control (A: 875 ng, B: 7.5 µg). M: 
molecular marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). 
Sample were loaded on 12% polyacrylamide gels then blot was probed with a 
polyclonal antibody (G49) specific to CPMV particles used at a concentration of 
1:2000. The expected position of CPMV L and S CPs is indicated on the side of the 
figures. 
Figure 4 shows that most of the CPMV eVLPs.Tat precipitate in the centrifuge before the 
DEAE chromatography step, indeed the signal corresponding to the sample that was loaded 
on DEAE column (lane LOAD) has an intensity visibly weaker than the TSP sample. 
Moreover, the passage into DEAE resin seems to increase the CPMV eVLPs.Tat loss as 
underlined by lane FT of figure 4 in which the signal corresponding to the particles is faint. 
Considering these results and in order to avoid CPMV eVLPs.Tat loss, other two 
experiments using different pH were conducted. In particular, either sodium phosphate 0.1 
M pH 6 or pH 8 were used either for the extraction of TSP or for anion-exchange 
chromatography steps but none of these pH allowed to improve the stability of the CPMV 
eVLPs.Tat. Using the pH 6 extraction buffer the particles precipitation was even more 
pronounced, while using pH 8 extraction buffer the behaviour of the CPMV eVLPs.Tat 
was exactly the same of the one obtained with pH 7 (data not shown).  
On the basis of the obtained results, other purification experiments using hydrophobic 
interactions chromatography (HIC) were done.  Different HIC resins based on different 
adsorbent medium (phenyl-, butyl- and octyl-sepharose) were tested. 
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The first experiment done at atmospheric pressure gave promising results; indeed, the 
western blot analysis done on aliquots corresponding to every step of the purification 
procedure showed that CPMV eVLPs.Tat were collected in the elution step of every HIC 
column tested. On the other hand, the coomassie staining analysis demonstrated that the 
elution fraction in which CPMV eVLPs.Tat were present resulted to be contaminated by 
other high molecular weigh proteins. In order to avoid these contaminations, more elution 
steps were tested but the yield of purified particles was too low and the loss in comparison 
to the initial protein extract was too high to consider this protocol suitable for CPMV 
eVLPs.Tat purification (data not shown). 
 
5.2.  Double sucrose cushion and Nycodenz gradient 
Given the above mentioned results, the purification protocol described in Peyret et al. 
(2015) was tested, which is based on either a sucrose cushion or nycodenz gradient and, as 
a consequence, it could be suited for the purification of those particles that tend to 
aggregates, as is the case of CPMV eVLPs.Tat. 
A purification test was conducted starting from 30 g of agroinfiltreted leaves, the TSP were 
extracted and clarified through filtration and centrifugation in order to remove cellular 
debris. The clarified extract was loaded on double sucrose cushion prepared with sucrose 
25% (2/13) and 70% (0.25/13). 
After centrifugation, a thick green band was visible at the interface between the 25% and 
70% sucrose layers. CPMV eVLPs typically co-sediment slightly below the green band 
with a partial overlapping with it.  
On the bottom of the tube a white pellet was formed, it was resuspended and collected. 
Thus the double sucrose cushion was fractionated collecting the following aliquots: 
A. The green band of the sucrose cushion, corresponding to the 70% sucrose 
layer; 
B. the surnatant of the sucrose cushion; 
C. the resuspended pellet. 
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In order to remove the sucrose, the aliquot A (7 ml) was dyalized over night against 20 mM 
ammonium bicarbonate pH 8.5. Due to the high osmotic pressure of the sucrose the volume 
of the CPMV eVLPs.Tat dialysate was raised to 20 ml.  
The dialysate was then concentrate to 5 ml using a 100 kDa cut off Centricon® tube. 
The results of the western blot and coomassie staining analysis of an aliquot of all the steps 
described before are reported in figure 5. 
 
Figure 5 SDS-page, western blot (A) and coomassie staining of the sucrose cushion 
step of the CPMV eVLPs.Tat purification. N: TSP extracted from wild type N. 
bethamiana; 1: TSP extracted from leaves infiltrated with A. tumefaciens harbouring 
the newpEAQ-HT-VP60/Tat; A: green band of the sucrose cushion corresponding to 
the 70% sucrose layer; B: surnatant of sucrose cushion; C: resuspended pellet obtained 
from the centrifugation of the sucrose cushion; 2: CPMV eVLPs.Tat dyalisate; 3: 
concentrated CPMV eVLPs.Tat. 10 µl (A) and 15 µl (B) of each sample were loaded 
on 12% polyacrylamide gels then blot was probed with a polyclonal antibody (G49) 
specific to CPMV particles used at a concentration of 1:2000 ; P: purified unmodified 
CPMV eVLPs as positive control (A: 875 ng, B: 7.5 µg). M: molecular marker 
(PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). The expected 
position of CPMV L and S CPs is indicated on the side of the figures. 
Figure 5-A showed that the CPMV eVLPs.Tat are correctly present in the concentrated 
dyalisate (lane 3); however, as underlined by the coomassie staining this sample resulted 
to be contaminated by other proteins so further purification steps are required. 
Further purification can be achieved with a Nycodenz gradient. Solutions of Nycodenz at 
20, 30, 40, 50, and 60% were prepared and the gradient was set up. The concentrated 
dyalisate CPMV eVLPs.Tat was loaded on the Nycodenz gradient and an 
ultracentrifugation at 40,000 rpm for 3 h at 4 °C was performed. After ultracentrifugation, 
a green band and a brown band were visible.  
Peyret et al. (2015) reported that after ultracentrifugation, the green contaminants usually 
sedimented towards the top of the gradient, while CPMV eVLPs typically sediment usually 
below the green impurities sometime in a more diffuse brown band. 
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Unexpectedly, the position of the green and brown band resulted to be inverted in 
comparison with that reported in Peyret et al. (2015). 
The Nycodenz gradient was fractionated and 500 µl aliquot were collected following the 
scheme reported (figure 6-A). The collected fractions were then analysed by western blot 
and coomassie staining analysis as reported in figure 6-B and C. 
 
Figure 6 Nycodenz gradient of the CPMV eVLPs.Tat. Schematic representation of 
the Nycodenz gradient after the ultracentrifugation (A) with the name and the number 
of collected aliquots. SDS-PAGE and subsequently western blot analysis (B) and 
coomassie staining (C) of the aliquots collected aliquots. Aliquots were loaded on 
12% polyacrylamide gels then blot was probed with a polyclonal antibody (G49) 
specific to CPMV particles used at a concentration of 1:2000. 2-B-3-G-4-5-6: 
aliquots collected from the Nycodenz gradient as reported in panel A, 15µl of each 
aliquots were loaded on gel; LOAD: sample loaded on Nycodenz gradient (12 µl); 
P: purified unmodified CPMV eVLPs as positive control (A: 875 ng, B: 7.5 µg). M: 
molecular marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). 
The expected position of CPMV L CP is indicated on the side of the figure in panel 
A. 
CPMV eVLPs.Tat was present either in the green band (lane G) and in the brown one (lane 
B), indeed a strong signal corresponding to the CPMV L CP are visible in both samples. 
The possible interaction between CPMV eVLPs and contaminant protein due to the 
presence of strong charged Tat peptide on particles surface could explain the lower position 
of the green band in comparison to the brown one. Unexpectedly figure 11-B underlines a 
strong specific signal in lane G corresponding to the green band that seems to contain the 
most of CPMV eVLPs.Tat. 
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Moreover, the coomassie staining analysis (figure 6-C) showed that CPMV eVLPs.Tat in 
the green band showed an higher degree of purity than the ones in the brow band, indeed 
in lane B two strong signals are visible at higher molecular weight that are not present in 
the lane G. On the other hand, some faint bands are visible even in lane G indicating the 
presence of some contaminant proteins. 
Considering that the use of CPMV eVLPs.Tat in vitro test with SH-SY5Y neuroblastoma 
cells require a higher purification level, the green band of the Nycodenz gradient were 0.2 
m filtrated in order to remove the contaminant protein. The filtrated sample was analysed 
by western blot but no signal corresponding to CPMV eVLPs.Tat was visible indicating 
the particles loss in the filtration step. These results could be explained with the presence 
of the Tat peptide on CPMV eVLPs surface that could promote particle aggregates 
formation. 
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DEVELOPMENT OF AN ECO-PESTICIDE 
 
1. Experimental design 
Pesticides are widely used in agriculture to maintain high product quality and reduce crop 
yield losses caused by plant diseases. However, several concerns have been raised about 
the pesticides impact on environment and human health. In the search for alternative 
solution, antimicrobial peptide (AMPs) have proven to be optimal candidates. 
BP100 AMPs is a cecropin A-mellitin hybridis derived from a undecapeptide peptide 
library obtained through combinatory chemistry approaches (Badosa et al., 2009). This 
peptide results to have bactericidal activity and antifungal properties, being at the same 
time high biocompatible (Badosa et al., 2007; Montesinos et al., 2008). 
Here we evaluate the use of the CPMV eVLPs for the expression of BP100; indeed,  the 
final application of these particles requires a no-replicative system in order to avoid the 
viral infection of plants that will be treated with particles displaying the anti-microbial 
peptide. 
BP100 peptide is characterised by a strong positive charge at neutral pH that facilitate the 
electrostatic attraction to phospholipid membranes of target microorganisms, thus making 
its pI out of the desirable range for the expression with the CPMV eVLPs expression 
system. As a  consequence, the BP100 sequence was optimized in order to decrease its pI. 
Vectors used for this part of the work were kindly provided by professor George P. 
Lomonossoff from the Department of Biological Chemistry at the John Innes Centre, 
(Norwich, UK) 
After cloning the BP100 peptide sequence in the expression vector pEAQ-HT-VP60, a 
small scale agroinfection of 1-2 N. benthamiana plant (4 leaves/plants) was carried on to 
check the expression of CPMV eVLPs displaying BP100 peptide (CPMV eVLPs.BP100). 
 
2. Cloning of BP100 peptide for the expression of CPMV 
eVLPs.BP100 
The BP100 peptide amminoacidic sequence was optimized (table 2) by the addition of one 
acid aminoacid at the peptide N-terminus and two at the C-terminus in order to decrease 
the peptide pI. 
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Table 2 Optimization of BP100 peptides for its expression with CPMV eVLPs system 
Aminoacids sequence KKLFKKILKYL 
Nucleotidic sequence AAG AAA CTT TTT AAG AAA ATT CTT AAG TAT CTT 
Peptide length 
(aminoacids) 
pI 
11 10.30 
Optimazed aminoacids 
sequence 
DKKLFKKILKYLED 
Optimazed nucleotidic 
sequence 
GAT AAG AAA CTT TTT AAG AAA ATT CTT AAG TAT 
CTT GAA GAT 
Peptide length 
(aminoacids) 
pI 
14 9.31 
 
The pI of the modified BP100 peptide results to be still higher than the optimal one, but 
considering the high presence of positive charge aminoacids (Lys) in the sequence, adding 
more acid aminoacids at the N- and/or C- teminus of the sequence could interfere with the 
assemble and the stability of the CPMV eVLPs particles and we proceed with the described 
modification.  
For the expression with the CPMV eVLPs system the nucleotidic optimized sequence 
encoding for BP100 peptide was cloned in the pEAQ-HT-VP60 vector within the sequence 
of the S CP located into the VP60 precursor sequence. 
Oligonucleotide pairs were designed to obtain NheI-compatible 5’- and AatII-compatible 
3’-end DNA fragments that were ligated into the NheI-AatII-digested vector. 
After ligation of the DNA fragments encoding BP100 peptide into pEAQ-HT-VP60 vector, 
the resulting pEAQ-HT-VP60.BP100 plasmid was transformed in E. coli DH5α strain 
competent cells by heat-shock. E. coli cells were plated on kanamycin containing medium 
(50 µg/ml) and PCR selected using vector-specific primers CPMV Seq-for and CPMV Seq 
rev, annealing respectively upstream and downstream of the insertion site. The length of 
the amplification fragments obtained is 200 bp plus the length of the BP100 inserted 
sequence, making in total of 242 bp. 
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Results of the PCR analysis on the colonies growth on selection medium after 
transformation with pEAQ-HT-VP60.BP100 vector are reported in figure 7. 
 
Figure 7 E. coli colonies transformed with pEAQ-HT-VP60 vector after ligation with 
BP100 oligonucleotide. PCR amplification products obtained with two vector-
specific primers (CPMV Seq for – CPMV Seq rev) were loaded on a 2% agarose gel. 
M: molecular marker (BenchTop 100bp DNA ladder - Promega); 1-5: number of E. 
coli DH5α colonies tested; P: positive control (using pEAQ-HT-VP60 vector as 
template); N: negative control. 
The PCR results showed that all the colonies tested were transformed; indeed, the resulting 
bands correspond to an amplicon of approximately 242 bp as expected.  
It is clearly visible the shift between the positive control and the amplicons derived from 
the colonies transformed with the pEAQ-HT-VP60.BP100 confirming the presence of the 
BP100 insert that increased the length of the fragment.  
Colonies were propagated in selective broth and plasmids were extracted, PCR analysed 
and sequenced to assess that the sequence of the insert was correct.  
Selected pEAQ-HT-VP60.BP100 resulting suitable from the PCR and sequencing analysis 
was transformed in competent cells of A. tumefaciens LBA4404 strain by electroporation 
and plated on kanamycin (50 µg/ml), rifampicin (50 µg/ml) and  streptomycin (100 µg/ml) 
containing medium. After three days 28 °C incubation, colonies were PCR selected using 
vector-specific primers CPMV Seq-for and CPMV Seq rev to asses their effective 
transformation. Positive A. tumefaciens LBA4404 colonies were propagated in selective 
broth and used for the next expression step. 
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3. Analysis of the expression in plant of CPMV eVLPs displaying 
BP100 
A small scale first trial was carried out in order to assess the expression in planta of CPMV 
eVLPs.BP100. 
4 leaves of N. benthamiana were infiltrated with a mixed suspension of A. tumefaciens 
carrying pEAQ-HT-24K or pEAQ-HT-VP60.BP100 plasmids.  
The agroinfiltrated leaves sampled at 6 dpi did not showed viral symptoms, obtaining the 
same result reported in figure 2 of the chapter 1 (page 65). 
TSP were extract from infiltrated leaves and analysed by SDS-page and western blot, using 
a polyclonal antibody specific to CPMV particles for the detection of specific signals. 
Results of this analysis are reported in figure 8.  
 
Figure 8 Western blot analysis of the TSP extracted from leaves agroinfiltrated for 
the expression on CPMV eVLPs.BP100. Samples were loaded on 12% 
polyacrylamide gels then blot was probed with a polyclonal antibody (G49) specific 
to CPMV particles used at a concentration of 1:2000. 1-2: 12 and 15 µl of TSP 
extracted from pEAQ-HT-VP60.BP100 infiltrated leaves; 3: pellet obtained from the 
centrifugation in order to obtain the TSP, pellet was resuspended in running buffer 
and loaded on gel (12 µl) P:875 ng of  purified unmodified CPMV eVLPs as positive 
control; P*: TSP extracted from pEAQ-HT-VP60 infiltreted leaves; M: molecular 
marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). The 
expected position of CPMV L and S CPs are indicated on the side of the figure. 
The results show in figure 8 confirmed the expression of CPMV eVLPs.BP100 in plant.  
Indeed, a strong signal corresponding to 35 kDa and two signals corresponding to 25-27 
kDa are clearly visible in lanes 1-2 corresponding to the protein extract of the leaves 
infiltrated for the expression of CPMV eVLPs.BP100. Other two signals are visible at 
molecular weight of approximatively 55 and 70 KDa, but being present also in the negative 
control (lane N: protein extract obtained from N. benthamiana plant inoculated with 
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infiltration buffer MMA) they could be considered aspecific signals. Finally, the tendency 
of this particles to aggregate is underlined by the presence of CPMV eVLPs.BP100 (lane 
3) that precipitated in the pellet obtained after the following centrifugation step.  
Considering the results, a large scale infection of N. benthamiana plants was carried out, 
to obtain infected tissue for particle purification. 
 
4. Purification of CMPV eVLPs.BP100  
 
4.1.  PEG 6000 precipitation based protocol  
 
A first small scale purification starting from 10 g of agroinfiltrated N. benthamiana plants 
was carried out in order to verify if the standard purification protocol based on the 
precipitation of CPMV eVLPs with Poly(ethylene)glycol (PEG) 6000 was suitable for the 
CPMV eVLPs.BP100. TSP were extracted and clarified through filtration and 
centrifugation in order to remove cellular debris. 
Polyethylene glycol 6000 (PEG 6000) to a final concentration of 4% and NaCl to 0.2 M 
were added to the supernatant; the sample was then stirred o/n at 4 ⁰C to precipitate the 
CPMV eVLPs.BP100 and then spinned to pellet the PEG precipitate. Other centrifugation 
steps were performed in order to further purified the precipitated particles. 
At every purification steps an aliquot of the sample was collected. At the end of the 
experiments all the aliquots collected were analysed by SDS-PAGE and western blot using 
a polyclonal antibody specific to CPMV particles for the detection of specific signals.  
At the same time, the purification protocol was carried out for the purification of 
unmodified CPMV eVLPs from N. bethamiana plant infiltrated with a mix containing A. 
tumefaciens carried pEAQ-HT-VP60 or pEAQ-HT-24K.  
The results of this analysis are reported in the figure 9. 
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Figure 9 Western blot analysis of the CPMV eVLPs.BP100 standard purification 
steps. Samples were loaded on 12% polyacrylamide gels then blot was probed with 
a polyclonal antibody (G49) specific to CPMV particles used at a concentration of 
1:2000. 1: 20 µl of TSP extracted from pEAQ-HT-VP60.BP100 infiltrated leaves; 2: 
20 µl of the surnatant of the first centrifugation done for a exctract clarification; 3: 
20 µl of sample with PEG6000 and NaCl before the centrifugation; 4: 6 µl of the 
pellet resuspended in ½ of the initial volume after the centrifugation of the sample 3; 
P: 875 ng of  purified unmodified CPMV eVLPs as positive control; P*: 20 µl of 
TSP extracted from pEAQ-HT-VP60 infiltreted leaves as positive control; M: 
molecular marker (PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific). 
The expected position of CPMV L and S CPs are indicated on the side of the figure. 
 
The standard protocol based on the precipitation with PEG 6000 is not suitable for the 
purification of CPMV eVLPs.BP100. Indeed, in figure 9 it is possible to follow the 
presence of the particles until the step corresponding to the sample in which PEG 6000 and 
NaCl were added over night (lane 3) wheras, in the following samples corresponding to 
the pellet precipitated after centrifugation, CPMV eVLPs.BP100 are not present. The use 
of PEG 6000 is not sufficient to precipitate the CPMV eVLPs.BP100 that remains in 
solution. 
Considering the results further purification experiments were carried out as describe in the 
following section. 
 
 
 
 
 
 
 
 
M							P 1												2											3									4										P*
35	kDa
25	kDa
L	CP
S	CP
RESULTS AND DISCUSSION  OTHER APPLICATIONS 
 157 
4.2.   CPMV eVLPs.BP100 precipitation experiments 
In order to overcome the problem arose with the standard protocol, the strategies planned 
in order to precipitation the CPMV eVLPs.BP100 are summarised below:  
A. Increase in the concentration of PEG 6000; 
B. Increase in the centrifugation speed after the over night step with PEG; 
C. PEG and ionic strength variation: particles precipitation experiments with PEG 
with differently either molecular weight or ionic strength; 
D. Increase in the centrifugation time after the over night with PEG. 
Starting from A and B strategies, they have been applied to the surnatant of the 
centrifugation done after the over night step at 4°C with PEG 6000 that, as reported in the 
previous section (Standard protocol: PEG 6000 precipitation), contains the CPMV 
eVLPs.BP100 that did not precipitate. This sample was divided into 2 aliquots in order to 
pursue the strategies A and B. In one of the two aliquots 4% of PEG 6000 was added in 
order to reach twice the concentration previously used and after the over night step at 4 °C 
the sample was spinned at 13 000 g for 20 minutes as reported in the standard protocol. 
The other aliquot was spinned for 20 minutes at a higher velocity (27 000 g) in comparison 
with that provided for by the standard protocol (13 000 g) following the strategy B. 
Aliquots derived from all the steps of the strategies A and B were collected and analysed 
by SDS-page and western blot. The western blot analysis underlines that neither the 
strategy A nor B allowed to precipitate the CPMV eVLPs.BP100 that remained in the 
surnatant (data not shown). 
Moving on strategy C, the TSP were extracted from 10 g of N. bethamiana pEAQ-HT-
VP60.BP100 infected leaves and divided into 6 independent sample which were incubated 
over night at 4 °C at different ionic strengths and PEG types.  
The details of this experiment are reported in table 3. 
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Table 3 strategy a for the CPMV eVLPs.BP100 precipitation 
Sample PEG molecular weight Ionic strength (NaCl M) 
1 3350 Normal (0.2 M) 
2 3350 Twice (0.4 M) 
3 4000 Normal (0.2 M) 
4 6000 No NaCl (0 M) 
5 6000 10 fold lower (20 mM) 
6 6000 Twice (0.4 M) 
7 8000 Normal (0.2 M) 
9 8000 Twice (0.4 M) 
10 20000 Normal (0.2 M) 
 
After the incubation over night at 4 °C in the condition reported in table 1, samples were 
spinned and either the resulted surnatant or pellet were analysed by SDS-page and western 
blot. The behaviour of the CPMV eVLPs.BP100 in the different conditions are shown in 
figure 10. 
 
Figure 10 Wester blot analysis of the 10 purification strategies schedule in table 3. 20 
µl of each sample were loaded on 12% polyacrylamide gels then blots were probed with 
a polyclonal antibody (G49) specific to CPMV particles used at a concentration of 
1:2000. The number indicated the strategy (table 3), and surnatant (S) and resuspended 
pellet (P) of every strategy were analysed. P:  1 µg of  purified unmodified CPMV 
eVLPs as positive control. M: molecular marker (PageRuler™ Plus Prestained Protein 
Ladder, Thermo Scientific). 
 
The figure 10 highlights the presence of CPMV L CP specific signals at approximatively 
40 kDa in all the surnatants loaded on the gel; only sample 1 is characterised by a faint 
signal in the pellet sample obtained from the centrifugation after the over night 
precipitation with peg 3350. However, this signal is too faint in comparison with the one 
of the surnatant to be considered relevant.  
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Considering that all the signals corresponding to the CPMV eVLPs.BP100 are present in 
the surnatants, they have been spinned at 30 000 g for 16 hours in the attempt to precipitate 
them. The pellets formed were resuspended and loaded on polyacrillamide gel to be 
analysed by western blot but again all the signals corresponding to the CPMV 
eVLPs.BP100 were clearly visible only in the surnatants (data not shown). 
 
4.3. Double sucrose cushion and Nycodenz gradient  
As reported in the previous section regarding CPMV eVLPS.Tat the protocols reported in 
Peyret et al., 2015 were tested to purify CPMV eVLPs.BP100 from 3 g of infiltrated N. 
benthamiana leaves.  
An aliquot of every purification step was collected and the Nycodenz gradient was 
fractionated in 11 aliquots. All the samples collected were analysed by SDS-PAGE and 
western blot.  
The results obtained showed that even the use of this protocol did not allow to purify the 
CPMV eVLPs.BP100 that are not present in the expected gradient band as reported in 
Payret et al. (2015) (data not shown). 
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CONCLUDING REMARKS 
	
The great advances in the last decade have turned the plant molecular farming from a 
theoretical science to an industrial and applicative biotechnological field.  
The development and refinement of expression technologies and their application for the 
production in a wide range of crop species of target molecules, result in a flurry of patents 
and industrial applications. 
As reported in Arntzen et al. (2015), pharmaceutical and agricultural biotechnology 
companies started to invest significantly in plant-based systems reflecting the realization 
of the potential of plant molecular farming. 
In this context, the use of plant viruses as in planta expression tools is a particularly 
promising approach. 
Plant viruses can be considered as innovative nanomaterials able to stabilize functional 
peptides on their surface; the resulting CVPs/eVLPs can be produced in plant without 
expensive production costs and may be implemented in a variety of industrial and 
biotechnological fields. 
However, the expression of peptides with CVPs/eVLPs is a cutting-edge technology that 
up to now it is not always well standardized and it is strongly peptide and viral particle 
dependent. Indeed, in this project some problem with the expression (PVX CVPs.FADK2) 
or purification (PVX CVPs.BANK1, TuMV CVPs.LIP1, CPMV eVLPs.BP100 and CPMV 
eVLPs.Tat) have been reported. 
In the future, in order to overcame these drawbacks, viral expression particles could be 
optimized through a synthetic biology approach in order to increase the particles stability. 
The sequence of the viral CPs could be analysed and modified in order to improve the 
particles stability when the peptide of interest is fused on their surface. Moreover, through 
bioinformatics tools a new exposal site on the particles surface could be explored in order 
to achieve the best peptide exposition.   
Nevertheless, in this project the therapeutic application of different viral expression system 
has been demonstrated. 
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In particular, CPMV eVLP.p524 results to be a potential pharmaceutical for the prevention 
of T1D; moreover, it has been demonstrated that TBSV CVPs.LIP1 and TBSV 
CVPs.FADK2 have a therapeutic potential in the treatment of RA. 
The use of viral particles for peptide display allows to increase the effects of the peptide 
itself. Indeed, CPMV eVLPs.p524 results to have a regulative effect that has not been 
achieve using the synthetic peptide p524 with IFA. 
The use of TBSV CVPs for peptide LIP1 display confirms this evidence since the 
therapeutic effect of the particles results to be higher in comparison to the injection of LIP1 
peptide alone. On the other hand, although TBSV CVPs.FADK2 showed regulative and 
therapeutic effects, the FADK2 synthetic peptide injected with IFA results to be more 
effective.   
These evidences are particularly interestingly considering that viral particles have been 
previously used before for the set up of vaccines (Jochmus et al., 1999) and never for the 
therapy of autoimmune disease. 
The role of a vaccine is to boost and stimulate the immune system in order to give the 
protection from a disease; on the contrary, in this project, it has been shown that 
CVPs/eVLPs displaying specific autoantigenic peptides can be used for the modulation of 
the immune system and for the induction of immunological tolerance against the 
autoantigenic peptide itself. 
The restore of the immunological tolerance occurs through the activation of a subset of 
regulatory and antiinflammatory cytokines driven by the autoantigenic peptide displayed 
on viral particles surface. 
RA and T1D are the two most widespread autoimmune diseases with a strong social 
impact, also in terms of public health costs.  
Considering the increasing availability of diagnostic tools, that combine genetic marker 
with the presence of specific autoantibodies, that allows to estimate the probability that a 
person has to develop T1D, the use of CPMV eVLPs.p524 in T1D preventive campaigns 
could markedly reduce the cost associated to this disease. Currently, patients need daily 
insulin injection throughout their life, the prevention of this disorder would avoid the 
damage of the pancreatic cells and the use of insulin. 
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Regarding the prevention of RA, the current therapy available for patients consist in the 
use of immunosuppressant and non-steroidal anti-inflammatiry drugs (NSAID). These 
pharmaceutical relieve pain and steam symptoms without blocking the course of the 
disease.  
However, the therapeutic effects of TBSV CVPs.LIP1 and TBSV CVPs.FADK2 would 
allow to treat RA avoiding the sides effect of immunosuppressant and NSAID drugs. 
Moreover, T1D and RA preclinical studies reported in this PhD thesis have demonstrated 
that viral particles displaying immunodominant peptides have showed a preventive and 
therapeutic effect without the use of any adjuvant. This could be due to the high density of 
peptide display on viral surface, that correspond to 6.1 x 10-3 and 6.4 x 10-2 peptide/nm2 
respectively for the CPMV and TBSV expression system. Although, the peptide superficial 
density reached with the TBSV expression system is ten-fold higher in comparison with 
the one reached with the CPMV based system, the latter results to be efficient as well. 
Moreover, beside the stabilization and the exposition of the peptides, miming a viral 
structure, CVPs and eVLPs elicit the immune system without the need of any other 
molecules (Lico et al., 2012). This evidence allows, not only to avoid the cost associated 
to the use of adjuvants but also, to avoid their side effects. 
The comparison between plant viruses with the traditional nanomaterial gives rise several 
shared characteristics. Indeed, plants viruses are robust nanoparticles with a simple, 
repetitive and ordered structure. These features, common to nanomaterials, gives plant 
viruses excellent candidate for the development of reagents to be exploited also in 
diagnostic field. In this context, a kit for SjS diagnosis has been developed using PVX 
CVPs.lipo as coating reagent for the set-up of a diagnostic ELISA.  
The comparison between the PVX CVPs.lipo-based ELISA and the same kit made using 
the synthetic peptide lipo have demonstrated that the use of PVX particles allows to 
increase the diagnostic sensitivity. Moreover, the use of the synthetic peptide did not 
provide reproducible results probably for its intrinsic peptide instability and its poorly 
absorption to the ELISA plate. This evidence is probably due to the flexibility and 
filamentous PVX structure that allows a high lipo peptide exposition. Furthermore, the 
filamentous viral particle shape results to be decisive for the diagnostic application; indeed, 
	 	 CONCLUDING REMARKS	
	
	164 
the two icosahedral virus based system (CPMV and TBSV) are not be suitable for this 
application.  
Moreover, the PVX CVPs.lipo based ELISA results to be remarkably stable up to 2 months 
at 4 °C.  
The results obtained in the set-up of the SjS diagnostic kit using the PVX CVPs.lipo could 
pave the way to the exploitation of plant viruses for the development of diagnostic tools 
able to improve the performance of current diagnostic procedures.  
Beside the improvement that CVPs particles could provide in the diagnostic field, another 
strength of this application relies on the inexpensive production process because plants are 
used as natural bioreactor for the CVPs expression and amplification. 
Finally, plant virus particles displaying biomarker peptides could be applied also to other 
diagnostic methods such as the immunofluorescence based one, chromatographic 
immunoassay or in a label-free immunoassay through the development of specific 
biosensor (Giavazzi et al., 2013).   
The last part of this project has explored other eVLPs application beside the therapeutic 
and diagnostic ones. In particular, the CPMV eVLPs expression system has been tested for 
the set-up of a biotechnological system for the internalization of peptide inside the cell and 
for the development of particles display an AMPs for the expression in plant of eco-
pesticide.  
Current pesticides are widely used in agricultural but serious concerns have been raise 
about the human health risks and the impact on environment. The development of eVLPs 
displaying AMP would lead to the development of a new form of biocontrol of plant 
pathogen. eVLPs are completely human and environmental safe because they are 
biodegradable molecule and, lacking the viral genome, not infective. 
Although, the development of these two applications of eVLPs is at an early stage and it 
does not allow to obtain results because of some problems in the purification step of either 
CPMV eVLPs.Tat or CPMV eVLPs.BP100, other peptide and viral expression system are 
in process of evaluation to achieve the final goal. 
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